{"meta":{"query_hash":"43ac0f224e9c","filters":{"venue":"Future Oncology"},"cohort_total":184,"direct_labels_cover":2,"predictions_cover":184,"exported":184,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/43ac0f224e9c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Future+Oncology"},"results":[{"id":"W1940218692","doi":"10.2217/fon.15.220","title":"The Development of Stereotactic Body Radiotherapy in the Past Decade: A Global Perspective","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Stereotactic radiotherapy; Radiation therapy; Radiation oncology; Perspective (graphical); Ablative case; Radiosurgery; Medical physics; Internal medicine","score_opus":0.016226992022652185,"score_gpt":0.3502143212516804,"score_spread":0.3339873292290282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940218692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027807392,0.88596356,0.00091089145,0.08661337,0.0035580106,0.000005762674,0.00014019561,0.000052307198,0.019975044],"genre_scores_gemma":[0.026047813,0.95383143,0.0010467154,0.012769749,0.0035936488,0.0000064967,0.00013319314,0.000020865375,0.0025500336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923337,0.00019061544,0.00010051224,0.00012729153,0.00022885198,0.00011934099],"domain_scores_gemma":[0.99692696,0.0007097476,0.00052488357,0.00006880832,0.0012214025,0.0005482219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022748932,0.0005490355,0.0005003652,0.0022131726,0.00059521786,0.0031529283,0.00058377185,0.0028221256,0.0070175086],"category_scores_gemma":[0.0022614368,0.00016431796,0.00039515944,0.0037484644,0.0013846812,0.004237881,0.0013023459,0.0031191928,0.0012463661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018486576,0.00012720999,0.0054717762,0.004437409,0.00005449394,0.0005075859,0.00061258,0.0010730227,0.0015963857,0.040602863,0.100883104,0.84444875],"study_design_scores_gemma":[0.00001097802,0.00016957741,0.0075192214,0.0023709259,0.00006266842,0.0014944184,0.001279539,0.00022056424,0.00072815747,0.00567244,0.9804427,0.00002874521],"about_ca_topic_score_codex":0.002426285,"about_ca_topic_score_gemma":0.0043044267,"teacher_disagreement_score":0.0070175086,"about_ca_system_score_codex":0.0019750982,"about_ca_system_score_gemma":0.0037106692,"threshold_uncertainty_score":0.023475945},"labels":[],"label_agreement":null},{"id":"W1972785878","doi":"10.2217/fon.10.145","title":"Novel Targeted Agents on the Horizon for Castration-Resistant Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Androgen receptor; Androgen deprivation therapy; Cancer research; Testosterone (patch); Orchiectomy; Androgen; Prostate; Cancer; Oncology; Internal medicine; Bioinformatics; Hormone; Biology","score_opus":0.09929114834197945,"score_gpt":0.43647364871926125,"score_spread":0.3371825003772818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972785878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003440263,0.9965785,0.000290296,0.000279681,0.00021348047,0.00001422673,0.00002499168,0.000018103367,0.0022365616],"genre_scores_gemma":[0.001236775,0.9951814,0.0006084004,0.0003092977,0.00014461088,0.000016813105,0.000059434504,0.000003771017,0.0024394512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998896,0.000020122214,0.000010656478,0.000016688107,0.00004912931,0.00001389542],"domain_scores_gemma":[0.9998847,0.00003751513,0.000020071555,0.000004457843,0.00003636396,0.000016945294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004336317,0.00087940803,0.0013338298,0.0017270863,0.0002672804,0.0006828022,0.00075668585,0.0009464852,0.0039621987],"category_scores_gemma":[0.00030153862,0.00024344606,0.00041174292,0.0014461805,0.00037507925,0.0011696579,0.00045820564,0.0020049566,0.0037368631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009898122,0.00015023228,0.00009658086,0.0049562524,0.00006291179,0.00028598393,0.00004304227,0.00039958995,0.0047802515,0.0031218072,0.02638451,0.9596198],"study_design_scores_gemma":[0.000046354067,0.00015389164,0.0006160114,0.0010848099,0.00006262883,0.0013425907,0.000034211498,0.00011147762,0.0010747918,0.0012085638,0.9942496,0.000015074242],"about_ca_topic_score_codex":0.001035503,"about_ca_topic_score_gemma":0.002902737,"teacher_disagreement_score":0.0039621987,"about_ca_system_score_codex":0.0006163248,"about_ca_system_score_gemma":0.0006097229,"threshold_uncertainty_score":0.013254821},"labels":[],"label_agreement":null},{"id":"W1977865587","doi":"10.2217/fon.10.105","title":"The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Solid tumor; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Cancer","score_opus":0.02649924056177988,"score_gpt":0.38462041893369553,"score_spread":0.35812117837191565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977865587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024343494,0.95616066,0.0019987072,0.0027758959,0.00080913014,0.000040551688,0.000084586165,0.000051687253,0.013735249],"genre_scores_gemma":[0.18902725,0.7926194,0.004552333,0.00204163,0.0020701766,0.00006923865,0.00017337278,0.000015487587,0.009431173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998863,0.0000363094,0.000009430143,0.000011350607,0.000033038275,0.000023578854],"domain_scores_gemma":[0.9999186,0.000025189911,0.000019119025,0.0000040885448,0.000014878542,0.000018108918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003732832,0.00025600204,0.00025308374,0.00048356317,0.00014158756,0.00050798606,0.00020110903,0.00038010933,0.0016959487],"category_scores_gemma":[0.00018487479,0.000066357396,0.00037461967,0.00028586687,0.00024994928,0.00038687818,0.00031023315,0.00084453094,0.00055098045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069034897,0.00039448615,0.0011805822,0.0016328058,0.00006678421,0.0009764958,0.00007918699,0.00064009806,0.0629444,0.01117797,0.008915633,0.91130126],"study_design_scores_gemma":[0.00034395827,0.005475714,0.007264163,0.0007451862,0.00018626891,0.0062865824,0.000099091434,0.0009696489,0.045990087,0.0061816704,0.92642605,0.00003164571],"about_ca_topic_score_codex":0.00019486589,"about_ca_topic_score_gemma":0.0005152441,"teacher_disagreement_score":0.0016959487,"about_ca_system_score_codex":0.00024647973,"about_ca_system_score_gemma":0.00024357563,"threshold_uncertainty_score":0.0056735277},"labels":[],"label_agreement":null},{"id":"W1987659344","doi":"10.2217/fon.14.167","title":"Stereotactic Body Radiotherapy: An Effective Local Treatment Modality for Hepatocellular Carcinoma","year":2014,"lang":"en","type":"review","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Radiation therapy; Oncology; Radiology; Liver cancer; Internal medicine","score_opus":0.07164260666451745,"score_gpt":0.3592313822499008,"score_spread":0.28758877558538337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987659344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008214911,0.99918145,0.000055129378,0.00014605872,0.000049213962,0.0000023127495,0.000011454986,0.000003615233,0.00046857307],"genre_scores_gemma":[0.00058315624,0.99905056,0.00006787237,0.00007876412,0.00006131226,0.0000021856067,0.000014892061,6.5544685e-7,0.00014057074],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998344,0.00003046671,0.000035651818,0.000024967265,0.00006507783,0.000009394504],"domain_scores_gemma":[0.9997452,0.000116108786,0.000058236576,0.0000065533336,0.00005910946,0.000014700351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039525836,0.00058007543,0.0011362231,0.0030929672,0.00023026488,0.00070873904,0.0005019789,0.00060470967,0.0028115192],"category_scores_gemma":[0.00067040295,0.00016771782,0.00056171964,0.0031935498,0.00033214764,0.00097373157,0.00040229264,0.00071829563,0.0012065708],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032326003,0.00003258911,0.00035474385,0.028882744,0.00013267659,0.0003051892,0.000049287977,0.00019154725,0.00085186237,0.0009136121,0.020821074,0.9474324],"study_design_scores_gemma":[0.000021888587,0.00011895064,0.003865513,0.014768986,0.00057875214,0.008780587,0.00016361002,0.00011715251,0.00079178426,0.0018037338,0.96895087,0.000038247035],"about_ca_topic_score_codex":0.0012918974,"about_ca_topic_score_gemma":0.0026780204,"teacher_disagreement_score":0.0030929672,"about_ca_system_score_codex":0.00049870176,"about_ca_system_score_gemma":0.00085029873,"threshold_uncertainty_score":0.009405494},"labels":[],"label_agreement":null},{"id":"W1988301011","doi":"10.2217/fon.09.58","title":"If Cancer Stem Cells are Resistant to Current Therapies, What’s Next?","year":2009,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Cancer; Metastasis; Medicine; Tumor microenvironment; Cancer stem cell; Cancer research; Oncology; Internal medicine; Library science; Computer science","score_opus":0.02391622463582073,"score_gpt":0.3389130197994513,"score_spread":0.3149967951636306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988301011","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031164564,0.011257641,0.0001282726,0.04610781,0.9416461,0.000008185216,0.000017386881,0.000022923625,0.00078049337],"genre_scores_gemma":[0.0006391371,0.017019577,0.000248421,0.049653802,0.92202985,0.00001983533,0.000021449254,0.000022863092,0.010345218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645895,0.00070181704,0.00056262646,0.00035993877,0.0016942561,0.00022247968],"domain_scores_gemma":[0.98342127,0.0075152656,0.00082434964,0.00032728692,0.006134079,0.0017776913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071746632,0.0022673665,0.0031345303,0.0019807036,0.0021920155,0.0054610353,0.0028743835,0.013401264,0.0049520372],"category_scores_gemma":[0.016141245,0.0007993497,0.0021325226,0.00082889583,0.0031730009,0.0041428274,0.0010993027,0.023935117,0.0049112774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040919876,0.000015672562,0.000033645138,0.00031744473,0.000025501698,0.00013940323,0.000017853126,0.000031415075,0.00012753585,0.0005855942,0.9866937,0.011971384],"study_design_scores_gemma":[0.00004558287,0.00003901197,0.00021910787,0.00031283582,0.00007157848,0.00034456095,0.0000611764,0.00010531806,0.00022682064,0.0014682448,0.99707925,0.000026584677],"about_ca_topic_score_codex":0.0016380146,"about_ca_topic_score_gemma":0.0050614416,"teacher_disagreement_score":0.013401264,"about_ca_system_score_codex":0.0022729565,"about_ca_system_score_gemma":0.0023433063,"threshold_uncertainty_score":0.03794366},"labels":[],"label_agreement":null},{"id":"W1996531785","doi":"10.2217/fon.09.26","title":"Role of The<i>MTHFR</i>Polymorphisms in Cancer Risk Modification and Treatment","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Methylenetetrahydrofolate reductase; Single-nucleotide polymorphism; Medicine; Pharmacogenetics; Pharmacology; Antimetabolite; Cancer; Methotrexate; Bioinformatics; Cancer research; Allele; Internal medicine; Genetics; Biology; Genotype; Gene","score_opus":0.053843940651838354,"score_gpt":0.40758050055623274,"score_spread":0.3537365599043944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996531785","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1836396,0.73431987,0.005579494,0.050824303,0.0015066242,0.00013567449,0.0020395815,0.00017066428,0.02178423],"genre_scores_gemma":[0.76764286,0.21270818,0.004352089,0.007087023,0.0029402866,0.00016341773,0.0014228307,0.000041159547,0.0036421062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836296,0.000851777,0.00012649792,0.00023218784,0.00030951484,0.00011703096],"domain_scores_gemma":[0.9975562,0.00096198753,0.00082413596,0.00014346268,0.00028613827,0.00022814999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017817994,0.00024531802,0.0008463153,0.0005614488,0.000248629,0.00085596554,0.00051934714,0.0011942185,0.001988905],"category_scores_gemma":[0.0070936335,0.00013139739,0.0010552679,0.001097791,0.000373127,0.00029581608,0.000310287,0.0010700363,0.00035217463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023927344,0.0007300379,0.31323022,0.0019983093,0.0037962985,0.0005843462,0.00019009573,0.0019965102,0.003309511,0.005479427,0.015513778,0.6507788],"study_design_scores_gemma":[0.00076295953,0.0022087728,0.8326066,0.0029777952,0.005964813,0.001732185,0.00024155209,0.0048933085,0.0029851366,0.011811006,0.13368605,0.00012984946],"about_ca_topic_score_codex":0.004452812,"about_ca_topic_score_gemma":0.002646961,"teacher_disagreement_score":0.004452812,"about_ca_system_score_codex":0.0008721004,"about_ca_system_score_gemma":0.00091439014,"threshold_uncertainty_score":0.009423196},"labels":[],"label_agreement":null},{"id":"W1999540397","doi":"10.2217/fon.14.163","title":"On the Contribution of S100A10 and Annexin A2 to Plasminogen Activation and Oncogenesis: An Enduring Ambiguity","year":2014,"lang":"en","type":"review","venue":"Future Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Carcinogenesis; Ambiguity; Annexin A2; Cancer research; Annexin; Cancer; Internal medicine; Pathology; Linguistics; Philosophy","score_opus":0.023088523636378807,"score_gpt":0.3250235927638751,"score_spread":0.3019350691274963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999540397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017436489,0.99747354,0.00019341947,0.000985266,0.00029422238,0.0000016269761,0.00000807587,0.000004948606,0.0008644217],"genre_scores_gemma":[0.0007792915,0.99783534,0.0001377321,0.00034290168,0.0003251935,0.0000030193426,0.000014998112,0.0000017885277,0.00055981835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997671,0.000039781862,0.00003183417,0.00004050549,0.000094866235,0.000025932584],"domain_scores_gemma":[0.99942124,0.0003016284,0.000057727426,0.00002049536,0.0001459864,0.000052936397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081200013,0.00067980756,0.0011931759,0.0021832336,0.00038936734,0.0013235108,0.00096113415,0.0021685823,0.0023931034],"category_scores_gemma":[0.0009238212,0.0003092112,0.00039468866,0.0022769882,0.0011270478,0.002651048,0.0010602605,0.0025006712,0.001427765],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075094,0.000048198868,0.0002336321,0.008200299,0.00006175745,0.00049589324,0.0001678391,0.00042343125,0.0026184614,0.016810777,0.02911105,0.9417535],"study_design_scores_gemma":[0.000007924046,0.000047883,0.00051691534,0.0015779588,0.00003491568,0.0016346021,0.00010489816,0.000082413586,0.0005369492,0.0067612375,0.9886785,0.000015810088],"about_ca_topic_score_codex":0.000936306,"about_ca_topic_score_gemma":0.0014759789,"teacher_disagreement_score":0.0023931034,"about_ca_system_score_codex":0.00088992744,"about_ca_system_score_gemma":0.0013466548,"threshold_uncertainty_score":0.008005679},"labels":[],"label_agreement":null},{"id":"W2000905384","doi":"10.2217/14796694.4.6.779","title":"The Future in Psychosocial Oncology: Screening for Emotional Distress – The Sixth Vital Sign","year":2008,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Alberta Heritage Foundation for Medical Research; Australian Government","keywords":"Biopsychosocial model; Psychosocial; Medicine; Survivorship curve; Distress; Healthcare system; Health care; Sign (mathematics); Pediatric oncology; Population; Intensive care medicine; Oncology; Psychiatry; Internal medicine; Clinical psychology; Cancer; Environmental health","score_opus":0.042005071059260594,"score_gpt":0.38833188258826906,"score_spread":0.34632681152900846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000905384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014357873,0.99367636,0.00017073957,0.0043948605,0.0006495325,0.0000035051228,0.0000046325995,0.0000063430666,0.0009503841],"genre_scores_gemma":[0.0017227035,0.99542123,0.00039808257,0.0013150513,0.0007060652,0.000006484272,0.00001071221,0.0000016517027,0.00041792987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992269,0.00032976072,0.000076258664,0.00005747124,0.000267848,0.000041764706],"domain_scores_gemma":[0.9979188,0.00118581,0.00021978206,0.000044819226,0.0004932032,0.00013759817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020205595,0.0007040714,0.0014326266,0.00211748,0.0005171916,0.0014321867,0.0007858266,0.0021420126,0.0021187519],"category_scores_gemma":[0.0027306017,0.00024667155,0.0004588635,0.0017896148,0.0011793362,0.0031109052,0.0011318529,0.0032608204,0.0012327718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002807465,0.000047111436,0.00088493095,0.005592226,0.000058619833,0.00019867122,0.0001449172,0.00013464862,0.000417041,0.0035982346,0.038763423,0.9501321],"study_design_scores_gemma":[0.00003577411,0.00030180506,0.008676503,0.023769505,0.0001762772,0.0078072,0.0015516677,0.00044277642,0.0004279965,0.0133643225,0.94335514,0.000091030604],"about_ca_topic_score_codex":0.0019429955,"about_ca_topic_score_gemma":0.003852473,"teacher_disagreement_score":0.0021420126,"about_ca_system_score_codex":0.00093842536,"about_ca_system_score_gemma":0.0023275078,"threshold_uncertainty_score":0.010685861},"labels":[],"label_agreement":null},{"id":"W2007775064","doi":"10.2217/14796694.1.4.511","title":"Notch Signaling in T-Cell Acute Lymphoblastic Leukemia","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chromosomal translocation; Lymphoblastic Leukemia; Leukemia; Gene; Disease; Cancer research; Etiology; Immunology; T cell; Bioinformatics; Biology; Genetics; Internal medicine; Immune system","score_opus":0.012584580818678671,"score_gpt":0.30736543521473103,"score_spread":0.29478085439605234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007775064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001804501,0.9975216,0.00023601031,0.0002808953,0.00025177756,0.000004198188,0.000012824446,0.000012915603,0.0014993945],"genre_scores_gemma":[0.0007229923,0.9976967,0.00020434108,0.00016676165,0.00015968601,0.0000047608874,0.000021801037,0.0000013213322,0.0010216588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998697,0.000021906731,0.000017545786,0.00002395018,0.000055496148,0.000011350592],"domain_scores_gemma":[0.9998753,0.000034642,0.000023086011,0.000005178068,0.000041163585,0.000020665017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042553316,0.00084764615,0.0011233991,0.0018083645,0.00030999488,0.0008595966,0.00094646774,0.0010687022,0.0022380222],"category_scores_gemma":[0.0003707881,0.0002704539,0.00025736445,0.002146949,0.0004413236,0.0011576175,0.00054876343,0.0013475554,0.0038859064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008562598,0.000058939906,0.00016963035,0.0056165447,0.000046720605,0.000513263,0.0000497799,0.0005327185,0.0028754375,0.0031591046,0.03682824,0.950064],"study_design_scores_gemma":[0.00002098834,0.00005528484,0.00057454774,0.0012301476,0.000044205266,0.0021687443,0.000046570043,0.00008512902,0.0005885352,0.0016753683,0.99349725,0.0000132639825],"about_ca_topic_score_codex":0.0011791548,"about_ca_topic_score_gemma":0.002025717,"teacher_disagreement_score":0.0022380222,"about_ca_system_score_codex":0.00075015775,"about_ca_system_score_gemma":0.0008489075,"threshold_uncertainty_score":0.007486999},"labels":[],"label_agreement":null},{"id":"W2011966810","doi":"10.2217/14796694.3.5.539","title":"Targeting the Rna-Binding Protein Sam68 As A Treatment For Cancer?","year":2007,"lang":"en","type":"review","venue":"Future Oncology","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Suppressor; RNA-binding protein; Oncogene; RNA; Biology; Carcinogenesis; Cancer research; Cancer; Breast cancer; Mammary tumor; Haploinsufficiency; Cell biology; Genetics; Gene; Phenotype","score_opus":0.05321973433173025,"score_gpt":0.42035839195967767,"score_spread":0.3671386576279474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011966810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016907109,0.9969025,0.00014896019,0.0009932658,0.00052975386,0.0000043681816,0.000009786591,0.000010757913,0.0012314146],"genre_scores_gemma":[0.0008540018,0.9961416,0.00024296285,0.0007404632,0.00042625188,0.000009476315,0.000021365475,0.0000026063274,0.0015612863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988997,0.000022126422,0.000011773825,0.00001962466,0.00004417052,0.000012248773],"domain_scores_gemma":[0.99981576,0.00007812873,0.000022874605,0.00000748924,0.000047822123,0.000028008382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060013705,0.0008482675,0.0011601836,0.0015439785,0.00033406704,0.000647212,0.00092058507,0.0015556441,0.0037800523],"category_scores_gemma":[0.00046648105,0.0002258593,0.00033082132,0.0014493136,0.00074243743,0.0014056715,0.00043367076,0.002124579,0.003970244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016585921,0.00010318114,0.00013722242,0.0040826118,0.0000678502,0.00032159363,0.000052610532,0.00029785468,0.0025794634,0.005050262,0.066951744,0.92018974],"study_design_scores_gemma":[0.00005231569,0.00012070519,0.00040912058,0.0007453546,0.000043983993,0.0012888378,0.000047706533,0.000069699694,0.00060218066,0.0021733984,0.99443394,0.000012799743],"about_ca_topic_score_codex":0.0007897708,"about_ca_topic_score_gemma":0.0020933473,"teacher_disagreement_score":0.0037800523,"about_ca_system_score_codex":0.00062848325,"about_ca_system_score_gemma":0.00058675697,"threshold_uncertainty_score":0.012645602},"labels":[],"label_agreement":null},{"id":"W2013307793","doi":"10.2217/14796694.2.5.627","title":"Tumor Dormancy and the Role of Metastasis Suppressor Genes In Regulating Ectopic Growth","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"Mechanisms of cancer metastasis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Metastasis; Ectopic expression; Metastasis suppressor; Suppressor; Dormancy; Metastasis Suppressor Gene; Cancer research; Medicine; Malignancy; Gene; Primary tumor; Cancer; Biology; Oncology; Internal medicine; Genetics; Botany","score_opus":0.011695508575961067,"score_gpt":0.2927156381989339,"score_spread":0.28102012962297285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013307793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002945389,0.996431,0.00032529622,0.00020045966,0.0001470346,0.000004545765,0.000010684877,0.000011228025,0.0025751784],"genre_scores_gemma":[0.0011861251,0.99661535,0.0003122302,0.00010317746,0.00007212681,0.0000064908495,0.000018101518,0.0000014882881,0.0016848134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999905,0.000015214851,0.000009668077,0.000017055092,0.000042064392,0.000011036226],"domain_scores_gemma":[0.9998925,0.000038320046,0.000019035784,0.0000048492543,0.00003054686,0.000014774962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029114707,0.00065227796,0.0008783655,0.0015500874,0.0002775492,0.0007759731,0.0006472551,0.0008351909,0.0024160487],"category_scores_gemma":[0.0002656304,0.00020523436,0.0002649126,0.0015907935,0.000492501,0.0011151566,0.00040574587,0.0009562015,0.003071222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007797304,0.00006253062,0.00023322627,0.005929196,0.000032885924,0.000486917,0.000083069266,0.00045538132,0.009529526,0.00814327,0.017419102,0.95754695],"study_design_scores_gemma":[0.000013470362,0.00007651521,0.00085987267,0.0009205216,0.000030168396,0.0021524848,0.000059662885,0.00008524311,0.0018134818,0.0031328746,0.99084365,0.000011994804],"about_ca_topic_score_codex":0.0007420512,"about_ca_topic_score_gemma":0.0012766266,"teacher_disagreement_score":0.0024160487,"about_ca_system_score_codex":0.0006309809,"about_ca_system_score_gemma":0.0006429792,"threshold_uncertainty_score":0.008082449},"labels":[],"label_agreement":null},{"id":"W2040148468","doi":"10.2217/fon.15.14","title":"Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Ablative case; Medicine; Prostate cancer; Radiation therapy; Radiosurgery; Prostate; Clinical trial; Medical physics; Cancer; Oncology; Stereotactic radiotherapy; Radiology; Internal medicine","score_opus":0.14483361662746125,"score_gpt":0.5161428575992442,"score_spread":0.3713092409717829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040148468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095371506,0.9987608,0.00006400602,0.00049683085,0.00013024654,0.000013933685,0.00002678184,0.0000032826267,0.00040885303],"genre_scores_gemma":[0.00072180416,0.99816823,0.00025203498,0.0005256373,0.00013536056,0.000021799675,0.000046680067,0.0000021894944,0.0001262732],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990645,0.00033174935,0.00024952932,0.000099819765,0.0002158407,0.000038588834],"domain_scores_gemma":[0.9939313,0.0044705323,0.00062060537,0.00009648718,0.0007471993,0.00013392317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003979056,0.000726929,0.0025923043,0.0018892384,0.00021947366,0.0014471193,0.0015029,0.0014272281,0.005771574],"category_scores_gemma":[0.0059373924,0.0003335442,0.0016584812,0.0022471917,0.0005011382,0.0016818406,0.0006511121,0.0017641716,0.0010623387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023703363,0.0000788597,0.00022445466,0.08210671,0.00040370724,0.00008673931,0.00005772345,0.00027989168,0.0005678248,0.0021151858,0.013993604,0.8998483],"study_design_scores_gemma":[0.00028376226,0.000641769,0.0016391741,0.07892524,0.0021182834,0.00095014466,0.00015255653,0.00018954814,0.0004955996,0.0040444164,0.9105139,0.00004558283],"about_ca_topic_score_codex":0.0007652708,"about_ca_topic_score_gemma":0.0021113288,"teacher_disagreement_score":0.005771574,"about_ca_system_score_codex":0.00072906923,"about_ca_system_score_gemma":0.0022105721,"threshold_uncertainty_score":0.021043539},"labels":[],"label_agreement":null},{"id":"W2059728548","doi":"10.2217/14796694.3.5.575","title":"Role of Dead Box 1 In Retinoblastoma and Neuroblastoma","year":2007,"lang":"en","type":"review","venue":"Future Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Retinoblastoma; Neuroblastoma; Cancer research; Medicine; Pediatric cancer; Gene; Cancer; Biology; Genetics; Internal medicine","score_opus":0.034367962801752076,"score_gpt":0.39189299673970984,"score_spread":0.35752503393795776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059728548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021575378,0.99844223,0.00011870708,0.0001430786,0.00008937532,0.0000023357998,0.000008823544,0.000005898271,0.0009736747],"genre_scores_gemma":[0.0009216496,0.997764,0.00019919254,0.000092286595,0.00007758448,0.0000038343296,0.000020558076,9.520664e-7,0.0009199605],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998926,0.000016714102,0.00001574924,0.000023183842,0.00004104317,0.000010766219],"domain_scores_gemma":[0.99988544,0.000044389533,0.000023637462,0.000004156335,0.00002876705,0.000013675434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039498002,0.00064920366,0.001071662,0.0018688819,0.0003114553,0.00067725976,0.0006663688,0.0008870182,0.0024307845],"category_scores_gemma":[0.00031347832,0.0002771544,0.00029189666,0.0016183393,0.0004897836,0.0010922748,0.00051290944,0.0011473594,0.0022296314],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008495593,0.000064752785,0.0003053577,0.008204679,0.000051527735,0.0007243981,0.000093490664,0.00055904966,0.0058521563,0.005340936,0.018959513,0.9597592],"study_design_scores_gemma":[0.000016748507,0.00006533098,0.001070119,0.0013829351,0.00004918249,0.0031878264,0.0000678631,0.000087512606,0.0015533498,0.002606165,0.98989713,0.000015969623],"about_ca_topic_score_codex":0.0011284756,"about_ca_topic_score_gemma":0.002047404,"teacher_disagreement_score":0.0024307845,"about_ca_system_score_codex":0.00070136384,"about_ca_system_score_gemma":0.0007763415,"threshold_uncertainty_score":0.008131802},"labels":[],"label_agreement":null},{"id":"W2068549807","doi":"10.2217/fon.14.208","title":"Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Sorafenib; Platelet-derived growth factor receptor; Tyrosine-kinase inhibitor; Receptor; Pharmacology; VEGF receptors; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Oncology; Cancer; Internal medicine; Growth factor; Hepatocellular carcinoma","score_opus":0.062285287748175884,"score_gpt":0.40467768940545695,"score_spread":0.3423924016572811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068549807","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78259146,0.17348875,0.007043937,0.0023124842,0.000307658,0.00092681573,0.0034414174,0.0002841529,0.029603332],"genre_scores_gemma":[0.9167252,0.060796473,0.005463931,0.0006237958,0.00018040018,0.00022198533,0.0064218123,0.00004429679,0.009522125],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999273,0.00000841813,0.0000056979425,0.000012259421,0.00002796266,0.000018319064],"domain_scores_gemma":[0.99992037,0.000006660291,0.000019062274,0.000005245991,0.000011374454,0.000037375976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000300846,0.0005335044,0.00037286992,0.0007356208,0.00022296119,0.00075307436,0.00032838885,0.00041048057,0.0015478263],"category_scores_gemma":[0.00018589899,0.00019511,0.00027069898,0.00046295297,0.00029295665,0.0003197256,0.00019346573,0.000876261,0.0009375741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005672671,0.0022223387,0.003528823,0.0011340949,0.00008339888,0.0009105755,0.000097529395,0.0034215054,0.5855078,0.0021000586,0.0040007043,0.39132044],"study_design_scores_gemma":[0.0068024006,0.052190393,0.05417448,0.00043837243,0.00062609324,0.016308507,0.00019166348,0.008511693,0.56775326,0.0018825874,0.2909036,0.00021695763],"about_ca_topic_score_codex":0.0008886047,"about_ca_topic_score_gemma":0.0013672125,"teacher_disagreement_score":0.0015478263,"about_ca_system_score_codex":0.0005557357,"about_ca_system_score_gemma":0.0005752921,"threshold_uncertainty_score":0.0051779747},"labels":[],"label_agreement":null},{"id":"W2102549074","doi":"10.2217/fon.13.149","title":"Best of International Stereotactic Radiosurgery Society Congress 2013: Stereotactic Body Radiation Therapy. Part II: Nonspinal Tumors","year":2013,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Radiosurgery; Medicine; Radiation oncology; Medical physics; Radiation therapy; Radiology","score_opus":0.010822688223576593,"score_gpt":0.28988377291502876,"score_spread":0.2790610846914522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102549074","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004910098,0.19900662,0.0051795403,0.06458399,0.34331664,0.0006673648,0.009729005,0.0010408391,0.37156588],"genre_scores_gemma":[0.014403656,0.14231199,0.00505756,0.010132475,0.09214314,0.0004059345,0.011163951,0.0012934301,0.72308785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989385,0.00011316345,0.000100808735,0.00013642779,0.0005418769,0.00016924359],"domain_scores_gemma":[0.9970643,0.00021684311,0.0003043759,0.00009859217,0.0013630843,0.00095282943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021324493,0.0017819614,0.0011537068,0.005682142,0.001952833,0.005924969,0.0011695136,0.0019014874,0.09282057],"category_scores_gemma":[0.0023297432,0.0005341664,0.00116344,0.0053505367,0.0006524402,0.002474335,0.0020866364,0.0024590152,0.041525982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047274305,0.000033626755,0.0002625918,0.0003354516,0.000008816581,0.00006008107,0.00005070264,0.000074939366,0.0005502741,0.00048530175,0.92221504,0.07587581],"study_design_scores_gemma":[0.0000050264903,0.000027298951,0.0013930645,0.00023137903,0.000007745066,0.00011746984,0.00007221085,0.000037183225,0.0003000676,0.0002869908,0.99751115,0.000010413252],"about_ca_topic_score_codex":0.004925604,"about_ca_topic_score_gemma":0.02137741,"teacher_disagreement_score":0.09282057,"about_ca_system_score_codex":0.0024538063,"about_ca_system_score_gemma":0.0036394158,"threshold_uncertainty_score":0.31051576},"labels":[],"label_agreement":null},{"id":"W2104167520","doi":"10.2217/fon.12.100","title":"Targeting Tumoral Hypoxia: Finding Opportunity in Complexity","year":2012,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"MEDLINE; Medicine; Hypoxia (environmental); Oncology; Internal medicine; Library science; Biology; Computer science","score_opus":0.02862364299242163,"score_gpt":0.3121951409280845,"score_spread":0.28357149793566283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104167520","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046345125,0.024967954,0.00026754025,0.03577675,0.9378972,0.000009419176,0.000026052607,0.000043561475,0.00096512213],"genre_scores_gemma":[0.0005031001,0.01619871,0.00014557866,0.013928508,0.96336406,0.0000105659365,0.000013582841,0.000019756228,0.005816178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974764,0.00047456587,0.00031772943,0.0002919926,0.0012524435,0.00018681573],"domain_scores_gemma":[0.98904395,0.00504968,0.00055107375,0.00027023238,0.0035432314,0.0015417677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006205143,0.0033278817,0.0031481648,0.0022837156,0.0018667254,0.006062557,0.0029468786,0.010612078,0.00557193],"category_scores_gemma":[0.011557338,0.000876162,0.001797675,0.00091976085,0.0029207156,0.0046099266,0.0013585227,0.022178758,0.0037105496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000613288,0.000015321237,0.000028446331,0.00040837371,0.000026433496,0.00015031829,0.00002118519,0.00004534449,0.00018650712,0.0010686462,0.98710895,0.010879119],"study_design_scores_gemma":[0.000045311917,0.00004118711,0.00018925936,0.00032465946,0.00005894866,0.00040294818,0.00005177469,0.00016596791,0.00023869541,0.0020019575,0.9964561,0.000023249137],"about_ca_topic_score_codex":0.00090996764,"about_ca_topic_score_gemma":0.0034720202,"teacher_disagreement_score":0.010612078,"about_ca_system_score_codex":0.0021077474,"about_ca_system_score_gemma":0.0019693887,"threshold_uncertainty_score":0.03281629},"labels":[],"label_agreement":null},{"id":"W2110353604","doi":"10.2217/fon.09.43","title":"Screening for Distress (The Sixth Vital Sign) in A Global Recession: Sustainable Approach to Maintain Patient-Centered Care","year":2009,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation","funders":"","keywords":"Distress; Medicine; Psychosocial; Psychological intervention; Recession; Great recession; Risk analysis (engineering); Intensive care medicine; Actuarial science; Psychiatry; Clinical psychology; Economics","score_opus":0.012508076597762697,"score_gpt":0.30319609214047266,"score_spread":0.29068801554270995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110353604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3375031,0.002401985,0.27690125,0.30693766,0.0006692079,0.001922929,0.0006994019,0.00045577536,0.07250874],"genre_scores_gemma":[0.9386205,0.0020331317,0.050325345,0.0030814002,0.00014429855,0.00075255486,0.00014573646,0.000018408175,0.004878623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99821556,0.0012435965,0.0000365582,0.00009978994,0.00013092844,0.00027366873],"domain_scores_gemma":[0.9989919,0.00029799592,0.00014743922,0.000054306674,0.00012767615,0.00038074658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036175805,0.00044173983,0.00044565642,0.0005979597,0.0009748956,0.001977363,0.0012728524,0.0017552543,0.0055382783],"category_scores_gemma":[0.004756191,0.00028247325,0.0006542884,0.0005219683,0.0010352993,0.0020008627,0.0034817446,0.0017686673,0.00044741243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000687938,0.0020693918,0.068124436,0.0009459036,0.00033939604,0.0012262547,0.0026484448,0.21439438,0.0028447434,0.24119484,0.056589555,0.40893468],"study_design_scores_gemma":[0.0009225275,0.0034408092,0.057956208,0.0012871437,0.0003774428,0.0012279018,0.011540555,0.47826296,0.0013462933,0.3662206,0.077134535,0.0002830223],"about_ca_topic_score_codex":0.008366176,"about_ca_topic_score_gemma":0.01882085,"teacher_disagreement_score":0.008366176,"about_ca_system_score_codex":0.002357807,"about_ca_system_score_gemma":0.008526443,"threshold_uncertainty_score":0.01913184},"labels":[],"label_agreement":null},{"id":"W2110984210","doi":"10.2217/fon.10.163","title":"Do Anthracyclines Still Have a Role in Adjuvant Chemotherapy of Breast Cancer?","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Anthracycline; Trastuzumab; Cardiotoxicity; Medicine; Breast cancer; Taxane; Oncology; Internal medicine; Chemotherapy; Cancer; Metastatic breast cancer","score_opus":0.029723272581336946,"score_gpt":0.4338935815551031,"score_spread":0.40417030897376616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110984210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120839104,0.9986009,0.00005281784,0.00060088973,0.00015194161,0.0000013364778,0.00000482839,0.0000018328021,0.0004646124],"genre_scores_gemma":[0.0008231924,0.99775875,0.00011459875,0.0005036679,0.00024756047,0.000002753405,0.000010693382,0.0000010950532,0.0005376873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976534,0.000051297826,0.000035913814,0.00003665311,0.00009231328,0.000018505369],"domain_scores_gemma":[0.99931026,0.00031825315,0.000105427054,0.000030598036,0.00018735723,0.000048105983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142474,0.00052345503,0.001560228,0.0008308958,0.00022765357,0.0009641851,0.00080926844,0.0012328258,0.0026079537],"category_scores_gemma":[0.0011928685,0.0003342005,0.00040497747,0.0014841168,0.0008098381,0.0022983185,0.00043092974,0.0023029153,0.0020865253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010392536,0.00005757938,0.00022742504,0.006398548,0.000054440192,0.0001324094,0.000058397727,0.00022797076,0.0013238667,0.0034020825,0.018129775,0.9698835],"study_design_scores_gemma":[0.000064475134,0.00015763176,0.001379544,0.0032963906,0.00009379735,0.0012158891,0.00008403499,0.00010941932,0.00041012,0.0027227444,0.9904502,0.00001572491],"about_ca_topic_score_codex":0.0014706433,"about_ca_topic_score_gemma":0.0035739816,"teacher_disagreement_score":0.0026079537,"about_ca_system_score_codex":0.0005791605,"about_ca_system_score_gemma":0.00084768,"threshold_uncertainty_score":0.008724451},"labels":[],"label_agreement":null},{"id":"W2118840104","doi":"10.1517/14796694.1.2.265","title":"DNA Repair Protein: Endo-Exonuclease as a new Frontier in Cancer Therapy","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BioPhage Pharma (Canada); Montreal General Hospital","funders":"","keywords":"DNA repair; Homologous recombination; Genome instability; Biology; DNA damage; Carcinogenesis; Cell cycle; Cancer cell; DNA repair protein XRCC4; Cell biology; Non-homologous end joining; Mutagenesis; DNA; Cancer research; Genetics; Cell; Mutation; Cancer; Nucleotide excision repair; Gene","score_opus":0.02811935777475067,"score_gpt":0.34946138741982097,"score_spread":0.3213420296450703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118840104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008670399,0.941783,0.014583857,0.013167629,0.0026912116,0.00009195147,0.0002508857,0.00028886792,0.018472232],"genre_scores_gemma":[0.09409357,0.8253267,0.017208904,0.0072535565,0.0022201748,0.000194243,0.0005994472,0.00010123962,0.05300223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998234,0.000039249197,0.000008494599,0.0000361891,0.0000680643,0.000024726834],"domain_scores_gemma":[0.99986255,0.00002947284,0.000024167288,0.000008973669,0.00004378339,0.000031016676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005675066,0.0004532598,0.0005475675,0.00067960576,0.00024367063,0.0009515411,0.0005135483,0.0011373769,0.0047204094],"category_scores_gemma":[0.0002900726,0.0001384199,0.00027959907,0.0006111542,0.0005930637,0.0010983103,0.00060470676,0.0021356062,0.0024450924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004070041,0.0004429693,0.0006539638,0.0030060713,0.00007571914,0.0005425383,0.00013100874,0.00085220597,0.070879005,0.043846235,0.06154348,0.81761986],"study_design_scores_gemma":[0.00008257132,0.0006691356,0.0010093331,0.0003974309,0.000050714407,0.0018125415,0.000048086004,0.0009565744,0.02457015,0.010969994,0.9594095,0.000024101691],"about_ca_topic_score_codex":0.00047127073,"about_ca_topic_score_gemma":0.00095902296,"teacher_disagreement_score":0.0047204094,"about_ca_system_score_codex":0.00082320836,"about_ca_system_score_gemma":0.00066683,"threshold_uncertainty_score":0.015791357},"labels":[],"label_agreement":null},{"id":"W2122558264","doi":"10.2217/fon.12.3","title":"The Current Role of Circulating Tumor Cells in the Diagnosis and Management of Bone Metastases in Advanced Prostate Cancer","year":2012,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Circulating tumor cell; Management of prostate cancer; Oncology; Cancer; Prostate-specific antigen; Prostate; Internal medicine; Disease; Disease monitoring; Metastasis","score_opus":0.05575054018666093,"score_gpt":0.4170604696478369,"score_spread":0.36130992946117596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122558264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010162769,0.9991872,0.000092375674,0.00020786273,0.00006897826,0.0000024047506,0.000007738866,0.0000032877101,0.00032856604],"genre_scores_gemma":[0.0004739064,0.9990276,0.00016512242,0.00010199038,0.00008305182,0.000003477699,0.000012719633,8.078358e-7,0.0001313475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997204,0.00006154964,0.00005335177,0.000043822318,0.00010227,0.000018579884],"domain_scores_gemma":[0.9993344,0.00034244696,0.00009292558,0.000016694785,0.00017519921,0.000038253143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009297662,0.00065371586,0.0015698784,0.0018753418,0.0002256273,0.0008433159,0.0009237948,0.0010697809,0.0019321302],"category_scores_gemma":[0.0012099774,0.00024831863,0.00048458084,0.0020298334,0.00053826004,0.0012421145,0.0005368174,0.0014251724,0.0014322277],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059330836,0.00004487813,0.00020005663,0.01419131,0.000055872617,0.0001313676,0.00004872469,0.00025392234,0.0009709988,0.0011412044,0.009999551,0.9729029],"study_design_scores_gemma":[0.000033732333,0.00026020862,0.0024482578,0.008426523,0.0002870326,0.0028487307,0.00015310785,0.00020000227,0.0008225085,0.0024362998,0.98204297,0.000040598145],"about_ca_topic_score_codex":0.0012753487,"about_ca_topic_score_gemma":0.0019515267,"teacher_disagreement_score":0.0019321302,"about_ca_system_score_codex":0.00051621645,"about_ca_system_score_gemma":0.0009752723,"threshold_uncertainty_score":0.006463647},"labels":[],"label_agreement":null},{"id":"W2123883580","doi":"10.1517/14796694.1.1.125","title":"Therapeutic implications of DNA methylation","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"DNA methylation; Epigenome; Epigenetics; Reprogramming; Epigenomics; Biology; Cancer research; Gene silencing; Cancer epigenetics; Genetics; Gene; Gene expression","score_opus":0.044460952282246086,"score_gpt":0.38730355226829977,"score_spread":0.3428425999860537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123883580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040549328,0.99317133,0.0007119001,0.0012165019,0.00033358164,0.000006587473,0.000016785947,0.000013757376,0.0041239904],"genre_scores_gemma":[0.0057434235,0.9883857,0.00088271574,0.000693141,0.0003359551,0.000018269697,0.000030188328,0.0000043094346,0.003906444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983966,0.00004172055,0.00001211343,0.0000323407,0.0000568125,0.000017262244],"domain_scores_gemma":[0.9998635,0.000064649554,0.000017657574,0.000008111882,0.00003064901,0.000015490637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054452894,0.0006107093,0.00085735315,0.0011471956,0.0002782126,0.0006917907,0.0008157059,0.0013705206,0.0037733929],"category_scores_gemma":[0.00051499315,0.00016996053,0.00033186437,0.00071444904,0.00068531564,0.00088002335,0.00062409183,0.0016023392,0.0019573793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007892007,0.000058580332,0.00022210607,0.0041323644,0.00005875764,0.00054959045,0.0001100387,0.0006241303,0.010550174,0.016575893,0.02345844,0.94358104],"study_design_scores_gemma":[0.000022528237,0.00008905656,0.0006149171,0.00085885247,0.00003445461,0.0026538752,0.00005183093,0.00015058472,0.0036882355,0.0065805768,0.9852401,0.000014975987],"about_ca_topic_score_codex":0.00081302534,"about_ca_topic_score_gemma":0.0018905839,"teacher_disagreement_score":0.0037733929,"about_ca_system_score_codex":0.0008197313,"about_ca_system_score_gemma":0.00056113873,"threshold_uncertainty_score":0.0126232505},"labels":[],"label_agreement":null},{"id":"W2125382892","doi":"10.2217/fon.11.63","title":"A New Frontier in Personalized Cancer Therapy: Mapping Molecular Changes","year":2011,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Cancer; Targeted therapy; Medicine; Computational biology; Precision medicine; Cancer therapy; Personalized medicine; Gene; Cancer research; Bioinformatics; Biology; Genetics; Internal medicine; Pathology","score_opus":0.040486513429424095,"score_gpt":0.33086589345659917,"score_spread":0.29037938002717506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125382892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045976776,0.9835512,0.0076497924,0.0035392628,0.00052424474,0.000016625543,0.000043609194,0.00007658866,0.004138843],"genre_scores_gemma":[0.00454938,0.98478544,0.005340663,0.0015371239,0.0006260563,0.000027279297,0.000060040125,0.000016213517,0.0030578354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99955446,0.0001377338,0.000021820562,0.000078333454,0.00017478531,0.000032811324],"domain_scores_gemma":[0.9993629,0.00038650146,0.000052357143,0.000039468738,0.00011168308,0.000047253572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011508781,0.0010125127,0.0020063787,0.0024194724,0.00034627836,0.0016623915,0.0012513621,0.0022384196,0.0033900605],"category_scores_gemma":[0.00095739285,0.0003031855,0.0005699109,0.0019108278,0.0017911778,0.0030300121,0.0008177543,0.00331707,0.0030369963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008292733,0.00010262683,0.0005281978,0.0045531476,0.00008535646,0.00043997975,0.00011175684,0.00079766935,0.015647268,0.03231114,0.040172376,0.9051676],"study_design_scores_gemma":[0.000020509473,0.00013517585,0.000996108,0.00089858536,0.00005382501,0.0038595262,0.0001324831,0.00067631254,0.007024877,0.021781916,0.96437675,0.00004395676],"about_ca_topic_score_codex":0.000856977,"about_ca_topic_score_gemma":0.001018879,"teacher_disagreement_score":0.0033900605,"about_ca_system_score_codex":0.0013697832,"about_ca_system_score_gemma":0.0009215324,"threshold_uncertainty_score":0.011340916},"labels":[],"label_agreement":null},{"id":"W2127753540","doi":"10.2217/14796694.2.1.15","title":"Dexrazoxane Use In the Prevention of Anthracycline Extravasation Injury","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Anthracycline; Medicine; Cardiotoxicity; Extravasation; Doxorubicin; Epirubicin; Daunorubicin; Idarubicin; Pharmacology; Chemotherapy; Internal medicine; Pathology; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.06209249161300837,"score_gpt":0.4201365793525218,"score_spread":0.3580440877395134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127753540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047164274,0.9984341,0.000090222326,0.00006859682,0.00004882303,0.0000061653946,0.000011774275,0.000006475157,0.0008620679],"genre_scores_gemma":[0.0021151288,0.9969676,0.00019584675,0.00007129245,0.000051150324,0.0000072979947,0.000026317253,0.0000012738474,0.0005640596],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99986136,0.00002835821,0.000025875615,0.000024080111,0.000049259335,0.000011065212],"domain_scores_gemma":[0.9998394,0.00006369903,0.000038667044,0.0000052869304,0.000039005856,0.000013928833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040470326,0.0005978927,0.0013350275,0.002020545,0.00021198578,0.0005014416,0.0007360061,0.00068546034,0.0032307887],"category_scores_gemma":[0.0003913394,0.00021875705,0.00044037637,0.0017896873,0.00023350203,0.0006175125,0.0002915443,0.0006725486,0.001601687],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019237824,0.00011926074,0.00034655107,0.0155548155,0.000109765075,0.00046475136,0.000053329783,0.00024152498,0.0029614777,0.0006428406,0.007555568,0.9717576],"study_design_scores_gemma":[0.00015252258,0.00075738935,0.0057204096,0.0064118425,0.0005000374,0.009122117,0.00012868724,0.00024523496,0.0043425984,0.0010367382,0.9715512,0.00003129418],"about_ca_topic_score_codex":0.0008976413,"about_ca_topic_score_gemma":0.0019136409,"teacher_disagreement_score":0.0032307887,"about_ca_system_score_codex":0.000355877,"about_ca_system_score_gemma":0.00054184196,"threshold_uncertainty_score":0.010808051},"labels":[],"label_agreement":null},{"id":"W2129628525","doi":"10.2217/fon.12.67","title":"Regulation of Plasmin Generation by the Annexin A2 Heterotetramer: A Shift in Perspective","year":2012,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Heterotetramer; Annexin A2; Medicine; Plasmin; Perspective (graphical); Biochemistry; Annexin; Immunology; Chemistry; Protein subunit; Enzyme","score_opus":0.007370285439260643,"score_gpt":0.27712821912352315,"score_spread":0.2697579336842625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129628525","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029169722,0.037987016,0.0005112214,0.070572145,0.8891234,0.000018635184,0.00005490417,0.00006671208,0.0013742914],"genre_scores_gemma":[0.002318779,0.028149277,0.0003584155,0.03676666,0.92154706,0.0000352883,0.000047549314,0.000035639427,0.010741355],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831176,0.00026866695,0.00026371,0.0002675154,0.0007365902,0.00015178452],"domain_scores_gemma":[0.99532026,0.0020464726,0.00035800456,0.00014507504,0.0014572226,0.00067298603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041870666,0.0024858392,0.0026214372,0.0014937395,0.0013055773,0.0045921216,0.0026391237,0.014155541,0.0038077],"category_scores_gemma":[0.0065608793,0.0009783808,0.001568648,0.0007762789,0.0021259987,0.0037057968,0.0012136817,0.02057435,0.002856014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025834728,0.000038161976,0.00004681856,0.00056957686,0.000052580122,0.0004426354,0.00002335896,0.000079369165,0.0011255412,0.0017750659,0.9788157,0.016772851],"study_design_scores_gemma":[0.00019918833,0.00010192511,0.0003612699,0.00030487427,0.000112972404,0.0008200511,0.000044549655,0.00037653427,0.001317153,0.0026179317,0.99370617,0.00003742609],"about_ca_topic_score_codex":0.000734806,"about_ca_topic_score_gemma":0.0017106712,"teacher_disagreement_score":0.014155541,"about_ca_system_score_codex":0.0026847164,"about_ca_system_score_gemma":0.0015902756,"threshold_uncertainty_score":0.022143543},"labels":[],"label_agreement":null},{"id":"W2131759521","doi":"10.2217/fon.11.134","title":"Oncolytic Viruses: Smart Therapeutics for Smart Cancers","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Oncolytic virus; Medicine; Cancer research; Cancer; Oncology; Internal medicine","score_opus":0.0324954202615448,"score_gpt":0.35812391936696386,"score_spread":0.3256284991054191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131759521","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005490972,0.024670972,0.00041847216,0.021456804,0.95173657,0.000019312625,0.000039063354,0.000059962214,0.0015439539],"genre_scores_gemma":[0.0010391163,0.031510256,0.000464204,0.025260633,0.9174908,0.000031140935,0.00005274215,0.00005471767,0.024096383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690837,0.0005307509,0.00039557932,0.0003140594,0.001634019,0.00021719454],"domain_scores_gemma":[0.9932799,0.0031264503,0.0003583592,0.00014468048,0.0021983369,0.0008923321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062240018,0.003881828,0.0026733023,0.0020935654,0.0017126357,0.0063352315,0.0030596051,0.012913061,0.0054032626],"category_scores_gemma":[0.008204826,0.0012592449,0.0021524348,0.00088293647,0.0024169832,0.004849495,0.00137945,0.021799177,0.005724585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075024625,0.00001751096,0.00001683672,0.00038018692,0.00002770244,0.00013413097,0.000016748369,0.000055256525,0.00033020723,0.0010975619,0.98489547,0.012953416],"study_design_scores_gemma":[0.000044331726,0.000036398113,0.00007860208,0.00014820331,0.000043451808,0.00028571676,0.00001954207,0.00014949265,0.00036988265,0.0010689389,0.99773717,0.000018260158],"about_ca_topic_score_codex":0.0008923158,"about_ca_topic_score_gemma":0.0027988434,"teacher_disagreement_score":0.012913061,"about_ca_system_score_codex":0.0025296647,"about_ca_system_score_gemma":0.0018858847,"threshold_uncertainty_score":0.03291607},"labels":[],"label_agreement":null},{"id":"W2132123971","doi":"10.2217/fon.09.65","title":"Physical Activity, Obesity and Risk for Esophageal Adenocarcinoma","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"Nova Scotia Health Research Foundation; Saskatchewan Health Research Foundation","keywords":"Medicine; Esophageal adenocarcinoma; Obesity; Physical activity; Esophageal cancer; Internal medicine; Adenocarcinoma; Oncology; Cancer; Physical therapy","score_opus":0.045424014411943936,"score_gpt":0.4123853684843281,"score_spread":0.36696135407238417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132123971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030704951,0.999154,0.000027718972,0.00009663363,0.000035651006,0.0000022495628,0.000011716608,0.000001690673,0.00036322573],"genre_scores_gemma":[0.0016391353,0.99790764,0.0000845425,0.000048652168,0.000040039653,0.0000036736265,0.000020866668,3.2050238e-7,0.00025510034],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998246,0.000039469654,0.00003293309,0.000029929324,0.00006076775,0.000012385093],"domain_scores_gemma":[0.99983287,0.00007119579,0.000048033933,0.0000031422612,0.000034955327,0.000009810848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039197883,0.000552643,0.0012933372,0.0016608965,0.0001644984,0.0005485015,0.00045752348,0.0006460478,0.0032499707],"category_scores_gemma":[0.0006255034,0.00021099107,0.0006070255,0.002165044,0.00016968155,0.00040980199,0.00031988873,0.0005601499,0.0009659432],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019778172,0.000109020635,0.0029056037,0.03605257,0.0006679967,0.00039478426,0.00008878965,0.00031201277,0.0012001205,0.0008184345,0.012221452,0.9450314],"study_design_scores_gemma":[0.00013656421,0.00077133835,0.055317078,0.038034774,0.0029881024,0.008430327,0.00040272248,0.00046027717,0.0013476309,0.002862641,0.88917786,0.00007067676],"about_ca_topic_score_codex":0.0021659196,"about_ca_topic_score_gemma":0.0042620497,"teacher_disagreement_score":0.0032499707,"about_ca_system_score_codex":0.00029634533,"about_ca_system_score_gemma":0.0008029221,"threshold_uncertainty_score":0.010872245},"labels":[],"label_agreement":null},{"id":"W2138368669","doi":"10.2217/fon.15.251","title":"Current State of Biomarkers in Ovarian Cancer Prognosis","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Carboplatin; Paclitaxel; Tumor microenvironment; Disease; Drug resistance; Oncology; Chemotherapy; Cancer; Serous fluid; Internal medicine; Bioinformatics; Cisplatin; Biology","score_opus":0.07496433028108566,"score_gpt":0.43021415235169136,"score_spread":0.3552498220706057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138368669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014573283,0.9981773,0.00020367706,0.00063146744,0.00018871122,0.0000044010776,0.000033578668,0.0000081712815,0.0006070563],"genre_scores_gemma":[0.0024357485,0.99594826,0.00046837048,0.00034179946,0.0003284509,0.000011613808,0.000078800025,0.0000023078153,0.00038474926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994789,0.00014453397,0.000093570525,0.00007540849,0.00016801305,0.000039643914],"domain_scores_gemma":[0.9984968,0.0008128856,0.00020048539,0.000036313548,0.00040045223,0.000053153697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016732432,0.00077843975,0.0014627569,0.0023630732,0.00025533314,0.0013713607,0.000979054,0.0009540716,0.0025276502],"category_scores_gemma":[0.0034790158,0.00024647362,0.0006889763,0.00251738,0.00060115085,0.0014794926,0.0008370612,0.0015801121,0.001185408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006242992,0.000028609555,0.0011881305,0.0075125536,0.00009861372,0.0000986695,0.00005275574,0.00029753815,0.0004666713,0.0022660703,0.0191898,0.9687382],"study_design_scores_gemma":[0.000020151216,0.0001494995,0.0040912847,0.0118392315,0.0004015676,0.0015621914,0.00017013775,0.00042059968,0.0009408179,0.0062456704,0.9741061,0.00005277678],"about_ca_topic_score_codex":0.0016009538,"about_ca_topic_score_gemma":0.0018820345,"teacher_disagreement_score":0.0025276502,"about_ca_system_score_codex":0.00084036356,"about_ca_system_score_gemma":0.0012732933,"threshold_uncertainty_score":0.008849025},"labels":[],"label_agreement":null},{"id":"W2138828358","doi":"10.2217/fon.09.119","title":"Nimotuzumab in Pediatric Glioma","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Nimotuzumab; Medicine; Context (archaeology); Glioma; Monoclonal antibody; Epidermal growth factor receptor; In vivo; Oncology; Cancer research; Pharmacology; Internal medicine; Immunology; Receptor; Antibody; Biology","score_opus":0.03178295124147681,"score_gpt":0.3674432645124994,"score_spread":0.33566031327102264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138828358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003642937,0.99846715,0.00006523946,0.00009484603,0.00006265807,0.000004140717,0.0000070886185,0.0000047354592,0.00092976424],"genre_scores_gemma":[0.001746975,0.9970715,0.00018984459,0.00013093611,0.000075257514,0.0000059872964,0.00002042104,0.0000010145079,0.00075805595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999038,0.000019898538,0.00001522013,0.000016749009,0.000035407713,0.000008840741],"domain_scores_gemma":[0.9999403,0.000018651584,0.00001627326,0.0000016624165,0.00001550068,0.0000075724824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028173038,0.0005350538,0.0008960655,0.0013080151,0.00015366448,0.00042835542,0.00037709577,0.0005674831,0.0016008073],"category_scores_gemma":[0.00024806045,0.00014475343,0.0002830661,0.0014772936,0.00017084964,0.0005163001,0.00033339986,0.0006590475,0.0011518367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010462814,0.00007219082,0.00023603535,0.008819404,0.00006780058,0.0006726385,0.00005299419,0.0002815326,0.0028695778,0.0011511467,0.014474253,0.9711978],"study_design_scores_gemma":[0.00006379987,0.0002199642,0.0020849572,0.0028169707,0.00018022345,0.0068020457,0.00005583163,0.0001561831,0.001977605,0.0010812061,0.9845463,0.000014927952],"about_ca_topic_score_codex":0.0011556024,"about_ca_topic_score_gemma":0.0024910683,"teacher_disagreement_score":0.0016008073,"about_ca_system_score_codex":0.00058490684,"about_ca_system_score_gemma":0.0006910086,"threshold_uncertainty_score":0.005355239},"labels":[],"label_agreement":null},{"id":"W2146149726","doi":"10.2217/fon.11.27","title":"Uroporphyrinogen Decarboxylase: Optimizing Radiotherapy for Head and Neck Cancer","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Head and neck cancer; Radiation therapy; Head and neck; MEDLINE; Library science; Gerontology; Internal medicine; Surgery; Biology; Computer science","score_opus":0.02470930482241154,"score_gpt":0.35983239870967565,"score_spread":0.33512309388726413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146149726","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057498404,0.034562726,0.00010920889,0.0481476,0.9162128,0.00001787589,0.000040863175,0.00002103203,0.0008303667],"genre_scores_gemma":[0.0004964612,0.019619638,0.000115012954,0.024969023,0.95123863,0.000021333528,0.000020486455,0.000012403276,0.00350705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567574,0.0012566017,0.00087519357,0.00046667262,0.0014559467,0.00026977906],"domain_scores_gemma":[0.9841374,0.007508702,0.0013023664,0.00032293305,0.0050494955,0.0016790921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008762443,0.0036670608,0.0042107445,0.002570253,0.0020521532,0.004984468,0.003107358,0.01750056,0.005547302],"category_scores_gemma":[0.019579537,0.0012141285,0.0029074869,0.0017004189,0.0020759641,0.003149235,0.0014296904,0.018682389,0.0037258677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001307083,0.000021729214,0.000060853563,0.000780738,0.00006745319,0.00014358717,0.000012045519,0.000041917843,0.00007273417,0.00018363571,0.9853275,0.013157101],"study_design_scores_gemma":[0.00028556766,0.00014306659,0.0009064838,0.0013873434,0.00049080054,0.00073392,0.00007369622,0.00019103063,0.000250481,0.00091650157,0.9945762,0.00004480358],"about_ca_topic_score_codex":0.0028433653,"about_ca_topic_score_gemma":0.0073361075,"teacher_disagreement_score":0.01750056,"about_ca_system_score_codex":0.0038528333,"about_ca_system_score_gemma":0.0034854228,"threshold_uncertainty_score":0.046340823},"labels":[],"label_agreement":null},{"id":"W2150622576","doi":"10.2217/fon.11.68","title":"An Essential Role for Programmed Death-1 in the Control of Autoimmunity: Implications for the Future of Hematopoietic Stem Cell Transplantation","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Autoimmunity; Immune system; Haematopoiesis; Stem cell; Antigen; Receptor; Lymphocyte; Immunology; Chimeric antigen receptor; Biology; Transplantation; Medicine; T cell; Cancer research; Cell biology; Internal medicine","score_opus":0.00991838873223511,"score_gpt":0.27529923583842625,"score_spread":0.26538084710619114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150622576","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000113154245,0.026663566,0.00027541845,0.044122506,0.92772067,0.000013542576,0.000030247775,0.000040285144,0.0010206784],"genre_scores_gemma":[0.001413331,0.022020392,0.00023645646,0.024157865,0.9457363,0.000015355607,0.00001874175,0.000020212341,0.0063813752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983247,0.0003291938,0.0002634809,0.00022910509,0.000702988,0.00015046544],"domain_scores_gemma":[0.99270177,0.0035192415,0.00039734787,0.00015311275,0.0022408594,0.0009876537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057647023,0.002646654,0.0023505252,0.0013388507,0.001542791,0.0042243865,0.0025864434,0.010502447,0.0033736997],"category_scores_gemma":[0.008329798,0.00070676144,0.0016219867,0.0005238261,0.002113519,0.0033470718,0.0011959535,0.021842806,0.0019927097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018132206,0.000026326747,0.00005089482,0.0005707633,0.00004962466,0.0003631778,0.000031477663,0.0000661127,0.00039080193,0.0015068289,0.9786501,0.018112576],"study_design_scores_gemma":[0.00011463953,0.00007991193,0.00031491122,0.0003549378,0.00009675968,0.0006758926,0.000059520622,0.00024416696,0.00047904818,0.0023647507,0.9951816,0.00003387407],"about_ca_topic_score_codex":0.00089484703,"about_ca_topic_score_gemma":0.0020969242,"teacher_disagreement_score":0.010502447,"about_ca_system_score_codex":0.001845864,"about_ca_system_score_gemma":0.0018025254,"threshold_uncertainty_score":0.03048706},"labels":[],"label_agreement":null},{"id":"W2152890358","doi":"10.2217/fon.11.37","title":"Improving Oncology Outcomes Through Targeted Therapeutics Will Require Electronic Delivery Systems","year":2011,"lang":"en","type":"review","venue":"Future Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Delivery system; Medical physics; Internal medicine; Pharmacology","score_opus":0.13691078854025826,"score_gpt":0.4455667963993569,"score_spread":0.30865600785909864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152890358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081617956,0.98848766,0.0013140714,0.0030307053,0.00022471891,0.00004242505,0.00007696703,0.000031031606,0.0059761824],"genre_scores_gemma":[0.004975929,0.9898386,0.0027774754,0.00088996335,0.00019025816,0.00004965045,0.000056909437,0.000004963026,0.0012162653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924964,0.0002616964,0.00010459748,0.00008614824,0.00026389357,0.000034026943],"domain_scores_gemma":[0.99768984,0.0015023173,0.00031576576,0.00009421123,0.00035575058,0.000042163534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002134703,0.00047176538,0.001141139,0.001461817,0.00020849866,0.0012434312,0.0007132908,0.0008708316,0.005276056],"category_scores_gemma":[0.0033795792,0.00016729296,0.0006776988,0.001930848,0.00040593738,0.0017221179,0.00062831223,0.0012252207,0.002075017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019605737,0.00007156873,0.00024959844,0.007523874,0.000062181534,0.000057945028,0.00003955089,0.00024267146,0.00066301704,0.0033100024,0.009029126,0.97873086],"study_design_scores_gemma":[0.000036050496,0.0002812226,0.00240419,0.012371808,0.00022800615,0.0010017375,0.00028288577,0.00023370072,0.0018318923,0.0043902127,0.9769106,0.000027723403],"about_ca_topic_score_codex":0.0009354963,"about_ca_topic_score_gemma":0.0015920859,"teacher_disagreement_score":0.005276056,"about_ca_system_score_codex":0.00085521827,"about_ca_system_score_gemma":0.0013058337,"threshold_uncertainty_score":0.017650187},"labels":[],"label_agreement":null},{"id":"W2159471993","doi":"10.2217/14796694.2.6.765","title":"Erbb Receptors and Epithelial-Cadherin–Catenin Complex In Human Carcinomas","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cadherin; Medicine; Receptor; Catenin; ErbB; Cancer research; Signal transduction; Internal medicine; Biology; Cell biology; Cell; Wnt signaling pathway; Genetics","score_opus":0.1385490509996071,"score_gpt":0.46228533226736784,"score_spread":0.3237362812677608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159471993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011091844,0.99881893,0.000064791624,0.00010666698,0.000100955505,0.0000026745965,0.0000056165422,0.000005520377,0.0007839612],"genre_scores_gemma":[0.00060004677,0.9982187,0.00010607634,0.00009011283,0.00009679772,0.0000029243959,0.000014994291,6.715752e-7,0.0008695211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983895,0.000024107374,0.000020155667,0.00002748909,0.00007376329,0.000015511425],"domain_scores_gemma":[0.99987125,0.000044335593,0.000019370671,0.0000044725084,0.000046266272,0.00001420356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003924675,0.0007840191,0.0012337974,0.0021506238,0.00023982425,0.00063935196,0.0006916624,0.0009325564,0.0032260166],"category_scores_gemma":[0.0003521936,0.00026389997,0.0003266017,0.0022610936,0.00035162678,0.0010494275,0.00043725167,0.0011282606,0.0027032478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007897299,0.000084255174,0.0002656855,0.008208491,0.00006056005,0.0005267335,0.00006483633,0.00030955262,0.0028376323,0.0022841855,0.031051543,0.95422757],"study_design_scores_gemma":[0.000018841674,0.00008382271,0.0012951164,0.0016707061,0.00007639914,0.003554938,0.00005471959,0.00006423852,0.0006820993,0.0012236986,0.9912617,0.000013694111],"about_ca_topic_score_codex":0.0012552291,"about_ca_topic_score_gemma":0.0021383627,"teacher_disagreement_score":0.0032260166,"about_ca_system_score_codex":0.00070039165,"about_ca_system_score_gemma":0.00072476297,"threshold_uncertainty_score":0.010792077},"labels":[],"label_agreement":null},{"id":"W2162077153","doi":"10.2217/fon.15.153","title":"Rapid Access Palliative Radiation Therapy Programs: An Efficient Model of Care","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Multidisciplinary approach; Palliative care; Narrative review; Radiation therapy; Radiation oncology; Medical physics; Intensive care medicine; Nursing; Internal medicine","score_opus":0.1773303789361742,"score_gpt":0.46115102360392446,"score_spread":0.28382064466775025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162077153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047077597,0.98774415,0.0013619113,0.002941922,0.00029117864,0.00005154304,0.000046092508,0.000024047957,0.007068371],"genre_scores_gemma":[0.0041130064,0.99153155,0.0023902152,0.0009157166,0.00017862991,0.000046266425,0.000058245332,0.0000057850316,0.0007606534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931,0.00026043618,0.00009427545,0.000072918185,0.00021354869,0.00004882533],"domain_scores_gemma":[0.99927706,0.00039749453,0.00010935355,0.000023278515,0.00014581994,0.000046998477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013686729,0.00055597705,0.00068089104,0.0015076337,0.00036728673,0.0018776755,0.0011482637,0.0014840171,0.0033952293],"category_scores_gemma":[0.002192945,0.00018178,0.0007034631,0.0014119672,0.00067670364,0.0019964695,0.0013254711,0.001822541,0.0011431805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033628618,0.00010006147,0.0004556995,0.034072675,0.00013812566,0.0001609209,0.00031421863,0.0009398893,0.0005412921,0.03366527,0.027447833,0.90213037],"study_design_scores_gemma":[0.000013624584,0.000086365726,0.00094730564,0.016132334,0.00012343259,0.0011985246,0.00022174661,0.0002317471,0.00022789757,0.005115532,0.9756821,0.000019344136],"about_ca_topic_score_codex":0.0023016243,"about_ca_topic_score_gemma":0.003667043,"teacher_disagreement_score":0.0033952293,"about_ca_system_score_codex":0.0017218465,"about_ca_system_score_gemma":0.0032048877,"threshold_uncertainty_score":0.012492895},"labels":[],"label_agreement":null},{"id":"W2163739312","doi":"10.2217/fon.14.254","title":"The Role of Oncolytic Virus Immunotherapies to Subvert Cancer Immune Evasion","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Oncolytic virus; Immunotherapy; Cancer immunotherapy; Evasion (ethics); Medicine; Immune system; Virotherapy; Cancer; Cancer treatment; Cancer therapy; Immunology; Immunity; Cancer vaccine; Cancer research; Internal medicine","score_opus":0.029638523226770033,"score_gpt":0.39245854366549215,"score_spread":0.36282002043872214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163739312","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040074202,0.9973476,0.00039422725,0.0002507668,0.00014463872,0.000006295493,0.000014792921,0.000009217127,0.0014316696],"genre_scores_gemma":[0.0031277353,0.99535745,0.00039778138,0.0001878009,0.000078789715,0.000010708928,0.00002624222,0.0000022642332,0.0008111765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998939,0.00002269672,0.000011624278,0.000018099356,0.000039326864,0.000014327439],"domain_scores_gemma":[0.9998691,0.00006206669,0.000018630632,0.0000054456855,0.00003279443,0.000012012182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048832333,0.00048298435,0.0006933576,0.0014793568,0.00020402389,0.0008003066,0.00049572776,0.00081560994,0.0017818842],"category_scores_gemma":[0.00035784752,0.00018690192,0.00032242294,0.0009564415,0.00038477176,0.0009163146,0.00046083867,0.0013686722,0.0009393915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007416159,0.0001135227,0.00020417255,0.012240143,0.00008599458,0.00027847133,0.00008520502,0.0008673921,0.012894373,0.018047497,0.01755232,0.93755674],"study_design_scores_gemma":[0.000012918285,0.000116492425,0.0004275758,0.0016650399,0.00005618741,0.0010105019,0.000043196847,0.00020781583,0.0037493801,0.002888326,0.98980486,0.000017665709],"about_ca_topic_score_codex":0.0005316749,"about_ca_topic_score_gemma":0.00086799386,"teacher_disagreement_score":0.0017818842,"about_ca_system_score_codex":0.00055684015,"about_ca_system_score_gemma":0.0006185106,"threshold_uncertainty_score":0.005961001},"labels":[],"label_agreement":null},{"id":"W2163922475","doi":"10.2217/14796694.5.1.85","title":"Subcellular Dynamics of The VHL Tumor Suppressor: On The Move for HIF Degradation","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Suppressor; Medicine; Dynamics (music); Cancer research; Degradation (telecommunications); Cell biology; Internal medicine; Cancer; Biology; Computer science","score_opus":0.018503948500397605,"score_gpt":0.2979376063545767,"score_spread":0.2794336578541791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163922475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028091558,0.9971008,0.00028327573,0.0005938113,0.00024276462,0.0000024100314,0.000011504691,0.000013585037,0.0014709632],"genre_scores_gemma":[0.0012933598,0.99604946,0.0002655093,0.00028657084,0.00019853096,0.0000043555333,0.000020541314,0.0000024987262,0.0018791364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989414,0.00001998804,0.000011659366,0.000017880975,0.000045036395,0.00001126923],"domain_scores_gemma":[0.9998555,0.00004548927,0.000022577438,0.000006896107,0.00005032203,0.00001924879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039206643,0.0006658959,0.0011201948,0.0010683953,0.00023808409,0.00096730434,0.0007066308,0.0012383525,0.002469875],"category_scores_gemma":[0.00039223224,0.00027042296,0.00027530536,0.001179497,0.00054048223,0.0016376293,0.0004740014,0.0013975605,0.0037053495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012151195,0.000051245286,0.00018107888,0.005450755,0.000050157825,0.0004526918,0.000057071557,0.00055244326,0.008017695,0.006520254,0.03850349,0.9400416],"study_design_scores_gemma":[0.00001598735,0.000047176985,0.00044194996,0.00056771096,0.000031210733,0.0014346475,0.00004054843,0.00010017445,0.0014409707,0.002394533,0.99347335,0.000011653549],"about_ca_topic_score_codex":0.0007764062,"about_ca_topic_score_gemma":0.0012660325,"teacher_disagreement_score":0.002469875,"about_ca_system_score_codex":0.0009767499,"about_ca_system_score_gemma":0.00068923214,"threshold_uncertainty_score":0.008262515},"labels":[],"label_agreement":null},{"id":"W2166859022","doi":"10.2217/fon.09.157","title":"Potential Use of Ultrasound for the Detection of Cell Changes in Cancer Treatment","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto Metropolitan University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Ultrasound; Oncology; Cancer; Internal medicine; Radiology","score_opus":0.03504508620806288,"score_gpt":0.3067117270932862,"score_spread":0.2716666408852233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166859022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003941701,0.99591947,0.0008833918,0.00025999476,0.00018500024,0.0000089401465,0.000011472951,0.000009345643,0.0023281456],"genre_scores_gemma":[0.0023275379,0.99436605,0.00095770747,0.00021384469,0.00019115134,0.000012041912,0.000026414618,0.0000027951608,0.0019023542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977094,0.000037418104,0.000020500655,0.000044152122,0.000105051215,0.000022026086],"domain_scores_gemma":[0.9995245,0.00027041772,0.000053501084,0.000012318035,0.000115110495,0.000024247127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084844127,0.00095760135,0.0012082648,0.002430603,0.00033920846,0.00095340953,0.0009572575,0.0016347854,0.0031585505],"category_scores_gemma":[0.00071773626,0.0004388418,0.0005283157,0.0020371722,0.0008137705,0.0015497406,0.00070947094,0.0015657792,0.0023312855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084671956,0.00015189745,0.00030041556,0.008461965,0.0000662646,0.00043965393,0.00011175761,0.0007306892,0.019772831,0.004633371,0.010888614,0.95435786],"study_design_scores_gemma":[0.00003081955,0.0002448509,0.0013997155,0.0021001953,0.00011497501,0.0034055137,0.00015767972,0.0005635694,0.013414337,0.0033587422,0.97514784,0.000061783496],"about_ca_topic_score_codex":0.0013276499,"about_ca_topic_score_gemma":0.002574441,"teacher_disagreement_score":0.0031585505,"about_ca_system_score_codex":0.00060794526,"about_ca_system_score_gemma":0.00077189464,"threshold_uncertainty_score":0.010566354},"labels":[],"label_agreement":null},{"id":"W2167775617","doi":"10.1517/14796694.1.2.149","title":"Zoledronic Acid: Past, Present and Future Roles in Cancer Treatment","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Zoledronic acid; Medicine; Breast cancer; Prostate cancer; Bone resorption; Bone metastasis; Osteoclast; Oncology; Multiple myeloma; Bone Density Conservation Agents; Cancer; Internal medicine; Bone disease; Clinical trial; Osteoporosis; Bone density","score_opus":0.044508007308810625,"score_gpt":0.42026815001778395,"score_spread":0.37576014270897334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167775617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059874368,0.99910283,0.00004458537,0.00020723854,0.00009357824,0.0000016417134,0.000004849567,0.0000033964382,0.00048191615],"genre_scores_gemma":[0.00052231696,0.9987381,0.00011817729,0.00013500557,0.00011790093,0.0000023159403,0.00000848321,5.2244974e-7,0.0003572549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998091,0.00003600675,0.00003181745,0.00003102866,0.00007614746,0.00001590726],"domain_scores_gemma":[0.99977666,0.00008430443,0.00004274366,0.000007005114,0.000058506565,0.000030780706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005687629,0.0006677875,0.0014395117,0.0022324848,0.00032508388,0.0011690714,0.000817904,0.0011335938,0.0038570305],"category_scores_gemma":[0.0005580431,0.00024354264,0.0004167294,0.0028329056,0.0006285401,0.0016897718,0.0005810241,0.001374163,0.0023512421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090969064,0.000051058763,0.00015040189,0.009062743,0.000052788877,0.0002403319,0.000064544816,0.0003386454,0.0009975408,0.003445384,0.021658445,0.9638472],"study_design_scores_gemma":[0.000037469297,0.0001075429,0.00077393686,0.0031786563,0.000079111196,0.001570319,0.000085027525,0.000105120824,0.00022124783,0.002397215,0.9914294,0.000015098405],"about_ca_topic_score_codex":0.0016895046,"about_ca_topic_score_gemma":0.0039501674,"teacher_disagreement_score":0.0038570305,"about_ca_system_score_codex":0.00087905955,"about_ca_system_score_gemma":0.001271292,"threshold_uncertainty_score":0.012903035},"labels":[],"label_agreement":null},{"id":"W2180994109","doi":"10.2217/fon.15.122","title":"The use of Myocardial Strain and Newer Echocardiography Imaging Techniques in Cancer Patients","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Radiology; Internal medicine; Strain (injury); Cardiology","score_opus":0.031183008621275602,"score_gpt":0.3107000548060012,"score_spread":0.2795170461847256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180994109","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73440444,0.2276874,0.0075661205,0.009304695,0.0006889428,0.00005733795,0.00025695004,0.00006468153,0.019969426],"genre_scores_gemma":[0.9273612,0.061806533,0.0063004913,0.0015689364,0.0010007087,0.000026913207,0.0001289649,0.00001764959,0.0017885388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968135,0.00013818352,0.000033569442,0.00003972818,0.00008259999,0.000024606368],"domain_scores_gemma":[0.9985398,0.0005018514,0.0005707547,0.000059123275,0.00022655191,0.00010188323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008643162,0.00021153451,0.00036318338,0.00047833557,0.00016568342,0.0007828011,0.00019903162,0.00038779556,0.0010597137],"category_scores_gemma":[0.002414711,0.000104914085,0.00026566559,0.0005681469,0.00021401444,0.0006449469,0.00023957377,0.00087154465,0.00012272091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012321215,0.00031376485,0.43778443,0.000581158,0.00024126505,0.0010826626,0.00023350226,0.0009187945,0.034611326,0.0011013001,0.001761346,0.5201383],"study_design_scores_gemma":[0.00010513876,0.0038614075,0.9175301,0.0007078042,0.00060136226,0.0071902764,0.000703711,0.0030292324,0.031008849,0.0016287471,0.033566736,0.00006653334],"about_ca_topic_score_codex":0.00056488573,"about_ca_topic_score_gemma":0.0019444366,"teacher_disagreement_score":0.0010597137,"about_ca_system_score_codex":0.00029867602,"about_ca_system_score_gemma":0.0003332778,"threshold_uncertainty_score":0.004570961},"labels":[],"label_agreement":null},{"id":"W2265842034","doi":"10.2217/fon.15.339","title":"Addressing Future Challenges for Cancer Services: Part I","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Healthcare Systems and Challenges","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Officer; Cancer survivorship; Family medicine; Public health; Survivorship curve; Management; Cancer; Nursing; Political science; Law","score_opus":0.27899764140582284,"score_gpt":0.5165407456196554,"score_spread":0.2375431042138325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265842034","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004916263,0.019382594,0.00038274936,0.9328447,0.026457693,0.00015567224,0.000058991467,0.000087119995,0.02013883],"genre_scores_gemma":[0.027855117,0.11280122,0.0043506175,0.70585346,0.065037705,0.001514145,0.0006934348,0.00033247133,0.081561945],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99058086,0.0031540117,0.00058731367,0.0005384207,0.002832248,0.002307016],"domain_scores_gemma":[0.96623933,0.0042964383,0.0015478134,0.00079742755,0.0056779142,0.021441054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010089482,0.00093486946,0.0007952156,0.001551398,0.0067949444,0.0145193655,0.0027777585,0.010732565,0.040444937],"category_scores_gemma":[0.029836245,0.0006783278,0.00085457764,0.002451304,0.004484907,0.009659108,0.010888926,0.013592318,0.010271714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000555278,0.000027859196,0.000373801,0.00026473822,0.0000066846897,0.00008597341,0.00052784145,0.000058461832,0.000053285057,0.0033948142,0.95975435,0.03544663],"study_design_scores_gemma":[0.00000708776,0.00003339304,0.0017718092,0.0013931887,0.00000434239,0.00029988092,0.0028201593,0.000064214284,0.000024232611,0.0041520484,0.98940814,0.000021632379],"about_ca_topic_score_codex":0.019021986,"about_ca_topic_score_gemma":0.0326879,"teacher_disagreement_score":0.040444937,"about_ca_system_score_codex":0.015800644,"about_ca_system_score_gemma":0.04869204,"threshold_uncertainty_score":0.13530183},"labels":[],"label_agreement":null},{"id":"W2339030197","doi":"10.2217/fon-2016-0130","title":"ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lenalidomide; Medicine; CHOP; Diffuse large B-cell lymphoma; Internal medicine; Clinical endpoint; Lymphoma; Oncology; Placebo; Pathology; Clinical trial; Multiple myeloma","score_opus":0.024355709995883844,"score_gpt":0.28347919032453645,"score_spread":0.2591234803286526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339030197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624131,0.020840691,0.0013240456,0.0014782513,0.001463921,0.0028987324,0.0028951894,0.00047139666,0.006214578],"genre_scores_gemma":[0.9855956,0.0035290378,0.0025891932,0.0010829165,0.00048947026,0.001945387,0.0015582254,0.000052880747,0.0031572925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987412,0.00071467087,0.00010994138,0.00020400835,0.000103002974,0.00012729545],"domain_scores_gemma":[0.9991472,0.00026887713,0.00024060355,0.00008394474,0.00004795377,0.00021144137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021228106,0.0011815818,0.0029395795,0.00057371345,0.00024519642,0.0011586292,0.0011398428,0.0013850294,0.007148249],"category_scores_gemma":[0.0023446688,0.00047315808,0.0014952124,0.00039614915,0.000875504,0.0014497711,0.000611354,0.0026505573,0.0010184825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96273375,0.005127855,0.0001781786,0.0005327622,0.0007463896,0.000024315126,0.00001993772,0.00045029775,0.0038745736,0.00012828705,0.00075848884,0.02542521],"study_design_scores_gemma":[0.7479,0.24073544,0.0027449725,0.0001327979,0.0012933566,0.00009049536,0.000046441874,0.0014296677,0.002509303,0.0005971168,0.0024780827,0.00004225022],"about_ca_topic_score_codex":0.00039689534,"about_ca_topic_score_gemma":0.0011119144,"teacher_disagreement_score":0.007148249,"about_ca_system_score_codex":0.00075950514,"about_ca_system_score_gemma":0.0007379442,"threshold_uncertainty_score":0.023913205},"labels":[],"label_agreement":null},{"id":"W2345789793","doi":"10.2217/fon-2016-0089","title":"The Continuing Evolution of Technology in Cancer Care","year":2016,"lang":"en","type":"review","venue":"Future Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; MEDLINE; Cancer; Oncology; Family medicine; Library science; Internal medicine; Computer science","score_opus":0.0127996165468772,"score_gpt":0.4311993263114619,"score_spread":0.4183997097645847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345789793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066791516,0.99636096,0.00011757993,0.0017454986,0.00055733195,0.0000022906518,0.0000110308065,0.000005349172,0.0011331448],"genre_scores_gemma":[0.0007235018,0.99667215,0.00022761847,0.0011378195,0.00074165786,0.000003575682,0.000015582618,0.0000024142785,0.00047566657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905676,0.00028167528,0.00011500857,0.0001017726,0.00036035714,0.000084420586],"domain_scores_gemma":[0.99658656,0.0022459803,0.0003368678,0.00006429513,0.0005579478,0.00020836909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022687872,0.0008161717,0.0013680969,0.0026287946,0.00049761625,0.0026776309,0.0010498196,0.0022642498,0.007476946],"category_scores_gemma":[0.003970761,0.00026165042,0.0006489813,0.0047496585,0.001524721,0.0044423738,0.0017542971,0.0031915468,0.0017469333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040017094,0.00003250436,0.0003198494,0.016988257,0.000058135465,0.00016603542,0.00017460604,0.00029900545,0.00045956834,0.013753549,0.05044837,0.9172602],"study_design_scores_gemma":[0.000007321596,0.000026918715,0.0005767888,0.005716454,0.000047714948,0.000464032,0.0001740067,0.000057530302,0.00007843941,0.004477846,0.98836017,0.000012770711],"about_ca_topic_score_codex":0.002179183,"about_ca_topic_score_gemma":0.006093336,"teacher_disagreement_score":0.007476946,"about_ca_system_score_codex":0.0021969122,"about_ca_system_score_gemma":0.0045565874,"threshold_uncertainty_score":0.02501291},"labels":[],"label_agreement":null},{"id":"W2564757287","doi":"10.2217/fon-2016-0444","title":"Phase II Trial of Capecitabine Plus Erlotinib Versus Capecitabine Alone in Patients with Advanced Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital; Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario; Western University","funders":"","keywords":"Capecitabine; KRAS; Medicine; Erlotinib; Colorectal cancer; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.018529053030290565,"score_gpt":0.3391485561134127,"score_spread":0.32061950308312215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564757287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98425335,0.00458673,0.00060560723,0.0013778615,0.00066863437,0.0035100586,0.001210326,0.00012185937,0.0036655774],"genre_scores_gemma":[0.9821016,0.0029364135,0.0015479864,0.0014054483,0.0005676843,0.0033242193,0.0020016714,0.000027344058,0.0060876724],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995472,0.00023595226,0.000021897493,0.000079393474,0.0000311502,0.00008444752],"domain_scores_gemma":[0.9993061,0.00015614378,0.00014296168,0.00005043924,0.000037250848,0.00030710857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014758215,0.0020352595,0.0023942501,0.00044160555,0.0003731101,0.0011148406,0.00083021715,0.0016303267,0.0068517686],"category_scores_gemma":[0.0013440377,0.0006491696,0.001538947,0.0004948046,0.00085819914,0.0010620995,0.00034947542,0.003491397,0.0011045424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9490215,0.016639618,0.0008527864,0.00052482187,0.0006936524,0.00008004092,0.00006948527,0.0008394707,0.004444219,0.000108329965,0.0016311632,0.025095],"study_design_scores_gemma":[0.8736259,0.1227789,0.0017075993,0.000021758004,0.00018633988,0.00005030421,0.000014163929,0.00042690415,0.0004536829,0.00008341467,0.0006407679,0.000010397794],"about_ca_topic_score_codex":0.00095643883,"about_ca_topic_score_gemma":0.003061492,"teacher_disagreement_score":0.0068517686,"about_ca_system_score_codex":0.00090969977,"about_ca_system_score_gemma":0.0012068052,"threshold_uncertainty_score":0.022921443},"labels":[],"label_agreement":null},{"id":"W2585002192","doi":"10.2217/fon-2016-0479","title":"A Multinational Report of Technical Factors on Stereotactic Body Radiotherapy for Oligometastases","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Elekta","keywords":"Medicine; Multinational corporation; Medical physics; Stereotactic radiotherapy; Radiation therapy; Radiosurgery; Oncology; Radiology","score_opus":0.03774357954866775,"score_gpt":0.3915182214295643,"score_spread":0.3537746418808965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585002192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97356397,0.0025426592,0.0015539599,0.0014793547,0.00011391757,0.00023184769,0.011279975,0.0000732164,0.009161075],"genre_scores_gemma":[0.9863697,0.0016535139,0.0016660035,0.0005901337,0.00008614548,0.00025715592,0.008515315,0.000034759018,0.00082725537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99507684,0.0013633948,0.0010704051,0.00043898163,0.0016380472,0.00041228265],"domain_scores_gemma":[0.96635723,0.009208205,0.014639672,0.00173012,0.0069489647,0.0011157809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071653496,0.00037052203,0.0003222641,0.0022302414,0.00048312757,0.0006590956,0.00047408632,0.00034864864,0.0013467118],"category_scores_gemma":[0.013705358,0.00016201042,0.00050250266,0.0051388917,0.00030177762,0.00037305587,0.00096745504,0.000380693,0.00031232924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049555103,0.00002515861,0.988653,0.0000854264,0.00004123724,0.000052096053,0.00020639514,0.00009772092,0.00019530498,0.000037099348,0.0015204306,0.0090364795],"study_design_scores_gemma":[0.0000038632643,0.000048768914,0.9956434,0.000051015544,0.00005704671,0.00016107567,0.00057024084,0.000101090955,0.00027152803,0.000012731658,0.0030737217,0.000005562978],"about_ca_topic_score_codex":0.018071856,"about_ca_topic_score_gemma":0.021056712,"teacher_disagreement_score":0.018071856,"about_ca_system_score_codex":0.0012465554,"about_ca_system_score_gemma":0.0019720842,"threshold_uncertainty_score":0.037894428},"labels":[],"label_agreement":null},{"id":"W2605759430","doi":"10.2217/fon-2017-0062","title":"ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Eribulin; Metastatic breast cancer; Observational study; Internal medicine; Quality of life (healthcare); Oncology; Breast cancer; Prospective cohort study; Cancer; Nursing","score_opus":0.05307339089581799,"score_gpt":0.408731362008138,"score_spread":0.35565797111232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605759430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990233,0.00052818045,0.000041190568,0.000018181454,0.000003661314,0.00002150858,0.00022099963,0.0000012437644,0.00014159037],"genre_scores_gemma":[0.9989172,0.00024267215,0.00010953989,0.000039259947,0.000020294481,0.00003960539,0.0005429409,0.0000010587344,0.00008750297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992963,0.00034116735,0.00006943343,0.00012113586,0.00010524325,0.00006670244],"domain_scores_gemma":[0.99845266,0.0002915946,0.0007921235,0.00010398534,0.0001002064,0.00025938917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012805564,0.00033734704,0.0006583805,0.0005087439,0.00040864124,0.00051125744,0.0002411562,0.00046084676,0.0008779421],"category_scores_gemma":[0.0018351863,0.000223302,0.0005067354,0.00097273575,0.00026553267,0.00038770892,0.00032790363,0.0005513416,0.00017201563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003436872,0.0004835298,0.99310356,0.000040851013,0.00017974549,0.00011862167,0.00007010235,0.000054196946,0.00043685196,0.000014866243,0.00010778514,0.0019531108],"study_design_scores_gemma":[0.00034348635,0.003026947,0.994948,0.000012505299,0.00019205209,0.00053434796,0.00014053215,0.00020082519,0.0001551885,0.000013529282,0.0004248531,0.000007627333],"about_ca_topic_score_codex":0.0011545956,"about_ca_topic_score_gemma":0.0011538079,"teacher_disagreement_score":0.0012805564,"about_ca_system_score_codex":0.00027001614,"about_ca_system_score_gemma":0.00028893325,"threshold_uncertainty_score":0.0067723393},"labels":[],"label_agreement":null},{"id":"W2609848358","doi":"10.2217/fon-2016-0556","title":"Current status of ramucirumab in gastroesophageal adenocarcinoma","year":2017,"lang":"en","type":"review","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ramucirumab; Medicine; Paclitaxel; Internal medicine; Oncology; Clinical trial; Adenocarcinoma; Gastroesophageal Junction; Chemotherapy; Cancer","score_opus":0.11055681038413291,"score_gpt":0.44322009009196317,"score_spread":0.3326632797078303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609848358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070700255,0.9995003,0.000017305232,0.000110938854,0.00003734595,0.000001959223,0.00000939699,0.0000026724424,0.00024936712],"genre_scores_gemma":[0.00074376323,0.9988273,0.00006121408,0.0001378727,0.000062807594,0.000004004753,0.000020164232,0.0000010333517,0.00014177267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972945,0.0000643308,0.000068476125,0.00004226448,0.000076064236,0.000019404308],"domain_scores_gemma":[0.9994987,0.0002768292,0.00010050289,0.000010205749,0.00008532986,0.000028311344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009805799,0.0005781088,0.0016533841,0.0018717884,0.00020741129,0.0012184903,0.0010507691,0.0009881274,0.0039677597],"category_scores_gemma":[0.0012947134,0.00028645343,0.00094809185,0.0014980957,0.0003032757,0.0011267939,0.00061198475,0.0013024551,0.0011872206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012155849,0.000039566916,0.00017284772,0.036727097,0.00020759755,0.00010731694,0.00005768251,0.00021517709,0.0004182901,0.0011240446,0.014760021,0.9460488],"study_design_scores_gemma":[0.00007989038,0.00022067867,0.0013011199,0.021199513,0.00089872995,0.0013255856,0.00009763035,0.00017029697,0.0004104895,0.0017266554,0.9725419,0.000027370652],"about_ca_topic_score_codex":0.0010071257,"about_ca_topic_score_gemma":0.0022466262,"teacher_disagreement_score":0.0039677597,"about_ca_system_score_codex":0.00045155655,"about_ca_system_score_gemma":0.000964356,"threshold_uncertainty_score":0.013273478},"labels":[],"label_agreement":null},{"id":"W2614021025","doi":"10.2217/fon-2017-0031","title":"Venetoclax for the treatment of patients with chronic lymphocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Venetoclax; Tumor lysis syndrome; Medicine; Chronic lymphocytic leukemia; Neutropenia; Oncology; Rituximab; Internal medicine; Clinical trial; Lymphoma; Leukemia; Immunology; Chemotherapy","score_opus":0.021146067308554253,"score_gpt":0.33432476656353816,"score_spread":0.3131786992549839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614021025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34983426,0.55922925,0.005513599,0.017246753,0.0017853798,0.0008817304,0.001226256,0.0008150911,0.06346769],"genre_scores_gemma":[0.88988405,0.08139632,0.0040366356,0.00699791,0.001820461,0.0003455407,0.0012315953,0.00004638325,0.014240987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990094,0.00003320358,0.00000685694,0.000012193593,0.000020056343,0.000026769974],"domain_scores_gemma":[0.999803,0.000052093852,0.000043113123,0.00001056326,0.000018973185,0.000072205505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002653932,0.00019913698,0.00034097146,0.00025961528,0.00036703504,0.0002623126,0.00015491765,0.00035337743,0.0044617373],"category_scores_gemma":[0.00052136614,0.000047909176,0.0002933362,0.000327653,0.0001813081,0.00021408014,0.00021477591,0.0009353292,0.0008769404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004221962,0.00046381628,0.012937142,0.0010618932,0.00012732459,0.002050952,0.0001994243,0.0003119591,0.020042302,0.0010772184,0.044823084,0.912683],"study_design_scores_gemma":[0.007361271,0.0141534,0.10933349,0.0010149871,0.00051392417,0.023344599,0.00021929023,0.0011373368,0.011215951,0.0021899932,0.8294548,0.0000610436],"about_ca_topic_score_codex":0.0007847721,"about_ca_topic_score_gemma":0.002716596,"teacher_disagreement_score":0.0044617373,"about_ca_system_score_codex":0.00034692767,"about_ca_system_score_gemma":0.00047976186,"threshold_uncertainty_score":0.014926016},"labels":[],"label_agreement":null},{"id":"W2770267656","doi":"10.2217/fon-2017-0427","title":"Utility of Molecular Tools for Extended Adjuvant Endocrine Therapy Decisions in Early Breast Cancer","year":2017,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Adjuvant; Endocrine system; Internal medicine; Cancer; Adjuvant therapy; Gynecology; Hormone","score_opus":0.018374104836761888,"score_gpt":0.3480047210297057,"score_spread":0.3296306161929438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770267656","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008483204,0.02081151,0.00039877873,0.066559985,0.91065174,0.00002157149,0.00006019487,0.000038767965,0.0013725385],"genre_scores_gemma":[0.0007693633,0.01176499,0.0003232555,0.021232473,0.96162,0.000025343075,0.000023040433,0.000022959252,0.0042186026],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951142,0.0015864986,0.00067669817,0.00050064514,0.0018452473,0.00027671992],"domain_scores_gemma":[0.96573013,0.021993399,0.0012756635,0.0007637979,0.008328067,0.0019089149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012993685,0.002610963,0.0023092423,0.0022906163,0.0014165059,0.005459145,0.0026350603,0.010258487,0.004421952],"category_scores_gemma":[0.033224925,0.0008830375,0.001974943,0.00090982846,0.0031711466,0.0039039874,0.0016837296,0.024519883,0.002984287],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012817037,0.000026020472,0.000101359,0.0004262956,0.0000484198,0.00022097457,0.000018656388,0.00005870278,0.00012281096,0.0012449834,0.9756084,0.02199525],"study_design_scores_gemma":[0.000117357435,0.00006177423,0.00046343665,0.00054046407,0.00013828995,0.0004530836,0.000047936104,0.0002709223,0.00032439042,0.002796147,0.9947562,0.000030016192],"about_ca_topic_score_codex":0.0011179753,"about_ca_topic_score_gemma":0.0024108307,"teacher_disagreement_score":0.012993685,"about_ca_system_score_codex":0.0024474522,"about_ca_system_score_gemma":0.003013657,"threshold_uncertainty_score":0.06871796},"labels":[],"label_agreement":null},{"id":"W2795150236","doi":"10.2217/fon-2018-0121","title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Celgene; Sanofi; Genentech; Ariad Pharmaceuticals; Amgen","keywords":"Venetoclax; Medicine; Clinical trial; Refractory (planetary science); Oncology; Internal medicine; Drug development; Chronic lymphocytic leukemia; Chemotherapy; Cancer; Drug; Leukemia; Pharmacology","score_opus":0.061213522298303284,"score_gpt":0.3801271580229051,"score_spread":0.3189136357246018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795150236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91459405,0.005193626,0.012865072,0.00221817,0.00073166564,0.052734897,0.0031638416,0.00021144943,0.008287278],"genre_scores_gemma":[0.8583454,0.007488488,0.05101257,0.0030359167,0.00050726644,0.0684733,0.0022571734,0.00009792967,0.008781956],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99912745,0.00049086695,0.000048616268,0.00013784156,0.00006843633,0.0001268014],"domain_scores_gemma":[0.9991386,0.000156318,0.00017134265,0.000115777686,0.00011291055,0.00030497657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032426408,0.0008893522,0.0012594062,0.00036067909,0.00044385184,0.0011080708,0.0005893068,0.0010317827,0.0059984247],"category_scores_gemma":[0.0016828785,0.00041607086,0.0011629509,0.00043264116,0.00062063645,0.0008368762,0.00044836325,0.002762962,0.00082182896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45424157,0.103944615,0.010875684,0.0032357282,0.0020572944,0.0008259684,0.0009983063,0.007787378,0.12002603,0.0075093084,0.015046328,0.27345172],"study_design_scores_gemma":[0.3559322,0.5670363,0.006833122,0.00022618783,0.0016234335,0.00075925235,0.00015946584,0.0043382775,0.015633646,0.0018429592,0.045549564,0.00006563222],"about_ca_topic_score_codex":0.00052780233,"about_ca_topic_score_gemma":0.002086293,"teacher_disagreement_score":0.0059984247,"about_ca_system_score_codex":0.0007372733,"about_ca_system_score_gemma":0.0038611786,"threshold_uncertainty_score":0.020066738},"labels":[],"label_agreement":null},{"id":"W2810071268","doi":"10.2217/fon-2018-0133","title":"Novel Multidisciplinary Approaches in the Management of Metastatic Epidural Spinal Cord Compression","year":2018,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Spinal cord compression; Multidisciplinary approach; Spinal cord","score_opus":0.08147662196166545,"score_gpt":0.3886051679304905,"score_spread":0.30712854596882505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810071268","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012333471,0.053816643,0.00035789039,0.05745558,0.8862195,0.000019312545,0.000026608725,0.000040548934,0.0019406005],"genre_scores_gemma":[0.000571036,0.02138446,0.00017214047,0.013697666,0.96229285,0.000010021229,0.0000108798295,0.000010445344,0.001850597],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964665,0.0007998616,0.00061934016,0.0003725453,0.0014923543,0.00024941456],"domain_scores_gemma":[0.9814161,0.010761685,0.0010717985,0.00028613137,0.0047303773,0.0017339085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054162988,0.0026538253,0.003216489,0.0027929023,0.0017143037,0.0047234953,0.0033491596,0.015100849,0.0043576355],"category_scores_gemma":[0.021478668,0.00095091836,0.0022043202,0.001178282,0.0024233484,0.0043356908,0.0014648777,0.023433901,0.0029464848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011118414,0.000046414883,0.00010430252,0.0011966322,0.000075456,0.00085577735,0.00004714033,0.00021436844,0.00015978835,0.0013461258,0.9542155,0.04162739],"study_design_scores_gemma":[0.00019379747,0.00012536322,0.0005757537,0.0021676703,0.00019935958,0.0029288204,0.000093126146,0.0005526916,0.00022166733,0.0022341996,0.99065,0.000057539328],"about_ca_topic_score_codex":0.001390948,"about_ca_topic_score_gemma":0.004479938,"teacher_disagreement_score":0.015100849,"about_ca_system_score_codex":0.0031529374,"about_ca_system_score_gemma":0.0023957926,"threshold_uncertainty_score":0.028644502},"labels":[],"label_agreement":null},{"id":"W2811498020","doi":"10.2217/fon-2017-0670","title":"Clinical Features and Psychological Aspects of the Decision-Making Process in Stage I Testicular Germ Cell Tumors","year":2018,"lang":"en","type":"review","venue":"Future Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Orchiectomy; Stage (stratigraphy); Multidisciplinary approach; Clinical decision making; Intensive care medicine; Clinical trial; Pathology; Surgery; Chemotherapy","score_opus":0.052891945787794444,"score_gpt":0.46689257135663637,"score_spread":0.41400062556884193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811498020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006851647,0.99789536,0.000076498,0.00042058955,0.00009510257,0.000005299991,0.000014946167,0.0000020552775,0.0008049335],"genre_scores_gemma":[0.008650077,0.99036485,0.00019997828,0.00029218628,0.00018566097,0.0000122619,0.000030463849,0.0000011815641,0.00026331306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964094,0.00016643568,0.00005281892,0.000038662834,0.00007318942,0.000027979406],"domain_scores_gemma":[0.9992742,0.00048463786,0.00011515533,0.000008795268,0.000091516384,0.000025685833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005632768,0.0004924029,0.0006841342,0.0011964366,0.00034410378,0.0010313763,0.000495827,0.0007918012,0.0015318809],"category_scores_gemma":[0.0022217077,0.00014359,0.0005554514,0.0011733068,0.00049292156,0.00091013283,0.0005186818,0.0010024565,0.00027291023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011426448,0.00008553518,0.0032979113,0.03356875,0.00030457453,0.00068608957,0.000986542,0.00036592718,0.0002823629,0.0035165693,0.015555146,0.9412364],"study_design_scores_gemma":[0.00005950565,0.00031885563,0.042360023,0.08393509,0.0015087299,0.017459244,0.0033233282,0.000510215,0.0005850436,0.008686423,0.84112984,0.00012360704],"about_ca_topic_score_codex":0.0024401555,"about_ca_topic_score_gemma":0.004666841,"teacher_disagreement_score":0.0024401555,"about_ca_system_score_codex":0.00067520165,"about_ca_system_score_gemma":0.0012259801,"threshold_uncertainty_score":0.0051246285},"labels":[],"label_agreement":null},{"id":"W2896248377","doi":"10.2217/fon-2018-0711","title":"Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Afatinib; Medicine; T790M; Observational study; Internal medicine; Lung cancer; Oncology; Clinical trial; Chemotherapy; Retrospective cohort study; Cancer; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.024571066342871796,"score_gpt":0.35720369986363815,"score_spread":0.33263263352076633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896248377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989421,0.00038294485,0.0000711131,0.00004425736,0.0000082907445,0.00003268251,0.00033141338,0.0000021148687,0.00018510535],"genre_scores_gemma":[0.9988225,0.00018231943,0.00011491683,0.00007837918,0.00002993011,0.000040609022,0.0006698684,0.0000016180958,0.00005985871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998546,0.0005196744,0.00020785934,0.00040376076,0.00017383172,0.00014896333],"domain_scores_gemma":[0.9956334,0.00058678025,0.0029862474,0.00021519196,0.00016192779,0.00041652806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012628188,0.00029412366,0.00077578827,0.00027668104,0.00044144076,0.00063768943,0.00045559308,0.0006039002,0.0010431211],"category_scores_gemma":[0.0030712003,0.00033421867,0.0012680672,0.0007372824,0.0003743744,0.000648835,0.00041322192,0.0008573834,0.00020469204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008949026,0.00075384777,0.9842307,0.00010584145,0.0007968577,0.00013070185,0.00008802415,0.00015311723,0.00058078853,0.000024856592,0.000338182,0.0038481646],"study_design_scores_gemma":[0.002551131,0.00859578,0.98406386,0.000049612052,0.00080350303,0.0011016814,0.00031850688,0.00096625177,0.00040139668,0.00008568042,0.0010377407,0.000024964618],"about_ca_topic_score_codex":0.0024103618,"about_ca_topic_score_gemma":0.003456602,"teacher_disagreement_score":0.0024103618,"about_ca_system_score_codex":0.0007863685,"about_ca_system_score_gemma":0.0009309798,"threshold_uncertainty_score":0.006678462},"labels":[],"label_agreement":null},{"id":"W2897194445","doi":"10.2217/fon-2018-0671","title":"Stage III Melanoma Incidence and Impact of Transitioning to the 8th AJCC Staging System: A US Population-Based Study","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Melanoma; Stage (stratigraphy); Incidence (geometry); Cancer registry; Population; AJCC staging system; Cancer; Oncology; Internal medicine; Cancer stage; Staging system; Cancer research; Environmental health","score_opus":0.011084545914195366,"score_gpt":0.3095916972263755,"score_spread":0.2985071513121801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897194445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832076,0.0002226776,0.000075455995,0.000049332673,0.00000623917,0.0000075098806,0.00069773814,0.0000043802365,0.00061585597],"genre_scores_gemma":[0.9992772,0.000074197735,0.000041834697,0.000020447975,0.0000056739427,0.0000045243687,0.00047766857,0.0000014667073,0.00009702519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99967515,0.00009255865,0.000030041516,0.00008191011,0.00006742602,0.000052938885],"domain_scores_gemma":[0.99922955,0.00008008424,0.00039786194,0.00006335741,0.000100885525,0.00012822995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043194805,0.00017729371,0.00013011516,0.00045098143,0.00020365752,0.00037976177,0.0002288708,0.00031835173,0.0013645906],"category_scores_gemma":[0.0015043289,0.00016676389,0.00036424215,0.00064746983,0.00017164109,0.00033392693,0.0002797041,0.00047401854,0.0002509687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057806334,0.00001929823,0.9989937,0.0000028697118,0.000024325553,0.000019008137,0.000013895208,0.000030652325,0.00005732821,0.000007737131,0.000108994616,0.0006644268],"study_design_scores_gemma":[0.0000037652962,0.000045340956,0.9995396,0.0000028485226,0.000014614488,0.000108004366,0.000043768665,0.00008968072,0.000020022097,0.000011982131,0.00011909135,0.0000014287554],"about_ca_topic_score_codex":0.00713404,"about_ca_topic_score_gemma":0.009731393,"teacher_disagreement_score":0.00713404,"about_ca_system_score_codex":0.0002771301,"about_ca_system_score_gemma":0.00024459074,"threshold_uncertainty_score":0.014185071},"labels":[],"label_agreement":null},{"id":"W2913371045","doi":"10.2217/fon-2018-0153","title":"Hot Topics in Epigenetic Regulation of Cancer Self-Renewal for Pancreatic Tumors: Future Trends","year":2019,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Epigenetics; Medicine; Pancreatic cancer; Cancer; Oncology; Cancer research; Internal medicine; Bioinformatics; Genetics; Biology","score_opus":0.015399920328488822,"score_gpt":0.3661090874161136,"score_spread":0.3507091670876248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913371045","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044074357,0.0133795785,0.00013474103,0.03418531,0.95107436,0.000012287002,0.00004791884,0.00006673658,0.0010549914],"genre_scores_gemma":[0.0003007336,0.011417882,0.00010286324,0.019343097,0.9605785,0.000011801524,0.00003902212,0.000032278083,0.008173796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753076,0.00044254283,0.0003335373,0.00026933633,0.0012372492,0.00018666153],"domain_scores_gemma":[0.9868832,0.0048207487,0.00075083086,0.00026726417,0.005006147,0.0022717516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005103611,0.0024470761,0.0026160968,0.0023355647,0.0019328974,0.005319878,0.0026536249,0.008695628,0.013361604],"category_scores_gemma":[0.011969334,0.00080432,0.0021185675,0.0010804742,0.0016974912,0.004685448,0.0016064277,0.015949158,0.010132253],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054579985,0.000013431669,0.000030642153,0.0003160295,0.0000186297,0.00007747835,0.0000135143255,0.000028846951,0.0001211618,0.00037949896,0.98808515,0.010861072],"study_design_scores_gemma":[0.00007527355,0.00005571972,0.00027433116,0.00044759997,0.00006502317,0.00026267438,0.000046586836,0.00014339907,0.00013987513,0.0015420734,0.99692553,0.000022056533],"about_ca_topic_score_codex":0.0010298172,"about_ca_topic_score_gemma":0.0033972773,"teacher_disagreement_score":0.013361604,"about_ca_system_score_codex":0.002556378,"about_ca_system_score_gemma":0.002420756,"threshold_uncertainty_score":0.044699013},"labels":[],"label_agreement":null},{"id":"W2955934677","doi":"10.2217/fon-2019-0010","title":"Utilization of Tumor Genomics in Clinical Practice: An International Survey among ASCO Members","year":2019,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Context (archaeology); Family medicine; Clinical Practice; Clinical trial; Clinical Oncology; Precision medicine; Personalized medicine; Internal medicine; Cancer; Pathology; Bioinformatics","score_opus":0.025159141984451617,"score_gpt":0.3726269263304013,"score_spread":0.34746778434594966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955934677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984829,0.0001602902,0.000057689456,0.00024697933,0.0000031226173,0.000011948762,0.00026578177,0.000002734636,0.00076856907],"genre_scores_gemma":[0.9993332,0.00016852948,0.000081742204,0.00010869092,0.000005369065,0.000012830336,0.00016842665,0.000001611308,0.00011961191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882156,0.00044975415,0.00016804576,0.00013848534,0.0002824834,0.00013980556],"domain_scores_gemma":[0.9930635,0.0016536729,0.0035762948,0.0001795729,0.00050228596,0.0010246446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014248093,0.00011863424,0.00015649485,0.0009008873,0.00033130136,0.0005566661,0.00025290524,0.00046572773,0.0014965208],"category_scores_gemma":[0.0051676184,0.0001712396,0.00014321493,0.0013613332,0.00033218914,0.0006366209,0.0005104218,0.00040077054,0.0002506447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020072446,0.000040237093,0.99691075,0.000012697524,0.000009963948,0.00003312614,0.0007439293,0.0000213044,0.00011919299,0.000010369665,0.00017824334,0.0019000678],"study_design_scores_gemma":[0.0000030034569,0.000084760926,0.99698657,0.00002062181,0.000005754576,0.00016070016,0.0020790864,0.00012683924,0.000055646447,0.000008734147,0.00046501204,0.0000032250705],"about_ca_topic_score_codex":0.006815183,"about_ca_topic_score_gemma":0.0066953464,"teacher_disagreement_score":0.006815183,"about_ca_system_score_codex":0.0004037484,"about_ca_system_score_gemma":0.00052033097,"threshold_uncertainty_score":0.013551056},"labels":[],"label_agreement":null},{"id":"W3011939837","doi":"10.2217/fon-2019-0796","title":"Quality of Life with Second or Third Line <i>Nab</i> -Paclitaxel-Based Regimens in Advanced Non-Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Quality of life (healthcare); Lung cancer; Paclitaxel; Internal medicine; Oncology; Nab-paclitaxel; Cancer; Physical therapy; Nursing; Immunotherapy","score_opus":0.022359610082821304,"score_gpt":0.36557717145172036,"score_spread":0.3432175613688991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011939837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958721,0.0031560839,0.00009969779,0.00012843468,0.000010093059,0.000024319274,0.00010513599,0.000007158546,0.00059697405],"genre_scores_gemma":[0.99900526,0.0005758765,0.0001065923,0.000050109014,0.0000072423054,0.000018234192,0.00013963244,7.722171e-7,0.000096273136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999851,0.00006291599,0.000012703325,0.000014537472,0.000033055832,0.000025708554],"domain_scores_gemma":[0.99968493,0.00007372141,0.0001529142,0.000009783125,0.000026975107,0.000051746265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055099063,0.00013437375,0.00032984914,0.000112312366,0.00010667801,0.00031452192,0.00011517617,0.0001587603,0.00072999496],"category_scores_gemma":[0.0007200636,0.000044587094,0.00048114976,0.00016877019,0.00012575761,0.00025167223,0.0001417859,0.0004049501,0.00007491627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02579459,0.00337549,0.60699785,0.0007136861,0.001428632,0.00027776312,0.00031895834,0.0034977074,0.015477601,0.00013577245,0.0025499845,0.33943206],"study_design_scores_gemma":[0.0016538261,0.043361846,0.94320834,0.000077229335,0.000524493,0.0009868502,0.00016978347,0.0025404063,0.0050629666,0.00011982155,0.002274318,0.000020149204],"about_ca_topic_score_codex":0.0006093087,"about_ca_topic_score_gemma":0.0011409596,"teacher_disagreement_score":0.00072999496,"about_ca_system_score_codex":0.000502626,"about_ca_system_score_gemma":0.00019638645,"threshold_uncertainty_score":0.0036468506},"labels":[],"label_agreement":null},{"id":"W3012293314","doi":"10.2217/fon-2020-0044","title":"MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Refractory (planetary science); Internal medicine; Placebo; Oncology; Randomized controlled trial; Myeloid; Pathology","score_opus":0.025895685441203825,"score_gpt":0.34770532389991754,"score_spread":0.3218096384587137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012293314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95414627,0.008008415,0.0016224536,0.0019315582,0.0016075663,0.016717631,0.004040163,0.0005471767,0.011378851],"genre_scores_gemma":[0.9388293,0.00873191,0.0063414555,0.0030933623,0.001081513,0.0178668,0.0048101526,0.00009818102,0.019147228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999718,0.00014972189,0.000014194966,0.000048770147,0.000031630792,0.000037749127],"domain_scores_gemma":[0.9996445,0.00006361559,0.00009647247,0.00002593408,0.00002485534,0.0001444452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009617419,0.0014904701,0.0014695836,0.00034534588,0.00035604162,0.00079336995,0.00084050366,0.0009919306,0.011361805],"category_scores_gemma":[0.0011322707,0.00038658638,0.0008603024,0.00031622127,0.0008905072,0.0007563694,0.00036621056,0.0024166105,0.0013635631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9496425,0.0065239742,0.00039868007,0.0012878273,0.0005726442,0.0000526955,0.00005924822,0.00041598064,0.0053747976,0.0007006515,0.0037114266,0.031259656],"study_design_scores_gemma":[0.96016145,0.036229968,0.00056068425,0.000050265186,0.00013986968,0.000034225584,0.000020050094,0.00024332946,0.0003780822,0.00020249395,0.0019720602,0.0000075767307],"about_ca_topic_score_codex":0.00064762135,"about_ca_topic_score_gemma":0.0026937004,"teacher_disagreement_score":0.011361805,"about_ca_system_score_codex":0.00055751385,"about_ca_system_score_gemma":0.0013970461,"threshold_uncertainty_score":0.038009048},"labels":[],"label_agreement":null},{"id":"W3016845792","doi":"10.2217/fon-2020-0247","title":"NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"NuCana","keywords":"Gemcitabine; Medicine; Cisplatin; Tolerability; Oncology; Internal medicine; Gallbladder cancer; Chemotherapy; Cancer; Adverse effect","score_opus":0.0405994358779115,"score_gpt":0.337366737760424,"score_spread":0.2967673018825125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016845792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709804,0.006252752,0.0002521366,0.0005682707,0.00032611916,0.0012880814,0.00055981165,0.000047273028,0.0036075818],"genre_scores_gemma":[0.989828,0.003693436,0.0011079316,0.0005847667,0.00019368579,0.0010925224,0.0007380461,0.00001721195,0.0027444302],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992204,0.00053665094,0.000057001867,0.00006939215,0.00004295888,0.00007354295],"domain_scores_gemma":[0.9992173,0.00025893113,0.00015662459,0.00005317187,0.000038758353,0.00027525643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018124363,0.00047924745,0.001533931,0.00034431164,0.00022684429,0.0005855505,0.0005371182,0.00082738465,0.0059418357],"category_scores_gemma":[0.001527517,0.00030273895,0.0010222825,0.00041166495,0.00051579956,0.0008165233,0.00038850712,0.0017746422,0.00058122433],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9270294,0.009227069,0.0010062826,0.00081258937,0.0006617939,0.000049736936,0.00007386489,0.00058978464,0.00453227,0.00030667256,0.0013967738,0.05431384],"study_design_scores_gemma":[0.4439402,0.53979754,0.007248109,0.00015820895,0.0011665598,0.00015164481,0.0000928122,0.0013134803,0.0023665647,0.0004254262,0.0033102636,0.000029195635],"about_ca_topic_score_codex":0.00069565227,"about_ca_topic_score_gemma":0.003302556,"teacher_disagreement_score":0.0059418357,"about_ca_system_score_codex":0.0006672538,"about_ca_system_score_gemma":0.00090618967,"threshold_uncertainty_score":0.019877434},"labels":[],"label_agreement":null},{"id":"W3032832010","doi":"10.2217/fon-2020-0184","title":"Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Head and neck; Oncology; Basal cell; Internal medicine; Head and neck cancer; Radiation therapy; Surgery; Immunotherapy; Cancer","score_opus":0.013909977618455905,"score_gpt":0.2772550983325816,"score_spread":0.2633451207141257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032832010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92790794,0.012449759,0.002152125,0.0016145285,0.001054939,0.039619807,0.003148211,0.0003063067,0.011746366],"genre_scores_gemma":[0.9579143,0.004711063,0.0042655463,0.0017175995,0.00062334916,0.020685196,0.0017718734,0.000047946683,0.008263057],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99881774,0.0005121503,0.000121068726,0.00021641121,0.0001342132,0.00019838773],"domain_scores_gemma":[0.99934715,0.00008433695,0.00013776109,0.00009165383,0.00004667311,0.00029247272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002465941,0.0010033887,0.0019073499,0.00062929903,0.0009925588,0.001116838,0.0011735008,0.0021643487,0.011359824],"category_scores_gemma":[0.0010765782,0.0007137447,0.0011327076,0.0007804415,0.0013533636,0.0016912412,0.0006511497,0.00330539,0.0017674353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7913667,0.054551803,0.0013927374,0.0020432349,0.00074534497,0.00012241761,0.00014598707,0.0004984577,0.03363847,0.00085879583,0.0036592241,0.110976845],"study_design_scores_gemma":[0.6580005,0.3234338,0.003553895,0.00011943038,0.00043545064,0.00013704832,0.000034911227,0.00023766137,0.005120021,0.00023103207,0.00866989,0.000026347705],"about_ca_topic_score_codex":0.001131738,"about_ca_topic_score_gemma":0.0036415532,"teacher_disagreement_score":0.011359824,"about_ca_system_score_codex":0.0011992668,"about_ca_system_score_gemma":0.002654459,"threshold_uncertainty_score":0.03800237},"labels":[],"label_agreement":null},{"id":"W3039747873","doi":"10.2217/fon-2020-0248","title":"Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Nivolumab; Meta-analysis; Lung cancer; Oncology; Internal medicine; Systematic review; MEDLINE; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.022236132718494908,"score_gpt":0.3398117127824406,"score_spread":0.3175755800639457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039747873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026263094,0.9957535,0.000432864,0.00020187491,0.00016243474,0.00012210071,0.00041774195,0.000015018366,0.00026815129],"genre_scores_gemma":[0.187046,0.8069726,0.0021317527,0.0014986058,0.00038667617,0.000489011,0.0010554794,0.000035640576,0.00038422906],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9905235,0.0051342756,0.002316973,0.0008541675,0.0009178801,0.00025324695],"domain_scores_gemma":[0.9832186,0.013576504,0.0017501181,0.00047320809,0.0008348538,0.0001465866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01505922,0.0022359544,0.013953368,0.0030066434,0.00040644658,0.0027960606,0.0015160794,0.0018402763,0.003338741],"category_scores_gemma":[0.033814438,0.0011192994,0.030581867,0.0033775643,0.00059439463,0.0015822351,0.001253157,0.002413433,0.00033387603],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024656495,0.00001954539,0.0028045464,0.29013827,0.6848479,0.00007648573,0.000045311797,0.0006072544,0.00019609778,0.00021386363,0.0007334015,0.01785172],"study_design_scores_gemma":[0.0006311348,0.00014266917,0.0023680625,0.01756661,0.97639114,0.0000673933,0.000020827496,0.00017151907,0.00009934964,0.00029967594,0.002223382,0.000018182169],"about_ca_topic_score_codex":0.0055842134,"about_ca_topic_score_gemma":0.01382804,"teacher_disagreement_score":0.01505922,"about_ca_system_score_codex":0.0023896385,"about_ca_system_score_gemma":0.0028293624,"threshold_uncertainty_score":0.0796417},"labels":[],"label_agreement":null},{"id":"W3049532301","doi":"10.2217/fon-2020-0573","title":"POLARIS: a Prospective, Multicenter, Noninterventional Study Assessing Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical trial; Breast cancer; Hormone receptor; Cancer; Clinical Practice; Gynecology; Family medicine","score_opus":0.015351142844713004,"score_gpt":0.35120742469913363,"score_spread":0.3358562818544206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049532301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9184882,0.006048754,0.0022310195,0.0025443665,0.00052049384,0.028005779,0.022835555,0.00015916703,0.019166514],"genre_scores_gemma":[0.9183152,0.0040024817,0.0070978436,0.0030975582,0.0011738853,0.037662856,0.021115193,0.00008579496,0.007449213],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982539,0.0010869604,0.00006930816,0.00023379286,0.00019576235,0.00016037867],"domain_scores_gemma":[0.9974831,0.0004402887,0.0006544938,0.00020043988,0.00038497307,0.0008367416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004428172,0.0012795969,0.0012122374,0.00042861394,0.0008153547,0.0013095589,0.0011123165,0.00075410993,0.0063218847],"category_scores_gemma":[0.0033414997,0.00060729403,0.0007225399,0.0011726773,0.00092282356,0.00093449233,0.0009245578,0.0017667079,0.0016904306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7721131,0.020003194,0.12589835,0.0021311657,0.0023838691,0.0005518982,0.0004970322,0.0007372357,0.008828838,0.002352153,0.021008708,0.04349438],"study_design_scores_gemma":[0.57644975,0.18644078,0.19189991,0.00036630032,0.0029077989,0.0008849902,0.0006357574,0.0012046425,0.0023325481,0.0015771819,0.035200085,0.000100182486],"about_ca_topic_score_codex":0.0022853133,"about_ca_topic_score_gemma":0.0047775684,"teacher_disagreement_score":0.0063218847,"about_ca_system_score_codex":0.0011402582,"about_ca_system_score_gemma":0.003734629,"threshold_uncertainty_score":0.023418725},"labels":[],"label_agreement":null},{"id":"W3082658746","doi":"10.2217/fon-2020-0740","title":"Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Lung cancer; Internal medicine; Oncology; T790M; Clinical trial; Cancer; Adenocarcinoma; Erlotinib; Epidermal growth factor receptor","score_opus":0.010261673574810951,"score_gpt":0.31282478021966725,"score_spread":0.3025631066448563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082658746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430674,0.003158758,0.0001117055,0.00017545374,0.000019358928,0.000096172625,0.0014554479,0.000009362241,0.00066693145],"genre_scores_gemma":[0.9962908,0.00059070246,0.000183732,0.00016048054,0.000024584499,0.00006901472,0.0025273045,0.000004754605,0.00014865541],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991353,0.00038762277,0.00007527884,0.00016204515,0.00012393923,0.000115760085],"domain_scores_gemma":[0.99886525,0.00023769909,0.0004243897,0.00012492662,0.000088023684,0.00025978012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023680811,0.0005167819,0.0010083008,0.00035578563,0.00021997708,0.0009163434,0.00042556826,0.00047386764,0.00091401173],"category_scores_gemma":[0.001484398,0.00023287327,0.002236446,0.00095760997,0.00037034124,0.0005044439,0.00050946407,0.00078347273,0.00016681034],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108804986,0.000564069,0.8276692,0.0007095492,0.009942994,0.00034241733,0.0002356479,0.0014244671,0.003801826,0.00017564985,0.0033790949,0.04295009],"study_design_scores_gemma":[0.018486798,0.010847217,0.9564753,0.00011224851,0.006771218,0.00073271006,0.00025091777,0.0011053182,0.0008231138,0.00031814468,0.004027954,0.000049035032],"about_ca_topic_score_codex":0.0022579816,"about_ca_topic_score_gemma":0.00835734,"teacher_disagreement_score":0.0023680811,"about_ca_system_score_codex":0.0009222961,"about_ca_system_score_gemma":0.0010515157,"threshold_uncertainty_score":0.01252377},"labels":[],"label_agreement":null},{"id":"W3082666946","doi":"10.2217/fon-2020-0521","title":"Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Biotech; Celgene; Genentech; Amgen","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Clinical trial; Oncology; Internal medicine; Antigen; Population; Chimeric antigen receptor; Antibody; Antibody-drug conjugate; Drug; Immunology; Immunotherapy; Cancer research; Cancer; Pharmacology; Monoclonal antibody","score_opus":0.08867892424622806,"score_gpt":0.4105295756180951,"score_spread":0.3218506513718671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082666946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026332008,0.99853873,0.00008012601,0.00013189585,0.00007533347,0.0000058468045,0.000020148353,0.000007342892,0.0008772968],"genre_scores_gemma":[0.0010689442,0.99810946,0.00012396085,0.00012497813,0.00005460442,0.00000646933,0.000034989753,0.0000013619317,0.00047529337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999899,0.00001959002,0.000015047158,0.00001606438,0.00003929141,0.000010930756],"domain_scores_gemma":[0.9999008,0.00004323317,0.000019789357,0.0000021873707,0.000023961114,0.000010033035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032922992,0.00044905083,0.00091282855,0.0014533866,0.00016183333,0.00051556464,0.00045379633,0.00048837985,0.003472583],"category_scores_gemma":[0.00032454694,0.0001654736,0.00047567723,0.0011970196,0.00017351816,0.0005921729,0.00040013305,0.0010820142,0.0014501053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014837226,0.00006795173,0.000096946074,0.019629795,0.00012410806,0.00016029653,0.00005050621,0.0003610699,0.0024799742,0.0016071135,0.01721995,0.958054],"study_design_scores_gemma":[0.000051746538,0.000222625,0.00079050055,0.0044182977,0.0002740474,0.0012876717,0.000038026836,0.00013963267,0.0007309039,0.0010813535,0.9909499,0.000015228958],"about_ca_topic_score_codex":0.0007624606,"about_ca_topic_score_gemma":0.0016988493,"teacher_disagreement_score":0.003472583,"about_ca_system_score_codex":0.0003736627,"about_ca_system_score_gemma":0.00056637207,"threshold_uncertainty_score":0.011617005},"labels":[],"label_agreement":null},{"id":"W3082708938","doi":"10.2217/fon-2020-0586","title":"Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Nivolumab; Axitinib; Avelumab; Medicine; Ipilimumab; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Combination therapy; Cabozantinib; Tyrosine-kinase inhibitor; Targeted therapy; Sunitinib; Cancer","score_opus":0.04777237359308242,"score_gpt":0.34571873806411063,"score_spread":0.2979463644710282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082708938","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024460422,0.99850225,0.00007474456,0.00010598825,0.00008154131,0.0000069510606,0.000024753625,0.00000588363,0.0009533613],"genre_scores_gemma":[0.001257268,0.997775,0.00012334829,0.00013098803,0.00006210966,0.0000074680256,0.000046065572,0.0000010301153,0.00059660425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999013,0.000019180805,0.000015203539,0.00001624837,0.000039210725,0.000008831222],"domain_scores_gemma":[0.9999267,0.00003173678,0.000017274864,0.0000018499187,0.00001604789,0.0000063823745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024395002,0.0004701418,0.00084316765,0.0014817494,0.00016160727,0.0004469048,0.00045007333,0.00043836283,0.0039033084],"category_scores_gemma":[0.00027188775,0.00014117679,0.00055964745,0.0011838767,0.00014585603,0.0004871271,0.00032669512,0.0009212703,0.0011446162],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010244669,0.000074916585,0.00011801509,0.019338267,0.0002118015,0.00014899069,0.000036202182,0.00030856076,0.0017268272,0.0013565312,0.01889925,0.9576781],"study_design_scores_gemma":[0.000077977544,0.00023633458,0.0012103029,0.005052777,0.00043479586,0.0017642988,0.000043828375,0.00016914621,0.0006960364,0.0009548676,0.98934144,0.000018229728],"about_ca_topic_score_codex":0.00078504963,"about_ca_topic_score_gemma":0.0024549516,"teacher_disagreement_score":0.0039033084,"about_ca_system_score_codex":0.0003006602,"about_ca_system_score_gemma":0.0004853716,"threshold_uncertainty_score":0.013057828},"labels":[],"label_agreement":null},{"id":"W3107254051","doi":"10.2217/fon-2020-0655","title":"Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Microsatellite instability; Endometrial cancer; Medicine; DNA mismatch repair; Oncology; Internal medicine; Immune checkpoint; Immune system; Cancer; Cancer research; Immunotherapy; Microsatellite; Immunology; Gene; Genetics; Biology","score_opus":0.08592308035728641,"score_gpt":0.4281559395685617,"score_spread":0.3422328592112753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107254051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002125881,0.99889994,0.000048226302,0.00008677714,0.00005936957,0.0000056718054,0.000017789533,0.0000042212796,0.0006653552],"genre_scores_gemma":[0.0011272519,0.99822146,0.00010073071,0.00012666782,0.000039855895,0.0000068500726,0.00003131367,9.223193e-7,0.00034490414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999027,0.000022678594,0.000017847395,0.000017257786,0.000030891755,0.0000085521415],"domain_scores_gemma":[0.9998989,0.00005407074,0.000018817664,0.0000021522267,0.000019363597,0.0000067286505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028222532,0.0004301518,0.00085593446,0.0011467038,0.00015338488,0.00047477393,0.0004214885,0.00040283182,0.0038280038],"category_scores_gemma":[0.00036713728,0.00013758587,0.00054914306,0.0009889271,0.00014175453,0.00043303292,0.00036746272,0.0007890896,0.00095850276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012948131,0.00005173686,0.00009403397,0.031848148,0.00017042655,0.000108308326,0.000043539723,0.0002591735,0.001336115,0.00098246,0.010698985,0.95427763],"study_design_scores_gemma":[0.00010330867,0.00036390912,0.0015851052,0.015582856,0.00080777664,0.0018272457,0.0000740802,0.00020203028,0.00088991,0.0012323644,0.9773107,0.000020504694],"about_ca_topic_score_codex":0.00072059076,"about_ca_topic_score_gemma":0.0020179304,"teacher_disagreement_score":0.0038280038,"about_ca_system_score_codex":0.00029605418,"about_ca_system_score_gemma":0.00055026636,"threshold_uncertainty_score":0.012805879},"labels":[],"label_agreement":null},{"id":"W3119071615","doi":"10.2217/fon-2020-1048","title":"MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Medical Research Council; Cancer Research UK","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Anemia; Constitutional symptoms; Internal medicine; Bone marrow","score_opus":0.005068712736830131,"score_gpt":0.23042734607706353,"score_spread":0.2253586333402334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119071615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657882,0.01715935,0.00035847665,0.0025004547,0.0006126672,0.00040344553,0.0012560796,0.00010817736,0.011813237],"genre_scores_gemma":[0.99031466,0.003953429,0.0005145404,0.001193054,0.0002834387,0.00025484525,0.0008238246,0.00000993734,0.0026522456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999871,0.000054888184,0.000009262752,0.00001816602,0.0000141802775,0.00003246712],"domain_scores_gemma":[0.99969804,0.00008842231,0.000065294094,0.000014034915,0.000011762296,0.00012241991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047664376,0.0003743355,0.0007980262,0.00024490344,0.00020693622,0.0006967856,0.00027277626,0.0005354765,0.0052097905],"category_scores_gemma":[0.0007691896,0.00014678875,0.00055097335,0.0002479659,0.00024229151,0.00070918293,0.00026415748,0.0010408816,0.00052197825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7058152,0.0059798895,0.0072828988,0.0006394524,0.0009334337,0.00036639805,0.000112031965,0.0016859536,0.008617202,0.0009348555,0.008935201,0.2586975],"study_design_scores_gemma":[0.51552504,0.38234603,0.05706986,0.0004481776,0.0019380274,0.0014600691,0.00031526483,0.0044827876,0.003430029,0.0019152814,0.03098643,0.000082916944],"about_ca_topic_score_codex":0.00060998305,"about_ca_topic_score_gemma":0.002878738,"teacher_disagreement_score":0.0052097905,"about_ca_system_score_codex":0.00045305074,"about_ca_system_score_gemma":0.0005994413,"threshold_uncertainty_score":0.017428517},"labels":[],"label_agreement":null},{"id":"W3120514166","doi":"10.2217/fon-2020-0544","title":"Prognostic Significance of <i>CTNNB1</i> Mutation in Recurrence of Sporadic Desmoid Tumors","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mutation; Internal medicine; Cochrane Library; Odds ratio; Oncology; Meta-analysis; Pathology; Gastroenterology; Genetics; Gene; Biology","score_opus":0.04797565248730175,"score_gpt":0.3812897989768649,"score_spread":0.33331414648956315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120514166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021302,0.99739265,0.00006620404,0.000092356306,0.000041768544,0.000019230441,0.00010097231,0.0000023413913,0.0001543038],"genre_scores_gemma":[0.067863,0.93094784,0.00035982893,0.00024842986,0.00012781392,0.00006635403,0.00025475767,0.0000051773422,0.00012683426],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9975853,0.0007945785,0.00087385,0.0002912746,0.0003810541,0.000073967],"domain_scores_gemma":[0.9856646,0.011028511,0.0022972547,0.00020286083,0.0007015087,0.00010531551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004499779,0.000786834,0.0044935225,0.0039363718,0.00025473133,0.0015054897,0.00088407757,0.0010942764,0.0020580248],"category_scores_gemma":[0.016543314,0.00047301876,0.0073444736,0.004727036,0.0003775402,0.00086993503,0.00058602873,0.00069284666,0.0001542467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002296613,0.00004165388,0.026926285,0.68624127,0.14062145,0.00036677357,0.00020055869,0.00049074856,0.0007179756,0.0002888092,0.002374998,0.13943282],"study_design_scores_gemma":[0.0006334093,0.000594313,0.06919269,0.2270097,0.6770561,0.0017095521,0.0002937748,0.00043396483,0.00067556056,0.00080698635,0.021515235,0.00007885748],"about_ca_topic_score_codex":0.0029577594,"about_ca_topic_score_gemma":0.005576368,"teacher_disagreement_score":0.004499779,"about_ca_system_score_codex":0.0009043537,"about_ca_system_score_gemma":0.0013740564,"threshold_uncertainty_score":0.023797393},"labels":[],"label_agreement":null},{"id":"W3133493210","doi":"10.2217/fon-2020-1274","title":"Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- <i>IDH1</i> Cholangiocarcinoma","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Agios Pharmaceuticals","keywords":"IDH1; Isocitrate dehydrogenase; Medicine; Cancer research; Intrahepatic Cholangiocarcinoma; Downregulation and upregulation; Mutant; Internal medicine; Oncology; Biology; Gene; Enzyme; Genetics","score_opus":0.014789206426278585,"score_gpt":0.2702181729730269,"score_spread":0.25542896654674835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133493210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972166,0.0009794728,0.00021221647,0.000031587293,0.000005781303,0.0000230331,0.00022790291,0.000020760785,0.001282741],"genre_scores_gemma":[0.9986141,0.0002500353,0.00030704224,0.000018782037,0.000003698321,0.00002241258,0.00028453316,0.0000060944944,0.00049330376],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999354,0.000016073593,0.000006267823,0.000010863694,0.000014412303,0.000016977989],"domain_scores_gemma":[0.99983597,0.00003459379,0.000054730288,0.000013620211,0.000017343087,0.000043734362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001863057,0.00010767887,0.00015410925,0.00024767194,0.000092341754,0.00021167213,0.00008251297,0.00016455157,0.0017773067],"category_scores_gemma":[0.00016483424,0.00008006326,0.00013285025,0.00014985554,0.00015517845,0.00013972718,0.00008125134,0.00031935243,0.00022442643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061720726,0.00030106667,0.024605962,0.00009744208,0.00003788354,0.0002196025,0.000047125162,0.00016790445,0.95432895,0.000107600354,0.00027485046,0.013639474],"study_design_scores_gemma":[0.0002872395,0.010262006,0.33593282,0.000020931911,0.00012497352,0.002237034,0.00016192083,0.00090584764,0.64664996,0.000115155606,0.0032895713,0.0000126246105],"about_ca_topic_score_codex":0.00040169986,"about_ca_topic_score_gemma":0.00057787384,"teacher_disagreement_score":0.0017773067,"about_ca_system_score_codex":0.00029360421,"about_ca_system_score_gemma":0.00013162839,"threshold_uncertainty_score":0.005945742},"labels":[],"label_agreement":null},{"id":"W3134027539","doi":"10.2217/fon-2020-1264","title":"CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Trastuzumab; Real world evidence; Cancer; Gynecology","score_opus":0.061872516632544144,"score_gpt":0.45566446360252355,"score_spread":0.39379194696997943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134027539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040744615,0.9985728,0.00009213619,0.00022697505,0.00006415277,0.00008961833,0.00030168923,0.0000043929526,0.00024073783],"genre_scores_gemma":[0.0045273704,0.994484,0.00028354963,0.00030242483,0.000049462855,0.00012744969,0.00017094647,0.0000025410948,0.000052228195],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948791,0.0016533858,0.0019505003,0.00044580598,0.00087839924,0.00019286784],"domain_scores_gemma":[0.973565,0.02052725,0.0036158988,0.00029656576,0.0018031135,0.00019220942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007340411,0.0014493619,0.0057733366,0.009160914,0.0004943937,0.0024192252,0.0015366048,0.0014003163,0.0057470715],"category_scores_gemma":[0.03286784,0.00081413076,0.006541298,0.009029248,0.00066255406,0.001786761,0.0012885832,0.0012283213,0.00047060678],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016730338,0.0000141549735,0.0006066737,0.94115895,0.0063001206,0.000078373065,0.000100081925,0.00010653706,0.00016006337,0.00027045066,0.0018878322,0.049149398],"study_design_scores_gemma":[0.00015311448,0.00014922438,0.0031132842,0.9004779,0.062257923,0.00037761923,0.00019505543,0.000073080315,0.00018475633,0.00044713874,0.032540545,0.000030417754],"about_ca_topic_score_codex":0.0048723207,"about_ca_topic_score_gemma":0.016082747,"teacher_disagreement_score":0.009160914,"about_ca_system_score_codex":0.00246552,"about_ca_system_score_gemma":0.009783769,"threshold_uncertainty_score":0.038820267},"labels":[],"label_agreement":null},{"id":"W3134053447","doi":"10.2217/fon-2020-1210","title":"Role of Cedazuridine/Decitabine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Azacitidine; Myelodysplastic syndromes; Oncology; International Prognostic Scoring System; Internal medicine; Pharmacology; Bone marrow; DNA methylation","score_opus":0.025056787831958822,"score_gpt":0.34893973370480036,"score_spread":0.32388294587284155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134053447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002061352,0.99892324,0.000057816815,0.00010083027,0.00006436788,0.0000038461826,0.000013616254,0.0000039455417,0.0006261811],"genre_scores_gemma":[0.001052535,0.9982938,0.00014163223,0.000111682304,0.000050484734,0.000004611271,0.00003148444,9.600687e-7,0.0003126642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987614,0.000027200074,0.000022058486,0.00001988046,0.000043001462,0.000011712068],"domain_scores_gemma":[0.999846,0.00007362788,0.00002702408,0.00000420517,0.00003584933,0.000013213373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003926988,0.00047776822,0.0009593771,0.0014977141,0.00016782564,0.0005519318,0.00055779313,0.00055336667,0.0026505322],"category_scores_gemma":[0.00042150117,0.00015650514,0.00049850333,0.0010612786,0.00021839903,0.0006140668,0.0003913077,0.0012049577,0.0011005773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001135309,0.000053374715,0.00011170959,0.014620803,0.00010798866,0.00016844193,0.00004499019,0.0003470161,0.0017415542,0.0016262566,0.010747505,0.97031677],"study_design_scores_gemma":[0.00005566679,0.00028379736,0.0010711385,0.0055113127,0.00030192645,0.0020504936,0.000052313866,0.00015925891,0.000993716,0.0010913804,0.9884106,0.00001827894],"about_ca_topic_score_codex":0.0007176262,"about_ca_topic_score_gemma":0.0016701999,"teacher_disagreement_score":0.0026505322,"about_ca_system_score_codex":0.00033977552,"about_ca_system_score_gemma":0.00059906574,"threshold_uncertainty_score":0.008866906},"labels":[],"label_agreement":null},{"id":"W3134403963","doi":"10.2217/fon-2020-1269","title":"Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Oncology; Refractory (planetary science); Carfilzomib; Internal medicine; Pomalidomide","score_opus":0.050819269986887,"score_gpt":0.3395705788726691,"score_spread":0.2887513088857821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134403963","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93099165,0.013022727,0.0031184473,0.001826993,0.00083212974,0.033934392,0.0038293246,0.00018088128,0.012263548],"genre_scores_gemma":[0.92906606,0.007395224,0.0075893695,0.0034652685,0.0008668336,0.036672495,0.0033344745,0.00006218814,0.011548108],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990453,0.0004749883,0.000068033514,0.00016005276,0.00008624653,0.00016538979],"domain_scores_gemma":[0.99942124,0.00009058746,0.00010379448,0.000047091587,0.000059838185,0.00027755473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034266114,0.0016489704,0.00250744,0.00047569285,0.00042235566,0.0014506433,0.0012171946,0.001300296,0.0074813743],"category_scores_gemma":[0.0012876518,0.0006650438,0.0023955193,0.0005394521,0.0008881476,0.0011737926,0.0007051152,0.0029452622,0.001383377],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8676599,0.04257989,0.0036814031,0.0028907224,0.003028228,0.00027585743,0.00023990782,0.0022768292,0.012335673,0.0014606419,0.0043523824,0.059218585],"study_design_scores_gemma":[0.6029377,0.37169266,0.0037266514,0.00016257176,0.0023344175,0.00019451318,0.00009644531,0.0015920361,0.0021401013,0.0007245847,0.014353538,0.00004481113],"about_ca_topic_score_codex":0.0007694847,"about_ca_topic_score_gemma":0.0021911636,"teacher_disagreement_score":0.0074813743,"about_ca_system_score_codex":0.0012981868,"about_ca_system_score_gemma":0.0026360245,"threshold_uncertainty_score":0.025027692},"labels":[],"label_agreement":null},{"id":"W3156107342","doi":"10.2217/fon-2021-0284","title":"Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Karyopharm Therapeutics","keywords":"Medicine; Quality of life (healthcare); Liposarcoma; Intensive care medicine; MEDLINE; Pathology; Nursing; Sarcoma","score_opus":0.01391288335984998,"score_gpt":0.28914602250048677,"score_spread":0.2752331391406368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156107342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978551,0.0016860721,0.000063659856,0.00006402346,0.000009496709,0.000037511993,0.000038063714,0.0000031282643,0.00024292002],"genre_scores_gemma":[0.9991203,0.0004631482,0.00012466629,0.000041269635,0.000020041429,0.000037485017,0.000050407412,4.05283e-7,0.00014236782],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998307,0.00008881268,0.000016920045,0.00001765878,0.000025995447,0.000019848527],"domain_scores_gemma":[0.9997907,0.00008616465,0.0000666534,0.000007870826,0.0000126915775,0.000035968882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073036,0.00019860604,0.00066857587,0.00014733156,0.00008343189,0.00018158751,0.000105506915,0.0001741535,0.0011077119],"category_scores_gemma":[0.0007268317,0.00008276144,0.00042089005,0.000109114575,0.00016135306,0.0002961482,0.0001693221,0.0003265849,0.000081774546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35852593,0.013617505,0.14835748,0.0019653821,0.0024996742,0.00036081934,0.0005194758,0.004883546,0.05864548,0.00019704417,0.0009860777,0.4094416],"study_design_scores_gemma":[0.049223073,0.42757583,0.5078854,0.00014313524,0.0011827222,0.0007843958,0.00038382466,0.0033002854,0.0070295953,0.00022798445,0.0022311106,0.000032621516],"about_ca_topic_score_codex":0.00011815906,"about_ca_topic_score_gemma":0.0003712453,"teacher_disagreement_score":0.0011077119,"about_ca_system_score_codex":0.00015094028,"about_ca_system_score_gemma":0.00011465708,"threshold_uncertainty_score":0.0038625598},"labels":[],"label_agreement":null},{"id":"W3159545343","doi":"10.2217/fon-2021-0153","title":"Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; FANCA; PALB2; Prostate cancer; Oncology; Genetic testing; Internal medicine; Cancer; DNA repair; Gene; Mutation; Fanconi anemia; Genetics; Germline mutation","score_opus":0.0559407481845942,"score_gpt":0.38897862257168647,"score_spread":0.33303787438709226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159545343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998412,0.00029473522,0.00009390201,0.00011171023,0.0000029664793,0.000005511984,0.0007290858,0.000004800161,0.0003451635],"genre_scores_gemma":[0.9994754,0.00006293736,0.00005638753,0.000017383189,0.0000030717433,0.000002585486,0.0003492586,0.0000012185933,0.000031669355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870145,0.00043045814,0.00019053686,0.0003089511,0.00022362817,0.0001450449],"domain_scores_gemma":[0.9927341,0.0017289802,0.0044656564,0.00026580546,0.00031709185,0.0004883649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009569283,0.00013493178,0.00019177842,0.0009750271,0.00025655987,0.0006618709,0.00047161066,0.0004461822,0.0022104743],"category_scores_gemma":[0.006168746,0.0001512884,0.00023902301,0.0016322542,0.00031271297,0.00050828874,0.00049405335,0.00041075613,0.00024252725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064100925,0.000012066545,0.9984939,0.000008530113,0.000016278214,0.000048029433,0.000031753538,0.000060636718,0.00006373136,0.000013983535,0.00008801581,0.0010989986],"study_design_scores_gemma":[0.0000028162633,0.000055184817,0.99856704,0.000009603925,0.000009531804,0.0005698978,0.00021921289,0.00026091302,0.00008479076,0.000030144749,0.00018666113,0.000004169839],"about_ca_topic_score_codex":0.0043567587,"about_ca_topic_score_gemma":0.006476633,"teacher_disagreement_score":0.0043567587,"about_ca_system_score_codex":0.00043432094,"about_ca_system_score_gemma":0.0003830925,"threshold_uncertainty_score":0.00866282},"labels":[],"label_agreement":null},{"id":"W3185533154","doi":"10.2217/fon-2021-0370","title":"Prediction and Characterization of Diffuse Large B-Cell Lymphoma Cell-of-Origin Subtypes Using Targeted Sequencing","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Foundation Medicine; H. Lundbeck A/S; Amgen; TG Therapeutics; Genentech; Celgene; F. Hoffmann-La Roche","keywords":"Exome sequencing; Somatic cell; DNA sequencing; Germinal center; Carcinogenesis; Diffuse large B-cell lymphoma; Biology; Ion semiconductor sequencing; Computational biology; Cell of origin; Germline mutation; Genetics; Cell; DNA; Mutation; Gene; B cell; Antibody","score_opus":0.018923713725034052,"score_gpt":0.262826755363928,"score_spread":0.24390304163889398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185533154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938258,0.0008561668,0.003760101,0.000027376846,0.0000042582155,0.000044151788,0.0005588652,0.000043774828,0.00087958475],"genre_scores_gemma":[0.9943558,0.0003634913,0.0037889453,0.00003444167,0.000008872531,0.000030783434,0.0010018655,0.0000140223065,0.00040188074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977297,0.00003081848,0.000021085318,0.00007371728,0.00005636431,0.00004503227],"domain_scores_gemma":[0.9996275,0.00010733122,0.00008957456,0.000042781972,0.00007853292,0.000054211818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029129314,0.00023536102,0.00031059954,0.0016478044,0.00020431358,0.00079525233,0.00019648291,0.00040998272,0.0008779629],"category_scores_gemma":[0.0007477166,0.000119703094,0.00016781123,0.000553363,0.00014013975,0.00017484918,0.0003115373,0.00018692901,0.0004230818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006275544,0.00006782293,0.6804011,0.00012344662,0.00007797607,0.0006094386,0.00019082024,0.00060994964,0.27229378,0.0002721025,0.0002646681,0.04446133],"study_design_scores_gemma":[0.000041994175,0.00038030552,0.88430196,0.00006924581,0.00030184898,0.0061340346,0.0007671299,0.014458083,0.0833951,0.00073402876,0.009396657,0.000019548803],"about_ca_topic_score_codex":0.0011886446,"about_ca_topic_score_gemma":0.002447627,"teacher_disagreement_score":0.0016478044,"about_ca_system_score_codex":0.00017799732,"about_ca_system_score_gemma":0.00017468736,"threshold_uncertainty_score":0.002937138},"labels":[],"label_agreement":null},{"id":"W3189019461","doi":"10.2217/fon-2021-0252","title":"Risk of Arterial and Venous Thromboembolic Events Among Patients with Colorectal Carcinoma: a Real-World, Population-Based Study","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Daiichi-Sankyo","keywords":"Medicine; Bevacizumab; Internal medicine; Colorectal cancer; Comorbidity; Odds ratio; Population; Cancer registry; Incidence (geometry); Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.006466433573509313,"score_gpt":0.2577060622099712,"score_spread":0.25123962863646193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189019461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989705,0.00018931272,0.00005116108,0.000061116756,0.0000035828273,0.000010761062,0.00045571508,0.00000291824,0.00025492284],"genre_scores_gemma":[0.99946886,0.0000901678,0.000043329957,0.000016159182,0.0000061476458,0.0000043903365,0.0003282142,5.999617e-7,0.00004217158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994336,0.0001372657,0.000057513935,0.0001030506,0.00018144492,0.000087063534],"domain_scores_gemma":[0.9981831,0.00022002673,0.0010036032,0.00010961054,0.0001968603,0.00028688493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052830135,0.00021361752,0.00024374382,0.00074700854,0.0003986288,0.0007562134,0.00044619266,0.00045256168,0.00088021404],"category_scores_gemma":[0.0030081247,0.0002484728,0.00036145598,0.0014054305,0.00039566512,0.00047460332,0.00037146706,0.000569312,0.00014486031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029678096,0.000016102467,0.99953866,0.000004142762,0.0000253872,0.000026462838,0.000024143521,0.00002276534,0.000032096927,0.0000040856276,0.000039155777,0.00023722959],"study_design_scores_gemma":[0.000005311992,0.00003731408,0.9994342,0.000002711755,0.000011351503,0.00014832262,0.00011507738,0.00015251063,0.000010818847,0.0000060464836,0.00007363786,0.0000026701155],"about_ca_topic_score_codex":0.057573058,"about_ca_topic_score_gemma":0.070972286,"teacher_disagreement_score":0.057573058,"about_ca_system_score_codex":0.00094026636,"about_ca_system_score_gemma":0.0008376234,"threshold_uncertainty_score":0.11447585},"labels":[],"label_agreement":null},{"id":"W3194698214","doi":"10.2217/fon-2021-0087","title":"The Impact of the Host Intestinal Microbiome on Carcinogenesis and the Response to Chemotherapy","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre","keywords":"Microbiome; Medicine; Intestinal Microbiome; Colorectal cancer; Dysbiosis; Antibiotics; Cancer; Disease; Fecal bacteriotherapy; Gut microbiome; Probiotic; Inflammatory bowel disease; Immunology; Bioinformatics; Internal medicine; Biology; Microbiology; Genetics; Bacteria","score_opus":0.015339263636311572,"score_gpt":0.3617463239256036,"score_spread":0.346407060289292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194698214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011585253,0.9985771,0.000091855225,0.000264885,0.00014022781,0.000003451386,0.000023433238,0.00000507052,0.00077805296],"genre_scores_gemma":[0.00060094905,0.99876535,0.00008175016,0.000098494944,0.00009271778,0.0000041304397,0.000023527276,9.134912e-7,0.0003321834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983597,0.00003805103,0.000020929134,0.000025644891,0.000059736805,0.00001961954],"domain_scores_gemma":[0.99976486,0.0001170088,0.00003396536,0.000006237122,0.00005944478,0.000018472441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039693166,0.00053709844,0.0010658152,0.0014482851,0.000184349,0.00090441277,0.0005405641,0.0007757221,0.0036609194],"category_scores_gemma":[0.0007763917,0.00016851115,0.00047036706,0.0012109246,0.00028141684,0.00074969145,0.00056728814,0.0011327594,0.0017094715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095271855,0.00005860026,0.000244226,0.022661764,0.000119584896,0.00015611868,0.000051752733,0.0003279879,0.0021600607,0.003793075,0.022957508,0.94737405],"study_design_scores_gemma":[0.000013755044,0.00012117553,0.0016276581,0.007108284,0.00015916959,0.0011350868,0.000065867804,0.00010343345,0.000710011,0.0021156652,0.9868204,0.00001943479],"about_ca_topic_score_codex":0.000833411,"about_ca_topic_score_gemma":0.0013599609,"teacher_disagreement_score":0.0036609194,"about_ca_system_score_codex":0.0005321527,"about_ca_system_score_gemma":0.00083524786,"threshold_uncertainty_score":0.012246966},"labels":[],"label_agreement":null},{"id":"W3194931280","doi":"10.2217/fon-2021-0575","title":"Relugolix, An Oral Gonadotropin-Releasing Hormone Antagonist for the Treatment of Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Prostate cancer; Testosterone (patch); Gonadotropin-releasing hormone antagonist; Hormone antagonist; Internal medicine; Androgen deprivation therapy; Antagonist; Gonadotropin-releasing hormone; Endocrinology; Androgen; Agonist; Urology; Leuprorelin; Hormone; Cancer; Luteinizing hormone; Receptor","score_opus":0.04279694177607753,"score_gpt":0.39304045283617983,"score_spread":0.3502435110601023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194931280","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51811296,0.431796,0.0057831756,0.0036124364,0.0010493192,0.00090610655,0.0020687352,0.0010051498,0.035666145],"genre_scores_gemma":[0.853604,0.115891576,0.00625299,0.00286079,0.00050271436,0.00032625196,0.0034114097,0.000086742824,0.01706348],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999391,0.000016487911,0.0000030097585,0.0000096772255,0.000019168949,0.000012587391],"domain_scores_gemma":[0.9999447,0.000010513809,0.000016876847,0.0000031808881,0.000004911738,0.000019832718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016390561,0.00023464537,0.0003969489,0.000235911,0.00014291768,0.00020278017,0.00020006477,0.00019392616,0.002865778],"category_scores_gemma":[0.0001418811,0.000068977504,0.00030116312,0.0002346637,0.00015560028,0.00013582209,0.00016674593,0.0007084065,0.00067949604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00928504,0.0021480925,0.0029719395,0.0026018668,0.00023273037,0.0009084092,0.000084521016,0.00053127867,0.06179599,0.0013073991,0.018810784,0.899322],"study_design_scores_gemma":[0.04017981,0.16460189,0.10855309,0.0012512428,0.00097536517,0.037680198,0.00034880653,0.0038601283,0.068359286,0.0020363263,0.5719173,0.00023662437],"about_ca_topic_score_codex":0.00063139026,"about_ca_topic_score_gemma":0.0022743032,"teacher_disagreement_score":0.002865778,"about_ca_system_score_codex":0.00018601173,"about_ca_system_score_gemma":0.00034620494,"threshold_uncertainty_score":0.0095870495},"labels":[],"label_agreement":null},{"id":"W3195219055","doi":"10.2217/fon-2021-0598","title":"Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer","year":2021,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Internal medicine; Regimen; Oncology; Microsatellite instability; Clinical trial; Cancer; DNA mismatch repair; Colorectal cancer","score_opus":0.03426658383925036,"score_gpt":0.38266468537824544,"score_spread":0.3483981015389951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195219055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89500546,0.07690725,0.00065039506,0.002993089,0.00064066926,0.0010723468,0.0024795115,0.00015132317,0.020099895],"genre_scores_gemma":[0.9813596,0.010661484,0.0006642848,0.0015514912,0.0002557539,0.00043874836,0.0015027333,0.000018891164,0.003546977],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99973804,0.0001359834,0.00002013233,0.000028451468,0.000049440467,0.000027890446],"domain_scores_gemma":[0.99967563,0.00010264912,0.00009938484,0.000018007762,0.000026184303,0.00007809834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083631306,0.00023768832,0.0007153869,0.0001981517,0.000140261,0.00048239523,0.00022290381,0.0004376691,0.004146267],"category_scores_gemma":[0.0014537845,0.00013032253,0.0007253772,0.00019850665,0.00023266574,0.00042993962,0.00015805311,0.001074985,0.00058303314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26932994,0.0056989626,0.0108918995,0.0033254363,0.0016260478,0.00018009242,0.00012619421,0.002002048,0.010648028,0.00083432236,0.017600575,0.6777365],"study_design_scores_gemma":[0.41070625,0.40775442,0.08192235,0.0017359491,0.003081776,0.0018133654,0.0002275817,0.0051858225,0.008444784,0.002478228,0.07654684,0.00010264526],"about_ca_topic_score_codex":0.00027766908,"about_ca_topic_score_gemma":0.0011758981,"teacher_disagreement_score":0.004146267,"about_ca_system_score_codex":0.0005511761,"about_ca_system_score_gemma":0.0004365649,"threshold_uncertainty_score":0.0138706565},"labels":[],"label_agreement":null},{"id":"W3195595411","doi":"10.2217/fon-2021-0608","title":"Brigatinib Versus Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Internal medicine","score_opus":0.010820770635600545,"score_gpt":0.3412207235650259,"score_spread":0.33039995292942537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195595411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98112535,0.007983806,0.00032988095,0.0009805149,0.0007336765,0.0018008287,0.0010403553,0.00013601582,0.005869516],"genre_scores_gemma":[0.98754483,0.0034391747,0.0007335635,0.00064473646,0.00025252058,0.0014287947,0.0008072986,0.000019523617,0.005129489],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999632,0.0001856311,0.000034556564,0.00004251645,0.000025678886,0.000079699275],"domain_scores_gemma":[0.9994987,0.00013737405,0.00013207643,0.000029270586,0.000025039632,0.00017753312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011298987,0.0006741626,0.0014618023,0.000318224,0.00024260287,0.0008206575,0.000639518,0.00086484716,0.007363842],"category_scores_gemma":[0.0014326613,0.00026862085,0.001265487,0.00031953762,0.0004690858,0.0007041858,0.0002700522,0.002157313,0.00089274615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95311713,0.004311066,0.00037518633,0.000543043,0.00048892305,0.000035530702,0.000046537894,0.0004751127,0.0035123152,0.00016842627,0.001419753,0.035506953],"study_design_scores_gemma":[0.74400395,0.24226063,0.0047565023,0.00013854612,0.0010304282,0.00010951416,0.00006775046,0.0015475871,0.0022632494,0.00044485126,0.0033472942,0.000029696655],"about_ca_topic_score_codex":0.0011509461,"about_ca_topic_score_gemma":0.004593046,"teacher_disagreement_score":0.007363842,"about_ca_system_score_codex":0.00073588936,"about_ca_system_score_gemma":0.0010331346,"threshold_uncertainty_score":0.02463454},"labels":[],"label_agreement":null},{"id":"W3197275659","doi":"10.2217/fon-2021-0856","title":"The Importance and Value of Engaging Patients in Cancer Research","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Future Earth","funders":"","keywords":"Medicine; Value (mathematics); Cancer; Oncology; Internal medicine; Statistics","score_opus":0.047100962230293676,"score_gpt":0.33322040555019083,"score_spread":0.28611944331989714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197275659","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066050164,0.021282716,0.007701659,0.8586965,0.0019563604,0.00012039111,0.00027871714,0.00006137798,0.043852083],"genre_scores_gemma":[0.9310052,0.015803006,0.0065969303,0.038034637,0.0049859276,0.00012300206,0.00012289724,0.00005168892,0.0032767581],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.94847983,0.04543895,0.0011804554,0.0006214065,0.0030039167,0.0012755529],"domain_scores_gemma":[0.5624719,0.36185572,0.021037942,0.010578413,0.014955927,0.02910012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05035654,0.0002751513,0.0005169853,0.0015339961,0.001591998,0.0070936442,0.0010793838,0.005822449,0.010307619],"category_scores_gemma":[0.23610911,0.0003995809,0.0005327777,0.0014777819,0.0036304388,0.0058186245,0.0034439482,0.00597995,0.0009950622],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021840124,0.0013928676,0.20062825,0.0020976628,0.0005936028,0.0016081705,0.00504712,0.005436675,0.0011504443,0.12017019,0.11553222,0.5441588],"study_design_scores_gemma":[0.00069484377,0.001593305,0.14851597,0.005314422,0.0008355354,0.0061491476,0.023857381,0.013655517,0.0016987264,0.49872556,0.29865494,0.00030460567],"about_ca_topic_score_codex":0.0020272243,"about_ca_topic_score_gemma":0.004818429,"teacher_disagreement_score":0.05035654,"about_ca_system_score_codex":0.0026006906,"about_ca_system_score_gemma":0.007562765,"threshold_uncertainty_score":0.26631403},"labels":[],"label_agreement":null},{"id":"W3207977249","doi":"10.2217/fon-2021-0753","title":"Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology","score_opus":0.015681021701659328,"score_gpt":0.3375341293603767,"score_spread":0.3218531076587174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207977249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98099774,0.0053177197,0.0006964489,0.001141022,0.00045443178,0.005021019,0.0011081197,0.00010998728,0.0051534963],"genre_scores_gemma":[0.98132277,0.0030207857,0.0017930382,0.001512677,0.0003882935,0.0050666593,0.0015802033,0.000022947308,0.005292627],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994861,0.00027851356,0.000035032495,0.0000807883,0.00004076378,0.00007885875],"domain_scores_gemma":[0.9994746,0.00009315504,0.00013239356,0.00004040726,0.000031016472,0.00022851636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018592956,0.0010808097,0.001151024,0.00050397887,0.00036631394,0.0008323697,0.0008815226,0.0012408338,0.0055025327],"category_scores_gemma":[0.00081904733,0.00037378547,0.0010714531,0.00050593837,0.00085225434,0.0009195173,0.00050558976,0.0022100327,0.00083664106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8872203,0.029017057,0.0018582803,0.001077197,0.0006962161,0.000066256966,0.0000799788,0.0009536023,0.010286498,0.0006932502,0.0020212748,0.06603006],"study_design_scores_gemma":[0.72667587,0.26506588,0.0024952646,0.000061701816,0.00029292057,0.00010248219,0.00004017603,0.00046490593,0.0013467235,0.000276603,0.0031567807,0.00002076975],"about_ca_topic_score_codex":0.00072692934,"about_ca_topic_score_gemma":0.0033943825,"teacher_disagreement_score":0.0055025327,"about_ca_system_score_codex":0.0007919699,"about_ca_system_score_gemma":0.001483269,"threshold_uncertainty_score":0.018407762},"labels":[],"label_agreement":null},{"id":"W3209015618","doi":"10.2217/fon-2021-1110","title":"The role of Globo H and SSEA-4 in the Development and Progression of Cancer, and their Potential as Therapeutic Targets","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Glycosylation; Carcinogenesis; Cell biology; Cancer cell; Ceramide; Glycan; Cancer; Embryonic stem cell; Galectin; Cell; Biology; Biochemistry; Glycoprotein; Apoptosis; Gene; Genetics","score_opus":0.01578068486255948,"score_gpt":0.36895346338895224,"score_spread":0.3531727785263928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209015618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016455248,0.9983584,0.000109785266,0.00027986406,0.00012395535,0.0000027745002,0.000018807963,0.0000060112943,0.0009357887],"genre_scores_gemma":[0.00059466925,0.99861956,0.000111155496,0.00010565714,0.00006858935,0.0000037344676,0.000025693498,9.284794e-7,0.00047009139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999242,0.000013236352,0.000010290192,0.0000142039735,0.000027715958,0.000010326487],"domain_scores_gemma":[0.99988174,0.00004423841,0.000016867063,0.0000039595625,0.00003618362,0.000016933549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031906425,0.0005241772,0.0006891428,0.0015587014,0.00020735573,0.0007681341,0.00043003738,0.00079158845,0.0028768675],"category_scores_gemma":[0.00036456453,0.0001728161,0.00028556422,0.0016332375,0.00030388086,0.00096707814,0.00047478775,0.0011817884,0.0015931202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010628252,0.00006479644,0.00023231421,0.0144093335,0.00007965433,0.0003149813,0.000066527595,0.00045509735,0.0043847985,0.006621536,0.026148902,0.94711566],"study_design_scores_gemma":[0.000010206333,0.00007581272,0.00070041994,0.001631607,0.00007462831,0.0012301882,0.00005225172,0.00007631747,0.00085350627,0.0019443255,0.9933373,0.000013472065],"about_ca_topic_score_codex":0.00084938563,"about_ca_topic_score_gemma":0.0012766764,"teacher_disagreement_score":0.0028768675,"about_ca_system_score_codex":0.000545742,"about_ca_system_score_gemma":0.00087960664,"threshold_uncertainty_score":0.009624124},"labels":[],"label_agreement":null},{"id":"W3212868920","doi":"10.2217/fon-2021-0592","title":"Patterns of Colorectal Cancer Diagnosis Among Younger Adults in a Real-World, Population-Based Cohort","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Quartile; Colorectal cancer; Population; Odds ratio; Demography; Logistic regression; Retrospective cohort study; Socioeconomic status; Internal medicine; Cohort; Cancer; Confidence interval","score_opus":0.011369034094014989,"score_gpt":0.3020783204879855,"score_spread":0.29070928639397053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212868920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96894896,0.022345232,0.0001811554,0.00069274695,0.000046201785,0.000039379618,0.005539009,0.000028367429,0.0021789367],"genre_scores_gemma":[0.9881308,0.008334145,0.0002212074,0.000215213,0.00003453175,0.000013648464,0.0027220566,0.0000045665993,0.00032398163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992525,0.00007674623,0.00008678013,0.00014902424,0.0003122805,0.00012250709],"domain_scores_gemma":[0.99864906,0.00013146021,0.00063930074,0.000043784043,0.00036526652,0.00017115223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006172274,0.00017378193,0.00026764124,0.0021629352,0.00042293585,0.0007739522,0.0005939648,0.00029187856,0.0006986158],"category_scores_gemma":[0.0019157879,0.00017461924,0.00041220846,0.003323952,0.00033405685,0.00027044798,0.00029053068,0.00025650312,0.00011336792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026311474,0.0000057662755,0.99408394,0.00012770898,0.000089914676,0.00010506177,0.00014140128,0.000044264663,0.00014121005,0.000018299339,0.0005427938,0.004673424],"study_design_scores_gemma":[0.0000011818483,0.000007786376,0.9992555,0.000034790646,0.000022600974,0.00011429607,0.00014264927,0.00002077371,0.000009369046,0.0000038092653,0.00038532694,0.0000018764342],"about_ca_topic_score_codex":0.6634955,"about_ca_topic_score_gemma":0.77637166,"teacher_disagreement_score":0.6634955,"about_ca_system_score_codex":0.0027058728,"about_ca_system_score_gemma":0.003553789,"threshold_uncertainty_score":0.6769725},"labels":[],"label_agreement":null},{"id":"W4205173478","doi":"10.2217/fon-2021-1096","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Clinical trial; Cancer; Nivolumab; Immunotherapy; Androgen receptor","score_opus":0.057886474600819124,"score_gpt":0.3914232047436411,"score_spread":0.333536730142822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205173478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96710724,0.0024472068,0.0011488927,0.0016524232,0.00090032263,0.015058649,0.0048538456,0.00031886713,0.0065126233],"genre_scores_gemma":[0.95844287,0.0018958561,0.0039266963,0.0036068908,0.0009649604,0.01619295,0.0051856963,0.00008140095,0.009702659],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993261,0.0003441733,0.000027621905,0.00013139512,0.000052260733,0.000118354386],"domain_scores_gemma":[0.9988949,0.00020848218,0.00020159243,0.000096321455,0.00007742194,0.0005213667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018502472,0.0020064856,0.0020215088,0.00047066264,0.00058452366,0.0013622852,0.0010692811,0.002259512,0.0101239635],"category_scores_gemma":[0.0016378461,0.0007293473,0.001776587,0.0005427977,0.0013755622,0.0014014728,0.0004156049,0.0038130414,0.001704914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9545907,0.020898413,0.0010172185,0.0003894042,0.00073450373,0.00006777638,0.00008249916,0.00042968927,0.004922209,0.00022374262,0.002653964,0.013989837],"study_design_scores_gemma":[0.9361807,0.061201148,0.0010388617,0.000010362667,0.00011883967,0.000031895524,0.000017244523,0.00023453211,0.00026560767,0.00012339518,0.0007682048,0.000009122461],"about_ca_topic_score_codex":0.0014700344,"about_ca_topic_score_gemma":0.00522629,"teacher_disagreement_score":0.0101239635,"about_ca_system_score_codex":0.0012003377,"about_ca_system_score_gemma":0.0021929585,"threshold_uncertainty_score":0.033868074},"labels":[],"label_agreement":null},{"id":"W4205361646","doi":"10.2217/fon-2021-1348","title":"Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?","year":2022,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Lung cancer; Internal medicine; Chemotherapy; MEDLINE; Cancer; Immunotherapy","score_opus":0.009674789902303988,"score_gpt":0.3116780937574068,"score_spread":0.3020033038551028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205361646","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025946438,0.023445327,0.0001978557,0.09147595,0.8834718,0.000015213012,0.00005139448,0.000043615517,0.0012728623],"genre_scores_gemma":[0.00038590847,0.012282342,0.00018507933,0.04165109,0.94244313,0.000020954772,0.000025289663,0.000028904458,0.0029773735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935715,0.0019847874,0.0010562043,0.00063007337,0.0023987056,0.00035880646],"domain_scores_gemma":[0.9599431,0.023144115,0.0019628475,0.000695143,0.010524718,0.00372994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014124738,0.0030079328,0.006049844,0.0028764985,0.0025251568,0.0077455402,0.0036711222,0.018285811,0.009005943],"category_scores_gemma":[0.04314921,0.0013164212,0.0030668657,0.0014248231,0.0026214272,0.006636776,0.0014253157,0.036624786,0.006724346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060541337,0.000014328193,0.000025596048,0.00034404328,0.000040092273,0.000055382345,0.0000071322643,0.000039036644,0.000029844612,0.00045599806,0.98750067,0.011427365],"study_design_scores_gemma":[0.00026400306,0.000093908224,0.00030972774,0.0016060733,0.0002587181,0.0003419785,0.00004921075,0.0003795864,0.00015258897,0.0038368234,0.9926523,0.00005504871],"about_ca_topic_score_codex":0.0018778176,"about_ca_topic_score_gemma":0.00569016,"teacher_disagreement_score":0.018285811,"about_ca_system_score_codex":0.0042480263,"about_ca_system_score_gemma":0.0046088523,"threshold_uncertainty_score":0.07469964},"labels":[],"label_agreement":null},{"id":"W4220676878","doi":"10.2217/fon-2021-1633","title":"Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Meta-analysis; Colorectal cancer; Hazard ratio; Microsatellite instability; Population; Adverse effect; Confidence interval; Cancer; Immunotherapy","score_opus":0.21069128582860736,"score_gpt":0.4535306718627213,"score_spread":0.24283938603411392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220676878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020519232,0.99560416,0.00058942847,0.0002366487,0.00015108382,0.00044828444,0.00045918464,0.000018946208,0.00044026625],"genre_scores_gemma":[0.07188746,0.92277634,0.002398961,0.00062543916,0.00015823293,0.0011910714,0.0006070549,0.000019368446,0.00033595986],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933466,0.0039489553,0.0012917587,0.0005336947,0.0007049778,0.00017403836],"domain_scores_gemma":[0.9875881,0.009663269,0.0016273762,0.00022278698,0.0007470166,0.00015147253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009573392,0.002291204,0.012499372,0.0047859983,0.00045428996,0.0023463469,0.0014749469,0.001588709,0.00524616],"category_scores_gemma":[0.030737814,0.0009097999,0.020106638,0.0047273505,0.00043667498,0.0013600243,0.0011202039,0.0017639439,0.00035814563],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020904269,0.000030542655,0.0010596566,0.6213269,0.3429268,0.000076351214,0.00005145437,0.0008408291,0.00020036868,0.00028402323,0.0011213497,0.029991282],"study_design_scores_gemma":[0.0011213375,0.00035571316,0.0022921436,0.08060252,0.9096081,0.0000875343,0.00004130725,0.00038118658,0.00014896323,0.00047816162,0.004858968,0.000024006666],"about_ca_topic_score_codex":0.008111907,"about_ca_topic_score_gemma":0.01783228,"teacher_disagreement_score":0.012499372,"about_ca_system_score_codex":0.0032785828,"about_ca_system_score_gemma":0.004614487,"threshold_uncertainty_score":0.050629497},"labels":[],"label_agreement":null},{"id":"W4224311311","doi":"10.2217/fon-2022-0045","title":"A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i> -mutated breast cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Medicine; Fulvestrant; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Estrogen receptor","score_opus":0.03373686270539864,"score_gpt":0.405549785522902,"score_spread":0.37181292281750333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421706,0.004542431,0.0012919854,0.0012911268,0.0006172962,0.007855824,0.002457338,0.00021965143,0.007507359],"genre_scores_gemma":[0.9589289,0.004435697,0.005068134,0.0030871828,0.0005878846,0.010988533,0.0049588084,0.00004946613,0.011895297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99957985,0.0002538618,0.00001811641,0.000043907723,0.000039678827,0.00006463651],"domain_scores_gemma":[0.99934953,0.00017377992,0.00012784042,0.000048522477,0.000034432695,0.0002659331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019955349,0.0011230321,0.0015271032,0.00037617196,0.00031594193,0.00079605303,0.0007182765,0.0010614586,0.0060000084],"category_scores_gemma":[0.0010549629,0.00034031758,0.0011725494,0.0002917328,0.00060306414,0.0005150963,0.00031181183,0.0023764477,0.0011551348],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89625365,0.027240101,0.0015269023,0.00065126363,0.00062144245,0.00009664636,0.00006168643,0.0012479536,0.0069609014,0.00048932823,0.0036971448,0.061152924],"study_design_scores_gemma":[0.87539643,0.119376145,0.0017565406,0.00003639279,0.00017854745,0.00006161508,0.000018752511,0.00059154007,0.0006940167,0.00018909821,0.0016911427,0.000009646808],"about_ca_topic_score_codex":0.0005890423,"about_ca_topic_score_gemma":0.0014603136,"teacher_disagreement_score":0.0060000084,"about_ca_system_score_codex":0.0005228945,"about_ca_system_score_gemma":0.0014182586,"threshold_uncertainty_score":0.020072043},"labels":[],"label_agreement":null},{"id":"W4254354993","doi":"10.2217/fon.15.340","title":"Addressing Future Challenges for Cancer Services: Part II","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.08915121470434152,"score_gpt":0.3078357438251544,"score_spread":0.21868452912081288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254354993","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008759957,0.036349162,0.00062718696,0.8757578,0.038851824,0.00033117703,0.00011836114,0.00010623796,0.04698226],"genre_scores_gemma":[0.03666385,0.1632726,0.004705943,0.5892009,0.06283659,0.0023177864,0.0010714877,0.00036332093,0.13956755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99160415,0.0026811033,0.0004925703,0.00042754094,0.0028089525,0.0019856512],"domain_scores_gemma":[0.9796616,0.0027993578,0.00095701084,0.00060206064,0.004407829,0.011572193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009230344,0.00088261644,0.000660693,0.0015764545,0.005256031,0.01198388,0.0024583882,0.0078793485,0.04035249],"category_scores_gemma":[0.023258679,0.00055219803,0.00080532505,0.002549327,0.0035836468,0.008000913,0.008338937,0.0093865665,0.00892296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007678842,0.000036460722,0.0004374517,0.0003853538,0.000006455647,0.000096953685,0.00054401025,0.00008512905,0.000067615416,0.006202069,0.93972903,0.052401774],"study_design_scores_gemma":[0.0000064854967,0.000032479726,0.0020519844,0.0015404936,0.0000036962235,0.00025892223,0.002067676,0.00006562206,0.000028466035,0.003831821,0.99009484,0.000017548791],"about_ca_topic_score_codex":0.019772978,"about_ca_topic_score_gemma":0.033020705,"teacher_disagreement_score":0.04035249,"about_ca_system_score_codex":0.015142471,"about_ca_system_score_gemma":0.044515323,"threshold_uncertainty_score":0.13499254},"labels":[],"label_agreement":null},{"id":"W4281396346","doi":"10.2217/fon-2021-1629","title":"Targeting <i>FGFR3</i> Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Helsinn","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Adjuvant; Bladder cancer; Cisplatin; Urothelial cancer; Urology; Randomized controlled trial; Adverse effect; Urothelial carcinoma; Cancer; Chemotherapy; Pathology","score_opus":0.019136890186583426,"score_gpt":0.3077494896688529,"score_spread":0.28861259948226947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281396346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536688,0.016141476,0.0021634118,0.0030201564,0.0005917864,0.0075020613,0.0053477827,0.00060557586,0.010958987],"genre_scores_gemma":[0.9678726,0.006650869,0.0040469123,0.0027096379,0.00025096946,0.0051355083,0.006209004,0.000086287204,0.0070380988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997534,0.00011685669,0.000014853288,0.000038033446,0.000029838222,0.000046981346],"domain_scores_gemma":[0.9997218,0.000050534585,0.000077234006,0.00002500632,0.000025178015,0.000100285564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012500874,0.0011085174,0.001359478,0.00021570783,0.00026644891,0.00088788616,0.0006152311,0.0011450807,0.0051482595],"category_scores_gemma":[0.000808869,0.0002689563,0.0011628207,0.00025098235,0.0005652738,0.0006473656,0.00032170725,0.0021484175,0.00095164444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71885854,0.015810246,0.002660011,0.004312626,0.0020207695,0.00021849544,0.00020611032,0.0026672836,0.050360646,0.0016305657,0.021204317,0.18005043],"study_design_scores_gemma":[0.81307715,0.16426528,0.0048481,0.00015466305,0.0006553707,0.0003925523,0.00005564186,0.0012405359,0.004232035,0.0007396633,0.01030004,0.000038962447],"about_ca_topic_score_codex":0.0008050343,"about_ca_topic_score_gemma":0.002379786,"teacher_disagreement_score":0.0051482595,"about_ca_system_score_codex":0.0007127312,"about_ca_system_score_gemma":0.0012152717,"threshold_uncertainty_score":0.017222643},"labels":[],"label_agreement":null},{"id":"W4281565440","doi":"10.2217/fon-2021-1255","title":"Pregnancy and Perinatal Outcomes Following Exposure to Antineoplastic Agents Around Pregnancy within the US FDA Adverse Event Reporting System","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ipsen; Amgen","keywords":"Medicine; Adverse Event Reporting System; Pregnancy; Abortion; Adverse effect; Obstetrics; Congenital malformations; Pharmacology","score_opus":0.020442522060643835,"score_gpt":0.31510395226613735,"score_spread":0.2946614302054935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281565440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72802347,0.24965003,0.0023300357,0.0014387894,0.0001323119,0.00021832006,0.008734738,0.000045409448,0.009426931],"genre_scores_gemma":[0.9285212,0.0675372,0.0009796106,0.00028272564,0.00008873759,0.00007347034,0.002109295,0.000008230167,0.00039952298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962351,0.0013413709,0.00096289197,0.00033531012,0.0009694108,0.00015594164],"domain_scores_gemma":[0.97771627,0.008088016,0.012369135,0.0003161755,0.0013385841,0.00017172417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038395736,0.0001678314,0.0002920442,0.002348843,0.00016119544,0.00051322294,0.00026533147,0.00023164866,0.0009090213],"category_scores_gemma":[0.01909062,0.0001098334,0.00062411535,0.002239815,0.00024146197,0.0004924428,0.0003707351,0.0003885305,0.00011521208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036821183,0.000021775288,0.9421259,0.0015133095,0.00057517,0.00085952104,0.00017613248,0.00021396138,0.00030502237,0.0002534753,0.0009630379,0.052624397],"study_design_scores_gemma":[0.00001096423,0.00022621805,0.98447615,0.0015355396,0.00063272665,0.0054441267,0.00037656561,0.00026678244,0.0007498289,0.00011594298,0.0061479984,0.00001712088],"about_ca_topic_score_codex":0.003490536,"about_ca_topic_score_gemma":0.0031341503,"teacher_disagreement_score":0.0038395736,"about_ca_system_score_codex":0.0005200072,"about_ca_system_score_gemma":0.0007237728,"threshold_uncertainty_score":0.020305812},"labels":[],"label_agreement":null},{"id":"W4282970409","doi":"10.2217/fon-2022-0380","title":"A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Oncology; Cystectomy; Bladder cancer; Internal medicine; Radiation therapy; Clinical trial; Cisplatin; Neoadjuvant therapy; Immune checkpoint; Chemotherapy; Cancer; Immunotherapy; Breast cancer","score_opus":0.04402021379365379,"score_gpt":0.4166381891270673,"score_spread":0.3726179753334135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282970409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847073,0.0018880934,0.00091776694,0.0015684015,0.00047681236,0.0041266447,0.0011546054,0.00011889303,0.005041496],"genre_scores_gemma":[0.97823936,0.0015141068,0.0029837512,0.002187304,0.00034627193,0.0054447986,0.0025035266,0.0000306338,0.006750233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99959666,0.00021000022,0.000017083214,0.00006806482,0.000034485616,0.00007387416],"domain_scores_gemma":[0.99941075,0.00008797052,0.000091092435,0.00004951916,0.000037969898,0.00032262935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013501414,0.0011890178,0.0013497935,0.00026114398,0.00038827147,0.00091780565,0.0005825773,0.0014254921,0.0034351628],"category_scores_gemma":[0.00085280027,0.00040751835,0.0008374869,0.0002120436,0.00083220954,0.00078178203,0.00027361495,0.0030684306,0.0006892952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78973466,0.07780874,0.0031905633,0.0006668888,0.00102834,0.00016383994,0.00021851814,0.0025294276,0.037457507,0.0008707629,0.00763773,0.07869301],"study_design_scores_gemma":[0.58701205,0.39637917,0.004226329,0.000039545503,0.0003182057,0.00015984937,0.00005486769,0.0016756754,0.0042285905,0.00046166955,0.0054133623,0.000030626197],"about_ca_topic_score_codex":0.0006174972,"about_ca_topic_score_gemma":0.0018957423,"teacher_disagreement_score":0.0034351628,"about_ca_system_score_codex":0.00079157867,"about_ca_system_score_gemma":0.0018422857,"threshold_uncertainty_score":0.0114917755},"labels":[],"label_agreement":null},{"id":"W4285798648","doi":"10.2217/fon-2022-0450","title":"Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"AbbVie","keywords":"Venetoclax; Medicine; Azacitidine; Myeloid leukemia; Internal medicine; Oncology; Maintenance therapy; Minimal residual disease; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.07129580869837542,"score_gpt":0.39482913439692097,"score_spread":0.32353332569854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285798648","genre_codex":"review","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11612173,0.80730015,0.0046483297,0.0052252463,0.0055056987,0.036807667,0.004384319,0.00024749528,0.019759433],"genre_scores_gemma":[0.36957443,0.5243582,0.012611471,0.012561081,0.0015605751,0.049282346,0.0038280848,0.00008437491,0.02613951],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956423,0.00023773368,0.000035542118,0.00006400108,0.00005497925,0.000043612825],"domain_scores_gemma":[0.9997764,0.00006794326,0.00005611072,0.000016817345,0.000030399005,0.00005230942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023544838,0.0006447856,0.0021869254,0.00027553304,0.00015158314,0.00086939015,0.0007787573,0.0010140723,0.0054314025],"category_scores_gemma":[0.0014907989,0.0002536959,0.0014316058,0.000424772,0.00032498132,0.0004920292,0.00030452764,0.0018951315,0.0009459119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28096563,0.004305576,0.0013942778,0.073375285,0.012938385,0.000286664,0.00021661207,0.0022079435,0.0075622923,0.00627341,0.02762539,0.5828485],"study_design_scores_gemma":[0.8306724,0.04111808,0.0039102705,0.008119592,0.010299917,0.00033884557,0.00008240255,0.0010558497,0.001413416,0.0021360687,0.10078894,0.00006423984],"about_ca_topic_score_codex":0.00059519487,"about_ca_topic_score_gemma":0.0018300263,"teacher_disagreement_score":0.0054314025,"about_ca_system_score_codex":0.0005397124,"about_ca_system_score_gemma":0.0012605553,"threshold_uncertainty_score":0.01816988},"labels":[],"label_agreement":null},{"id":"W4291019728","doi":"10.2217/fon-2022-0484","title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Rosetrees Trust; Cancer Research UK","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Placebo; Clinical trial; Oncology; Extramedullary hematopoiesis; Bone marrow; Haematopoiesis; Pathology; Stem cell","score_opus":0.02084345738915811,"score_gpt":0.3262002128301859,"score_spread":0.3053567554410278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291019728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96629244,0.007972532,0.0014544093,0.0013844857,0.0008733924,0.012664696,0.0042829304,0.00046832237,0.004606822],"genre_scores_gemma":[0.9575067,0.00539423,0.0037096494,0.0027028534,0.00096835685,0.015017858,0.005535427,0.000108706015,0.0090561835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994524,0.00028348222,0.000030546435,0.00008064493,0.000044684326,0.00010829837],"domain_scores_gemma":[0.99927336,0.00014114282,0.00019248163,0.00007382977,0.00006807112,0.00025120095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002428198,0.0020815171,0.002649994,0.0005147458,0.00042931136,0.0015576844,0.0013388366,0.0019912964,0.008080728],"category_scores_gemma":[0.0014249091,0.0007302813,0.0018195377,0.00040718305,0.001225254,0.0013517077,0.00052865595,0.003737227,0.0014626614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92630625,0.03241385,0.000644197,0.0010425835,0.00075059105,0.00006389369,0.00008437909,0.00079831295,0.01054135,0.00031619947,0.0027366742,0.024301812],"study_design_scores_gemma":[0.84118974,0.15432382,0.0015959267,0.000046545454,0.0002088391,0.00004933694,0.000035401743,0.00036271822,0.00090325077,0.00016800262,0.001101308,0.000015004515],"about_ca_topic_score_codex":0.0006859622,"about_ca_topic_score_gemma":0.0016040488,"teacher_disagreement_score":0.008080728,"about_ca_system_score_codex":0.0008967637,"about_ca_system_score_gemma":0.0013704363,"threshold_uncertainty_score":0.027032733},"labels":[],"label_agreement":null},{"id":"W4292884011","doi":"10.2217/fon-2022-0595","title":"HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Trastuzumab; Internal medicine; Chemotherapy; Oncology; Gastroesophageal Junction; Monoclonal antibody; Cancer; Adenocarcinoma; Antibody; Immunology; Breast cancer","score_opus":0.01669934964258832,"score_gpt":0.2941696805263527,"score_spread":0.2774703308837643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292884011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98216647,0.0038878433,0.0010902619,0.0006654187,0.00023399248,0.0067173024,0.0010550042,0.00011588308,0.004067704],"genre_scores_gemma":[0.9855123,0.002279846,0.0034643065,0.0009624198,0.00010019448,0.0040492225,0.0009383786,0.000026313413,0.0026669253],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958783,0.00015714086,0.000030126625,0.00008247671,0.000051571427,0.00009083772],"domain_scores_gemma":[0.9997397,0.000028071603,0.00006295976,0.000017745479,0.000014056371,0.0001374394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011986449,0.0005391653,0.0012120894,0.00049473974,0.00034544992,0.0008938258,0.0007193228,0.00086170953,0.0037838826],"category_scores_gemma":[0.0004678228,0.00031122053,0.00086312625,0.00034707802,0.0007408186,0.00078806723,0.0004282858,0.002227673,0.000593023],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6499197,0.049736064,0.004449927,0.0016579714,0.0012711624,0.00019082807,0.00020888782,0.002365812,0.060599122,0.0013275851,0.0028350973,0.22543788],"study_design_scores_gemma":[0.60071784,0.36346304,0.010462975,0.00015295515,0.00077252166,0.0002994942,0.00009868766,0.0014136876,0.010679202,0.0005525467,0.011338834,0.000048103684],"about_ca_topic_score_codex":0.0007270395,"about_ca_topic_score_gemma":0.003951804,"teacher_disagreement_score":0.0037838826,"about_ca_system_score_codex":0.00094718934,"about_ca_system_score_gemma":0.001441494,"threshold_uncertainty_score":0.012658358},"labels":[],"label_agreement":null},{"id":"W4313891690","doi":"10.2217/fon-2022-0898","title":"Many People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment up to 8 Years: A Plain Language Summary","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Clinical trial; Oncology; Lymphoma; Leukemia; Chemotherapy","score_opus":0.04235839675099185,"score_gpt":0.3464954461082819,"score_spread":0.3041370493572901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313891690","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0242086,0.30363512,0.004840021,0.3280862,0.039368283,0.0017262459,0.24733528,0.0012598886,0.04954031],"genre_scores_gemma":[0.18842646,0.24448307,0.012071676,0.28897962,0.07584174,0.0063976077,0.13643123,0.0015392898,0.045829333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881512,0.004784768,0.0033334503,0.00087282015,0.0023781827,0.00047967245],"domain_scores_gemma":[0.9193956,0.040661205,0.018976603,0.0016641315,0.017788017,0.0015143985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013032832,0.0011776912,0.0020850701,0.004781141,0.0006700445,0.0055619334,0.0014689246,0.0025510702,0.049747452],"category_scores_gemma":[0.06299729,0.00062527874,0.0028561824,0.004932337,0.00081563403,0.004216729,0.001641561,0.0031330558,0.01107449],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033604626,0.000074588825,0.010227229,0.027814304,0.00112164,0.00034576037,0.00044107344,0.00016235781,0.00042181788,0.0010221627,0.8433794,0.11162935],"study_design_scores_gemma":[0.003885,0.0016217105,0.0635648,0.050364006,0.004791007,0.0016684161,0.0021663427,0.00038014806,0.0013740661,0.0049428917,0.86477715,0.00046455272],"about_ca_topic_score_codex":0.0023130435,"about_ca_topic_score_gemma":0.0028413935,"teacher_disagreement_score":0.049747452,"about_ca_system_score_codex":0.0016309571,"about_ca_system_score_gemma":0.0027437715,"threshold_uncertainty_score":0.16642183},"labels":[],"label_agreement":null},{"id":"W4317433563","doi":"10.2217/fon-2022-0919","title":"A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; BC Cancer Agency; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Second line; Real world data; First line; Epidermal growth factor receptor; Gefitinib; Cancer; Erlotinib; Data science","score_opus":0.0400914084856207,"score_gpt":0.3892553444016239,"score_spread":0.3491639359160032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317433563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97942024,0.0047749244,0.00066122046,0.00044607194,0.000051606297,0.0005734033,0.011125566,0.00003721297,0.0029098392],"genre_scores_gemma":[0.96159154,0.0012208334,0.0011812012,0.00047932653,0.00012889436,0.0005324159,0.033822946,0.00003146297,0.0010113703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963785,0.0019710367,0.00040047194,0.0004135044,0.0006513174,0.00018505639],"domain_scores_gemma":[0.99533266,0.0011308439,0.0018667763,0.00064427615,0.0005636657,0.00046174193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006579688,0.0009292588,0.0016871417,0.00046927208,0.00041854344,0.0017265395,0.0006990207,0.0007933986,0.0021405537],"category_scores_gemma":[0.0035018593,0.0003935229,0.0027103866,0.0008398027,0.0005836013,0.0008043449,0.0006884043,0.0010101675,0.000800164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25290483,0.004568575,0.6180722,0.0035295165,0.025882306,0.00088756444,0.0005323688,0.005592855,0.01447447,0.0006381728,0.012317116,0.06059999],"study_design_scores_gemma":[0.043790836,0.053666923,0.8352541,0.0003449024,0.016232835,0.0026004068,0.00043737094,0.0034355368,0.009601639,0.00041829504,0.033986527,0.00023054887],"about_ca_topic_score_codex":0.0011281694,"about_ca_topic_score_gemma":0.0030715812,"teacher_disagreement_score":0.006579688,"about_ca_system_score_codex":0.0012210843,"about_ca_system_score_gemma":0.0012050064,"threshold_uncertainty_score":0.034797072},"labels":[],"label_agreement":null},{"id":"W4321597883","doi":"10.2217/fon-2023-0007","title":"Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Chemotherapy; Lung cancer; Cancer; Internal medicine; Oncology; Immunotherapy; Surgery","score_opus":0.015032802171098278,"score_gpt":0.3127348910883733,"score_spread":0.29770208891727507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321597883","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004679495,0.17126408,0.008348409,0.06746409,0.038578123,0.009935281,0.65540266,0.0018448981,0.042482972],"genre_scores_gemma":[0.046439428,0.20893176,0.021368839,0.21790114,0.045872986,0.045737796,0.35038373,0.002190603,0.061173726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98128647,0.0076600653,0.0062984,0.0008422208,0.0033403656,0.0005725345],"domain_scores_gemma":[0.90485376,0.060252953,0.015550363,0.0017616845,0.016264021,0.001317316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014568765,0.002422137,0.0042110686,0.005548738,0.0008584956,0.004209869,0.0023439126,0.0029820632,0.102140516],"category_scores_gemma":[0.08810683,0.0010585584,0.006531349,0.0069099874,0.0006706038,0.0027990444,0.0014580083,0.0037410907,0.028393552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005827783,0.00018752449,0.0020674737,0.0590676,0.001683581,0.00015810011,0.0001020409,0.00026230238,0.0003021314,0.00057222677,0.8618855,0.067883834],"study_design_scores_gemma":[0.014023057,0.0031798587,0.022629995,0.06336823,0.0070132506,0.00090363127,0.00042399103,0.0003656077,0.00094672025,0.0020625077,0.8848046,0.00027859415],"about_ca_topic_score_codex":0.006200343,"about_ca_topic_score_gemma":0.0068102563,"teacher_disagreement_score":0.102140516,"about_ca_system_score_codex":0.0023545409,"about_ca_system_score_gemma":0.00521007,"threshold_uncertainty_score":0.34169406},"labels":[],"label_agreement":null},{"id":"W4321599750","doi":"10.2217/fon-2022-1015","title":"Plain Language Summary of the iNNOVATE Study: Ibrutinib Plus Rituximab is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia","year":2023,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"Pharmacyclics","keywords":"Rituximab; Ibrutinib; Medicine; Internal medicine; Waldenstrom macroglobulinemia; Ofatumumab; Placebo; Oncology; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Pathology; Alternative medicine","score_opus":0.008499668118011266,"score_gpt":0.29985058565332007,"score_spread":0.2913509175353088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321599750","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009931275,0.30950344,0.00592121,0.20679544,0.08365439,0.008813373,0.3131941,0.0011820028,0.061004817],"genre_scores_gemma":[0.0577083,0.21395281,0.009012872,0.30906925,0.12676978,0.01990344,0.17927705,0.0012190324,0.08308752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394083,0.002818598,0.0013924439,0.00028783837,0.0012831764,0.00027710863],"domain_scores_gemma":[0.98150796,0.008690769,0.0038587423,0.00043754018,0.0044520926,0.0010530207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010173844,0.0015909025,0.0037673193,0.0017739472,0.00054839824,0.0037604265,0.0016569345,0.0027554191,0.04716361],"category_scores_gemma":[0.026966065,0.0006304729,0.0038342313,0.0029267236,0.00045230662,0.0018979098,0.00076365244,0.00369711,0.014306221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013281924,0.00014801908,0.0010098382,0.016996242,0.001320888,0.00015139392,0.000059240258,0.00017581206,0.00038291886,0.00054542883,0.89683574,0.069092445],"study_design_scores_gemma":[0.039285384,0.0055839103,0.020492192,0.020941876,0.0063540605,0.0005837944,0.00020108701,0.0003706561,0.0010036852,0.0026484344,0.9022661,0.00026879818],"about_ca_topic_score_codex":0.0023724255,"about_ca_topic_score_gemma":0.0025138955,"teacher_disagreement_score":0.04716361,"about_ca_system_score_codex":0.0014063121,"about_ca_system_score_gemma":0.0023844491,"threshold_uncertainty_score":0.15777797},"labels":[],"label_agreement":null},{"id":"W4323294773","doi":"10.2217/fon-2022-1059","title":"TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i> -positive non-small-cell lung cancer and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Brain metastasis; Clinical trial; Interim analysis; Clinical endpoint; Adverse effect; Adenocarcinoma; Metastasis","score_opus":0.012321025614561127,"score_gpt":0.38565660284578784,"score_spread":0.37333557723122673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323294773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570775,0.0059149344,0.004232592,0.0017456639,0.0002642787,0.009787624,0.008520666,0.00051592523,0.011940967],"genre_scores_gemma":[0.9553458,0.0039251605,0.007119439,0.00232659,0.00013959686,0.00652377,0.016816385,0.0002608933,0.0075423503],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995579,0.00017614703,0.000023337549,0.000074077434,0.00004883307,0.00011962797],"domain_scores_gemma":[0.99962795,0.000029272385,0.00008863646,0.000029296962,0.000043644897,0.00018115876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019075604,0.0012839908,0.0010610375,0.00036172624,0.0002816904,0.0009979488,0.00071953057,0.0009749143,0.0037089759],"category_scores_gemma":[0.00062435813,0.00036499402,0.0012978511,0.00045327796,0.0006322598,0.00076843466,0.00070183986,0.001997572,0.0009598041],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32885632,0.039149456,0.02469399,0.0039852946,0.00305172,0.00086604943,0.0006205571,0.009510906,0.32587552,0.0027852636,0.03879668,0.22180831],"study_design_scores_gemma":[0.44518515,0.40129548,0.050134983,0.00032399132,0.0024388663,0.0027252992,0.00039853744,0.0046576173,0.040952966,0.0010423006,0.050681714,0.00016312404],"about_ca_topic_score_codex":0.0015944077,"about_ca_topic_score_gemma":0.0055650617,"teacher_disagreement_score":0.0037089759,"about_ca_system_score_codex":0.001333744,"about_ca_system_score_gemma":0.002014456,"threshold_uncertainty_score":0.01240778},"labels":[],"label_agreement":null},{"id":"W4324128598","doi":"10.2217/fon-2022-0713","title":"Significant heterogeneity of published literature comparing radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma","year":2023,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cancer; Radiation oncology; Radiofrequency ablation; Internal medicine; Radiation therapy; Oncology; Family medicine; Ablation","score_opus":0.0769494634989859,"score_gpt":0.3020577114421249,"score_spread":0.225108247943139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324128598","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04422387,0.65678525,0.00095357205,0.25845107,0.020445436,0.00017130937,0.0022024864,0.000060088398,0.016706958],"genre_scores_gemma":[0.35880727,0.26449162,0.0015814061,0.3106328,0.06052546,0.00035261715,0.0018520928,0.00011168899,0.0016451237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881975,0.004934152,0.004212922,0.0006574193,0.0016701487,0.00032780683],"domain_scores_gemma":[0.8644878,0.11315359,0.010809797,0.0017638392,0.008608981,0.0011759269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014613624,0.00034186573,0.0023735745,0.0031635133,0.0005718332,0.0025884283,0.0009827324,0.003567455,0.003251386],"category_scores_gemma":[0.10753931,0.0002546597,0.0018488035,0.0054354095,0.0010716511,0.0013209475,0.0007573424,0.0018569193,0.000931155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130798705,0.00027835267,0.086544655,0.09713375,0.01889997,0.007953432,0.001584197,0.00087225164,0.0034274196,0.002785994,0.26767272,0.49976742],"study_design_scores_gemma":[0.008305044,0.0027956655,0.16630413,0.09493989,0.06487125,0.025447592,0.007008087,0.0012780341,0.00474749,0.018117348,0.6057656,0.0004198807],"about_ca_topic_score_codex":0.0015526873,"about_ca_topic_score_gemma":0.0035328032,"teacher_disagreement_score":0.014613624,"about_ca_system_score_codex":0.002618062,"about_ca_system_score_gemma":0.0024114684,"threshold_uncertainty_score":0.07728517},"labels":[],"label_agreement":null},{"id":"W4324128872","doi":"10.2217/fon-2022-0893","title":"Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Radiofrequency ablation; Hepatocellular carcinoma; Ablation; Radiosurgery; Meta-analysis; Sample size determination; Radiation therapy; Radiology; Nuclear medicine; Internal medicine","score_opus":0.11977150862180792,"score_gpt":0.3330833338833962,"score_spread":0.21331182526158832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324128872","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.116509125,0.87113434,0.004891567,0.00073944184,0.00075970043,0.00075474585,0.0034241762,0.00018614224,0.001600739],"genre_scores_gemma":[0.88442904,0.105851576,0.0036113474,0.0008472629,0.00051479245,0.0018261095,0.0015840672,0.00009112531,0.0012446656],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9914282,0.004810675,0.0014656514,0.0012905583,0.0007000595,0.00030493314],"domain_scores_gemma":[0.98175573,0.013806222,0.0027186,0.00074046856,0.0007751545,0.00020388652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01243374,0.0022968878,0.008859736,0.002528065,0.00043158318,0.002071221,0.0020014104,0.0017488769,0.003674282],"category_scores_gemma":[0.021790398,0.0010638833,0.036530923,0.003271819,0.0004112449,0.0013429628,0.001023213,0.0019716225,0.00039935525],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011286489,0.00003974145,0.022273751,0.045377176,0.9126647,0.00014359324,0.000049700462,0.001350962,0.0005033046,0.00012633868,0.0007267966,0.0054573985],"study_design_scores_gemma":[0.0012768797,0.0005582036,0.010986307,0.001847972,0.9828336,0.00008860296,0.00003361694,0.0010397008,0.00022601665,0.00017411745,0.00091736834,0.00001767189],"about_ca_topic_score_codex":0.00394634,"about_ca_topic_score_gemma":0.004935027,"teacher_disagreement_score":0.01243374,"about_ca_system_score_codex":0.0011377373,"about_ca_system_score_gemma":0.0008660903,"threshold_uncertainty_score":0.06575668},"labels":[],"label_agreement":null},{"id":"W4324129382","doi":"10.2217/fon-2022-0337","title":"Efficacy and Safety Evaluation of PSOX, DOF and SOX Regimens as Neoadjuvant Chemotherapy for Advanced Gastric Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society of Intestinal Research","funders":"","keywords":"Oxaliplatin; Medicine; Docetaxel; Internal medicine; Regimen; Chemotherapy; Oncology; Paclitaxel; Incidence (geometry); Cancer; Gastroenterology; Colorectal cancer","score_opus":0.021038032117836072,"score_gpt":0.3561469879927961,"score_spread":0.33510895587496004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324129382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700123,0.0025018859,0.000106920066,0.000025731857,0.000005426556,0.000021487123,0.000036474048,0.0000018429223,0.00029899093],"genre_scores_gemma":[0.99885476,0.0007736624,0.00016476857,0.000017530067,0.000011291524,0.000015812993,0.00007688854,5.742261e-7,0.00008480605],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971455,0.0001454942,0.000034692166,0.000027562002,0.000056948425,0.000020664515],"domain_scores_gemma":[0.9995192,0.00017542056,0.0001838581,0.000027501064,0.00003447035,0.000059548012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000597351,0.00009823758,0.0003167674,0.00017460708,0.00011708905,0.00015242814,0.00006653722,0.00012944356,0.00046243536],"category_scores_gemma":[0.0008251065,0.000053198924,0.00024699044,0.00016507787,0.00022810788,0.00018185558,0.00009451965,0.00016106408,0.00004981728],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07009291,0.0025184534,0.6913695,0.0007864375,0.00060167053,0.00065030134,0.0002456183,0.0017519508,0.028942041,0.00028600628,0.0003281437,0.20242701],"study_design_scores_gemma":[0.0028035615,0.17620783,0.7907919,0.00013687184,0.00097005913,0.0042658346,0.00033132985,0.002277627,0.016983368,0.00021299903,0.004992653,0.000025938103],"about_ca_topic_score_codex":0.00017142486,"about_ca_topic_score_gemma":0.00040466894,"teacher_disagreement_score":0.000597351,"about_ca_system_score_codex":0.00021192395,"about_ca_system_score_gemma":0.00023290189,"threshold_uncertainty_score":0.0031591654},"labels":[],"label_agreement":null},{"id":"W4362459260","doi":"10.2217/fon-2022-1035","title":"Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called <i>MET</i> exon 14 skipping","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Lung cancer; Exon; Cancer; Targeted therapy; Oncology; Cancer research; Internal medicine; Mutation; Exon skipping; Genetics; Gene; Biology","score_opus":0.017210099592399008,"score_gpt":0.35186459170477435,"score_spread":0.33465449211237536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362459260","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020810887,0.18622883,0.008168519,0.23934673,0.14246467,0.0016104052,0.074047655,0.0027709005,0.34328115],"genre_scores_gemma":[0.01156477,0.186629,0.0056601646,0.19707401,0.06403924,0.0015495906,0.050343733,0.0016950755,0.4814445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988669,0.0002568353,0.00025730603,0.000111033616,0.00041507708,0.0000928806],"domain_scores_gemma":[0.99435306,0.001719458,0.00081412337,0.00011212504,0.002592651,0.00040862543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013153746,0.00095553254,0.0014724294,0.0014730386,0.0006146969,0.003005084,0.0012622325,0.0026314124,0.18112761],"category_scores_gemma":[0.009799188,0.00037487084,0.001229349,0.0012860077,0.00046740932,0.0026989998,0.0009254982,0.0032476825,0.10658911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012530867,0.000015337107,0.000058709997,0.001257151,0.0000072342145,0.00011392794,0.000018855899,0.000046044748,0.0004049151,0.00073129305,0.9597888,0.037432402],"study_design_scores_gemma":[0.00002666831,0.000062503736,0.0002032832,0.00068903907,0.000012857356,0.00022579904,0.000017269465,0.000025551843,0.00019253259,0.00031469177,0.99822146,0.000008452042],"about_ca_topic_score_codex":0.0036867002,"about_ca_topic_score_gemma":0.0036240004,"teacher_disagreement_score":0.18112761,"about_ca_system_score_codex":0.0014758137,"about_ca_system_score_gemma":0.0024683704,"threshold_uncertainty_score":0.60593224},"labels":[],"label_agreement":null},{"id":"W4366236771","doi":"10.2217/fon-2022-1196","title":"Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"AstraZeneca","keywords":"Medicine; Mutant; Breast cancer; Oncology; Cancer; Line (geometry); Internal medicine; Cancer research; Genetics; Biology; Gene","score_opus":0.030193153996958478,"score_gpt":0.354143198096221,"score_spread":0.32395004409926254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366236771","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150139,0.0036529482,0.0037255646,0.0012889722,0.0016185994,0.058400683,0.003429234,0.000354581,0.012515495],"genre_scores_gemma":[0.92443234,0.002292856,0.0054503386,0.0028929943,0.0006606455,0.051388286,0.0022201696,0.0000796276,0.010582654],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915516,0.00033372283,0.000050254468,0.00018404106,0.000071511604,0.00020532751],"domain_scores_gemma":[0.9991316,0.0001331881,0.00013224316,0.00007081424,0.000056443118,0.00047574294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024466864,0.0017932737,0.0025780296,0.00044849643,0.00051123986,0.0015276298,0.0009277398,0.001533314,0.007970481],"category_scores_gemma":[0.0015834783,0.0007021169,0.0012499297,0.00037794944,0.0010981236,0.0011234393,0.00045708797,0.0037579606,0.001745276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93859947,0.027494632,0.00090243685,0.0004197065,0.00059177214,0.00007725199,0.00007016515,0.0013160459,0.006379207,0.00042066787,0.0013148185,0.022413805],"study_design_scores_gemma":[0.7526728,0.23971853,0.0017201217,0.000036302372,0.00038932095,0.00005393332,0.000032071028,0.00094532524,0.00091131125,0.000572752,0.0029256393,0.000021868851],"about_ca_topic_score_codex":0.0006227182,"about_ca_topic_score_gemma":0.0018446003,"teacher_disagreement_score":0.007970481,"about_ca_system_score_codex":0.0008857214,"about_ca_system_score_gemma":0.002263509,"threshold_uncertainty_score":0.0266639},"labels":[],"label_agreement":null},{"id":"W4377220744","doi":"10.2217/fon-2023-0082","title":"Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Amgen","keywords":"Daratumumab; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Oncology; Internal medicine","score_opus":0.024376566490560227,"score_gpt":0.32797371336154324,"score_spread":0.303597146870983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377220744","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004796155,0.1419744,0.003902967,0.188962,0.05945444,0.014874845,0.48435807,0.0017397156,0.099937394],"genre_scores_gemma":[0.03715049,0.16214506,0.01236534,0.30886465,0.067644216,0.040908284,0.23914447,0.0013415954,0.13043587],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942967,0.0028491814,0.001337992,0.0002801777,0.0010258085,0.000210165],"domain_scores_gemma":[0.97714216,0.011114481,0.0041869218,0.00047574594,0.005928611,0.0011520988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076480987,0.0013396945,0.002869443,0.0013736867,0.0007116249,0.0027781983,0.0016081004,0.0026660452,0.09283509],"category_scores_gemma":[0.031487133,0.00061603234,0.002532011,0.002148886,0.00036570558,0.0015142686,0.000957065,0.0035593656,0.02429569],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004314678,0.000107461725,0.0004045616,0.015904626,0.00036546306,0.00007999987,0.000056369558,0.00009548096,0.00022663333,0.0004069837,0.94031346,0.03772424],"study_design_scores_gemma":[0.012188667,0.0018731515,0.0064414283,0.017671274,0.0017420657,0.00023096817,0.00012609737,0.00017181916,0.00037164084,0.0011816692,0.9578942,0.000107063686],"about_ca_topic_score_codex":0.0049440833,"about_ca_topic_score_gemma":0.008132194,"teacher_disagreement_score":0.09283509,"about_ca_system_score_codex":0.0017668946,"about_ca_system_score_gemma":0.0048016156,"threshold_uncertainty_score":0.31056434},"labels":[],"label_agreement":null},{"id":"W4379599383","doi":"10.2217/fon-2022-0974","title":"Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; William Osler Health System; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical trial; Cancer; Oncology; Internal medicine; Meta-analysis; Lung cancer","score_opus":0.2703097231449354,"score_gpt":0.48395923251896045,"score_spread":0.21364950937402505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379599383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004433311,0.99241203,0.0014843098,0.0002408496,0.00017902894,0.00046339026,0.000477743,0.000026063753,0.0002833099],"genre_scores_gemma":[0.28577948,0.69973475,0.006562425,0.0016671111,0.00053816545,0.0038896601,0.0012735217,0.00006521584,0.0004896152],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9680255,0.022129674,0.005379296,0.002223605,0.0018175791,0.0004243653],"domain_scores_gemma":[0.9275791,0.062479135,0.0062382887,0.0014414561,0.0019445093,0.00031751877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03898145,0.0023404497,0.016398102,0.0045699556,0.0004286769,0.0030556107,0.0018629459,0.002148762,0.0031111918],"category_scores_gemma":[0.07248647,0.0011923863,0.028819213,0.005002804,0.0007956162,0.0018390695,0.001165908,0.001518665,0.00028859766],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038030203,0.000027324995,0.0038879635,0.30849713,0.66080517,0.00006942807,0.00005785568,0.0007131156,0.00019046607,0.00034570915,0.0007623113,0.020840686],"study_design_scores_gemma":[0.0021501228,0.00040620725,0.0038314268,0.026358316,0.9637924,0.00009726481,0.000035197194,0.00037562512,0.0001383244,0.0006576307,0.0021334125,0.000024112389],"about_ca_topic_score_codex":0.002325062,"about_ca_topic_score_gemma":0.0052913134,"teacher_disagreement_score":0.03898145,"about_ca_system_score_codex":0.0023869935,"about_ca_system_score_gemma":0.0026994685,"threshold_uncertainty_score":0.20615608},"labels":[],"label_agreement":null},{"id":"W4380291366","doi":"10.2217/fon-2022-1289","title":"Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Comprehensive Cancer Network; Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Oncology; Internal medicine; Dentistry","score_opus":0.010774628323068091,"score_gpt":0.32511510297901697,"score_spread":0.3143404746559489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380291366","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001791893,0.22228529,0.0025401572,0.057220384,0.07748818,0.002394033,0.5996756,0.00084162096,0.035762854],"genre_scores_gemma":[0.027508881,0.26758707,0.00889541,0.19215581,0.10035385,0.009518134,0.34755293,0.0015573929,0.04487066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98708934,0.0039276504,0.0040377164,0.0008039088,0.003540069,0.00060124864],"domain_scores_gemma":[0.9254662,0.036446232,0.011890604,0.0015906896,0.023218159,0.001388103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01034858,0.0020211663,0.0055834614,0.0059119044,0.0005737588,0.004299051,0.0035637685,0.0027930946,0.07398879],"category_scores_gemma":[0.07108535,0.0011243926,0.00758124,0.009543003,0.0005005775,0.0030499843,0.0014423076,0.004068209,0.019905062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017063145,0.000028547574,0.0008796037,0.032779075,0.0014346221,0.00008058563,0.000053403928,0.00015878795,0.00015418993,0.00032174794,0.92919964,0.033203438],"study_design_scores_gemma":[0.0059790895,0.00070412573,0.022803359,0.045435898,0.008363785,0.0004588563,0.00020918649,0.00016967989,0.00036892758,0.0013825598,0.91387784,0.00024670674],"about_ca_topic_score_codex":0.01639065,"about_ca_topic_score_gemma":0.018198606,"teacher_disagreement_score":0.07398879,"about_ca_system_score_codex":0.0028927648,"about_ca_system_score_gemma":0.0050629475,"threshold_uncertainty_score":0.24751717},"labels":[],"label_agreement":null},{"id":"W4382502641","doi":"10.2217/fon-2022-1157","title":"A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency; University of Calgary; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Cancer; Oncology; Internal medicine","score_opus":0.01778791242373024,"score_gpt":0.3120160915822968,"score_spread":0.2942281791585666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382502641","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021557542,0.52448946,0.008991042,0.06024892,0.042429913,0.0040864553,0.26163107,0.0014142176,0.075151525],"genre_scores_gemma":[0.13191691,0.37836525,0.016241992,0.15848468,0.061558057,0.0066122683,0.18629405,0.0012299181,0.059296954],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955935,0.0014307315,0.0013975053,0.00022321561,0.001142092,0.00021296478],"domain_scores_gemma":[0.9766142,0.011998882,0.0047137286,0.00052409404,0.005620162,0.00052907574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004919181,0.0014046023,0.0025844588,0.0029852039,0.00035035025,0.0020495348,0.0009095507,0.0012515396,0.027609948],"category_scores_gemma":[0.020576173,0.00039564175,0.0035907233,0.0032390717,0.00029317682,0.0012609174,0.00050160586,0.002028809,0.0069754324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012656387,0.00031380382,0.008799704,0.04283077,0.003850641,0.00069861044,0.00015873424,0.0007036447,0.0026709316,0.0006850067,0.7304851,0.19614671],"study_design_scores_gemma":[0.006565575,0.007367467,0.08225938,0.020025082,0.010393376,0.0031355554,0.00041746427,0.0005222219,0.0037267476,0.0020149671,0.86329126,0.0002808806],"about_ca_topic_score_codex":0.0018877418,"about_ca_topic_score_gemma":0.0022477647,"teacher_disagreement_score":0.027609948,"about_ca_system_score_codex":0.0009983982,"about_ca_system_score_gemma":0.0016147123,"threshold_uncertainty_score":0.09236449},"labels":[],"label_agreement":null},{"id":"W4384926029","doi":"10.2217/fon-2023-0436","title":"Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Pharmacy; Leukemia; Confidence interval; Family medicine","score_opus":0.028625381904688885,"score_gpt":0.32189952807874594,"score_spread":0.29327414617405706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384926029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955527,0.0012824389,0.00022816107,0.0002019759,0.000020024792,0.000029895415,0.0013812009,0.000008516074,0.0012950203],"genre_scores_gemma":[0.99799395,0.00031437053,0.00018152151,0.00009247308,0.000027711381,0.000029265591,0.0011198968,0.0000035320083,0.00023731585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857485,0.0005351435,0.00016485222,0.00032617463,0.00019646953,0.00020251774],"domain_scores_gemma":[0.99131876,0.0025515556,0.0052157897,0.00019849539,0.00023559413,0.00047974102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015345503,0.00019733416,0.00037206797,0.0005296059,0.00029764415,0.001006719,0.00034068196,0.0005115423,0.0026936708],"category_scores_gemma":[0.0072248653,0.00017054772,0.00063817855,0.0008050883,0.00018853822,0.0009527017,0.00039066363,0.0008259152,0.00030969002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015501266,0.00014535875,0.9903064,0.000058412963,0.00015488948,0.00006302638,0.00006624582,0.00025492357,0.00011830945,0.00006479157,0.00031852958,0.0068990537],"study_design_scores_gemma":[0.00013326542,0.0010503741,0.9940691,0.00005274729,0.00016381127,0.00049337087,0.00025887272,0.0018002237,0.00031940764,0.0001421615,0.0014952772,0.000021429083],"about_ca_topic_score_codex":0.0026016308,"about_ca_topic_score_gemma":0.003885449,"teacher_disagreement_score":0.0026936708,"about_ca_system_score_codex":0.00074974145,"about_ca_system_score_gemma":0.0005098819,"threshold_uncertainty_score":0.009011269},"labels":[],"label_agreement":null},{"id":"W4385442656","doi":"10.2217/fon-2023-0228","title":"TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer","score_opus":0.05001610890154408,"score_gpt":0.3967505803952925,"score_spread":0.3467344714937484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385442656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354998,0.0325469,0.001028084,0.0046725404,0.00033870793,0.0013843678,0.0022893548,0.00031040396,0.02192994],"genre_scores_gemma":[0.9706687,0.011202563,0.0015488482,0.0018482353,0.00016412923,0.00054021174,0.0027173206,0.00002962993,0.0112803625],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998803,0.000047626676,0.0000066088505,0.000019364494,0.00002155565,0.000024496107],"domain_scores_gemma":[0.9998659,0.000018900908,0.000028480574,0.000010488675,0.000009174658,0.000067071305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004994231,0.0002262736,0.00050575536,0.00024075923,0.00016807627,0.00038502493,0.00027823276,0.0004234742,0.0060699345],"category_scores_gemma":[0.00030598452,0.00010463853,0.00023818672,0.00023085093,0.00017053894,0.0003136571,0.00022841475,0.0007323634,0.00097586034],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10409565,0.0054673324,0.008752756,0.0010206044,0.0004362042,0.0004571206,0.000117882046,0.0017893855,0.058618113,0.0011376576,0.027943961,0.79016334],"study_design_scores_gemma":[0.24205981,0.27443,0.12177205,0.0005737792,0.0010751818,0.006416044,0.00021802704,0.0060916017,0.061324567,0.0024635694,0.28348863,0.00008660383],"about_ca_topic_score_codex":0.00055451534,"about_ca_topic_score_gemma":0.0032247594,"teacher_disagreement_score":0.0060699345,"about_ca_system_score_codex":0.00054302724,"about_ca_system_score_gemma":0.000509131,"threshold_uncertainty_score":0.020305932},"labels":[],"label_agreement":null},{"id":"W4385722927","doi":"10.2217/fon-2023-0135","title":"Plain Language Summary: Can Declines in Prostate-Specific Antigen Level Indicate How Long Patients with Advanced Prostate Cancer Will Live When Treated with Enzalutamide?","year":2023,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Prostate-specific antigen; Prostate; Cancer; Oncology; Urology; Internal medicine; Androgen receptor","score_opus":0.049068405312900805,"score_gpt":0.35826136092005,"score_spread":0.3091929556071492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385722927","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009092715,0.08695049,0.0026627525,0.511457,0.3142336,0.00096547924,0.044207312,0.0009534188,0.037660707],"genre_scores_gemma":[0.013061455,0.085512474,0.004445802,0.6327177,0.15714173,0.0033082739,0.023402551,0.0008705648,0.079539426],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9939027,0.0019689866,0.0020877444,0.00051568093,0.0012836424,0.0002412477],"domain_scores_gemma":[0.9397603,0.027077002,0.007903709,0.0010312238,0.022944702,0.0012830631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067359586,0.0016574229,0.004114628,0.002372476,0.0010983993,0.005237758,0.0036893426,0.0050872676,0.099117436],"category_scores_gemma":[0.07634236,0.0007070851,0.002666678,0.002604789,0.0016330354,0.004699648,0.0014516361,0.0072440268,0.052600347],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015641162,0.000012085694,0.00016533805,0.00318676,0.00004620244,0.000044869554,0.00003360222,0.000041446023,0.00005664108,0.00060321786,0.9829806,0.012672835],"study_design_scores_gemma":[0.0002827066,0.00018666121,0.0023502538,0.010236525,0.00016711105,0.0003104599,0.00023991124,0.00013075769,0.00017408913,0.0021301368,0.98371917,0.00007217078],"about_ca_topic_score_codex":0.009471888,"about_ca_topic_score_gemma":0.0075235693,"teacher_disagreement_score":0.099117436,"about_ca_system_score_codex":0.0031123532,"about_ca_system_score_gemma":0.004583046,"threshold_uncertainty_score":0.33158082},"labels":[],"label_agreement":null},{"id":"W4386407017","doi":"10.2217/fon-2023-0358","title":"Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Seagen","keywords":"Medicine; Stage (stratigraphy); Family medicine; Regimen; Alternative medicine; Lymphoma; Internal medicine; Pathology","score_opus":0.04817714389186973,"score_gpt":0.3564879811656919,"score_spread":0.3083108372738222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386407017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979765,0.00014076258,0.00003272639,0.00048154782,0.0000051327265,0.000016664708,0.00029623508,0.0000014012262,0.0010491083],"genre_scores_gemma":[0.9992198,0.000067409186,0.000076238335,0.00036413636,0.0000120684335,0.000013561323,0.000144633,0.0000012968663,0.00010084598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989102,0.00066327193,0.0000821949,0.00010232179,0.00013430245,0.000107751635],"domain_scores_gemma":[0.99322975,0.0021617413,0.003426325,0.0001489431,0.00027465983,0.0007585145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012875212,0.000095570984,0.00012591394,0.0004571684,0.00047935458,0.00076668215,0.0001907655,0.0005459488,0.004247789],"category_scores_gemma":[0.006973804,0.00014914278,0.00021747888,0.0006075453,0.00032771175,0.0007573215,0.0004391548,0.00058375846,0.0003287146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023813642,0.00026176526,0.99276865,0.000036874197,0.000053727574,0.00009774348,0.0014937391,0.0000596108,0.00011268502,0.00005497038,0.0015109887,0.0033111665],"study_design_scores_gemma":[0.00006765194,0.0003014578,0.9881741,0.00007965471,0.000040893665,0.000489592,0.008048333,0.00057780725,0.000096351054,0.00005723018,0.002053662,0.000013300167],"about_ca_topic_score_codex":0.008573456,"about_ca_topic_score_gemma":0.016420297,"teacher_disagreement_score":0.008573456,"about_ca_system_score_codex":0.0006660482,"about_ca_system_score_gemma":0.0005207309,"threshold_uncertainty_score":0.017047107},"labels":[],"label_agreement":null},{"id":"W4387950784","doi":"10.2217/fon-2023-0526","title":"TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Olaparib; Placebo; Androgen deprivation therapy; Clinical trial; Androgen receptor; Cancer; Poly ADP ribose polymerase; Gene; Pathology; Biology; Polymerase","score_opus":0.13084474820022168,"score_gpt":0.5230714336123913,"score_spread":0.3922266854121696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950784","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1372633,0.0075538047,0.008758244,0.005512243,0.0031651962,0.72671646,0.05447811,0.0017178294,0.05483481],"genre_scores_gemma":[0.19996902,0.005629554,0.01356596,0.011368705,0.0012638201,0.6851442,0.029452333,0.000290845,0.053315584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987458,0.0005851883,0.00008562968,0.00018967617,0.00016648308,0.0002272238],"domain_scores_gemma":[0.9982899,0.00018368608,0.00031316635,0.00018240426,0.00026163185,0.00076916366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004813264,0.0025904826,0.0029890665,0.00054720906,0.0013184946,0.0022248854,0.0025551019,0.0037896314,0.046097096],"category_scores_gemma":[0.0034218272,0.0012627653,0.0012827892,0.0008318623,0.0011518971,0.0017978392,0.00079578336,0.0059120576,0.011427703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8297661,0.020791257,0.0014824199,0.0040271822,0.0010960168,0.00031979178,0.0002657404,0.0020892408,0.009668626,0.0033531124,0.079423286,0.047717344],"study_design_scores_gemma":[0.9038705,0.040773515,0.0028044467,0.00031145127,0.00028509635,0.00016054422,0.00005447998,0.0013230317,0.0010235967,0.0013937766,0.047954354,0.000045147746],"about_ca_topic_score_codex":0.0015771029,"about_ca_topic_score_gemma":0.007986011,"teacher_disagreement_score":0.046097096,"about_ca_system_score_codex":0.001989493,"about_ca_system_score_gemma":0.007968955,"threshold_uncertainty_score":0.15421015},"labels":[],"label_agreement":null},{"id":"W4388227085","doi":"10.2217/fon-2023-0407","title":"The Effects of Adding Palbociclib to Endocrine Therapy to Treat Advanced Breast Cancer: A Plain Language Summary of a Study Using the PALOMA-2 and PALOMA-3 Trial Results","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Breast cancer; Medicine; Placebo; Internal medicine; Hormonal therapy; Cancer; Oncology; Clinical trial; Hormone therapy; Gynecology; Metastatic breast cancer; Alternative medicine; Pathology","score_opus":0.014905550092935559,"score_gpt":0.3629975390301803,"score_spread":0.34809198893724475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388227085","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015838789,0.8908964,0.0034352941,0.038633924,0.013559344,0.0058576455,0.014633378,0.00023809851,0.01690716],"genre_scores_gemma":[0.12472475,0.7102637,0.011576008,0.09388163,0.028352393,0.008602767,0.01240495,0.0003900185,0.0098039],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9824013,0.009346795,0.0045300736,0.0007013674,0.0026196663,0.00040072828],"domain_scores_gemma":[0.95959204,0.02446387,0.00824358,0.00085018406,0.006170813,0.0006795411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020803314,0.0020579551,0.005419932,0.002373,0.00063229084,0.0046462873,0.0013543913,0.0023203713,0.0066847345],"category_scores_gemma":[0.042593736,0.0008213988,0.013334185,0.0025923857,0.0007672182,0.0023519413,0.0010121858,0.0043338616,0.0015356905],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0706905,0.00084511866,0.007546496,0.26916686,0.05449498,0.00072439964,0.00085901906,0.001621759,0.004234194,0.0026731787,0.14828235,0.43886125],"study_design_scores_gemma":[0.08899448,0.036363818,0.039574653,0.17336898,0.2030514,0.0016462643,0.0013325658,0.0012156116,0.005079638,0.00611797,0.44254473,0.00070995867],"about_ca_topic_score_codex":0.0024429811,"about_ca_topic_score_gemma":0.0053905365,"teacher_disagreement_score":0.020803314,"about_ca_system_score_codex":0.0020308953,"about_ca_system_score_gemma":0.0032811377,"threshold_uncertainty_score":0.11001974},"labels":[],"label_agreement":null},{"id":"W4390051577","doi":"10.2217/fon-2023-0649","title":"Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Placebo; Prostate cancer; Androgen deprivation therapy; Prostate-specific antigen; Internal medicine; Oncology; Prostatectomy; Post-hoc analysis; Urology; Cancer; Pathology","score_opus":0.027742835420446907,"score_gpt":0.3413039054678971,"score_spread":0.31356107004745015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390051577","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33552432,0.5721233,0.0051889718,0.024159417,0.00943506,0.005074598,0.033721536,0.0002861841,0.014486662],"genre_scores_gemma":[0.7425886,0.16738553,0.008300345,0.026009237,0.020048829,0.005042621,0.021682853,0.0002933397,0.008648775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928645,0.004113905,0.0012986783,0.00044251262,0.0010873826,0.00019302119],"domain_scores_gemma":[0.9777975,0.012067302,0.004872379,0.0011779682,0.0035270364,0.0005577472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014831795,0.0010215441,0.0028551887,0.0008801994,0.00029875664,0.0021909187,0.000773253,0.001040893,0.005105788],"category_scores_gemma":[0.020786839,0.00034790256,0.009278076,0.0012080783,0.0004844661,0.0008825366,0.00072093937,0.0015740949,0.0007687397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20327637,0.0014750446,0.13491099,0.14858769,0.18316124,0.001093399,0.0013537816,0.0014195907,0.0068722516,0.0013096342,0.072555535,0.24398454],"study_design_scores_gemma":[0.05702733,0.03622884,0.52749884,0.023793533,0.2633185,0.0011956255,0.00093037076,0.0011290316,0.0024537053,0.0016936405,0.084139094,0.00059148594],"about_ca_topic_score_codex":0.0019301865,"about_ca_topic_score_gemma":0.0036395988,"teacher_disagreement_score":0.014831795,"about_ca_system_score_codex":0.00064926525,"about_ca_system_score_gemma":0.0016011746,"threshold_uncertainty_score":0.078439},"labels":[],"label_agreement":null},{"id":"W4390669468","doi":"10.2217/fon-2023-0263","title":"Bacterial Heat Shock Protein Genes During Induction Chemotherapy In Pediatric Patients with Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; W. Garfield Weston Foundation; Nova Scotia Health Research Foundation; Beatrice Hunter Cancer Research Institute","keywords":"Heat shock protein; Firmicutes; Gene; Leukemia; Bacteroidetes; Medicine; Cancer research; Microbiology; Biology; Immunology; Genetics","score_opus":0.0035952697782344854,"score_gpt":0.22994339109617107,"score_spread":0.22634812131793658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390669468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990754,0.00041557095,0.000060874478,0.000042033702,0.0000037713585,0.0000060827383,0.0001611484,0.0000034660052,0.00023160777],"genre_scores_gemma":[0.99928397,0.00021188252,0.00011487413,0.000029476552,0.0000058164624,0.0000063389775,0.00023817208,0.0000018627196,0.00010754091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975246,0.00005040858,0.000018624709,0.000044754262,0.000058473466,0.00007529274],"domain_scores_gemma":[0.99954104,0.00007607848,0.00022052051,0.000013283396,0.00005032722,0.00009883104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015094303,0.00018113705,0.00033066174,0.00044178788,0.00034694537,0.00038674084,0.00012145303,0.00023951348,0.0007972323],"category_scores_gemma":[0.0009739403,0.00013359697,0.00013086473,0.0007953335,0.00021798813,0.00021649348,0.0002727258,0.00045381294,0.0001398482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004924488,0.000041560277,0.991672,0.000022888265,0.000012331195,0.00042948665,0.00021412471,0.000049739,0.0025239266,0.000012588805,0.00014035398,0.0043886025],"study_design_scores_gemma":[0.000007180323,0.0003149188,0.99648774,0.000007634424,0.000021172198,0.0012559706,0.00042513272,0.000097788026,0.00095364026,0.000018183386,0.0004075947,0.0000030538322],"about_ca_topic_score_codex":0.002490084,"about_ca_topic_score_gemma":0.0027100644,"teacher_disagreement_score":0.002490084,"about_ca_system_score_codex":0.0004839005,"about_ca_system_score_gemma":0.00033065988,"threshold_uncertainty_score":0.0049512386},"labels":[],"label_agreement":null},{"id":"W4392238297","doi":"10.2217/fon-2023-0995","title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; World class; Class (philosophy); Internal medicine; Artificial intelligence; Computer science","score_opus":0.0196711530789508,"score_gpt":0.3296302245845405,"score_spread":0.3099590715055897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392238297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959031,0.0024088959,0.00020561765,0.00014876146,0.00004978064,0.00025572622,0.00039103467,0.000017295273,0.0006198631],"genre_scores_gemma":[0.99845695,0.0003780212,0.00020916529,0.00011736915,0.000050436774,0.0002610515,0.00034136913,0.0000024531166,0.00018312382],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99805474,0.0013444665,0.00013842338,0.00019228504,0.00013943961,0.0001307227],"domain_scores_gemma":[0.99839467,0.00053154066,0.0006882893,0.00014197612,0.000066495486,0.0001770121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045431885,0.00042879317,0.0009652918,0.00033228798,0.00021596241,0.0007452907,0.00048896845,0.0006551519,0.0012886518],"category_scores_gemma":[0.0033703602,0.00019552324,0.0014664083,0.00035441693,0.000485209,0.0005247308,0.0003881142,0.00087814155,0.00019139936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94334704,0.00490135,0.013332987,0.00046254243,0.003332584,0.000037069818,0.000087500965,0.0010192748,0.0028718,0.00021643357,0.00058280147,0.029808594],"study_design_scores_gemma":[0.5938322,0.26490876,0.120739944,0.0001529434,0.006479904,0.00020979128,0.00014686555,0.0049401484,0.0044350554,0.00080030144,0.003279243,0.00007485665],"about_ca_topic_score_codex":0.000898765,"about_ca_topic_score_gemma":0.0020783008,"teacher_disagreement_score":0.0045431885,"about_ca_system_score_codex":0.0009484152,"about_ca_system_score_gemma":0.0007464087,"threshold_uncertainty_score":0.02402693},"labels":[],"label_agreement":null},{"id":"W4394942521","doi":"10.2217/fon-2023-0679","title":"Belzutifan: a novel therapeutic for the management of von Hippel–Lindau disease and beyond","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Clinical trial; Hypoxia-inducible factors; Renal cell carcinoma; Von Hippel–Lindau disease; Bioinformatics; Cancer research; Oncology; Internal medicine; Gene; Biology","score_opus":0.025831623138017467,"score_gpt":0.34302117389177994,"score_spread":0.3171895507537625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394942521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016469043,0.99751496,0.00016115869,0.000474586,0.00023001563,0.0000053246645,0.000020534686,0.000010610355,0.0014181405],"genre_scores_gemma":[0.0009358797,0.9973431,0.00020533528,0.00031247278,0.0001627631,0.0000067150568,0.0000420591,0.0000018360972,0.000989812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999161,0.000014033666,0.000008962551,0.000015163105,0.000034086057,0.000011669432],"domain_scores_gemma":[0.9999114,0.000033703083,0.000013911051,0.0000026773075,0.000023298026,0.000014978563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030208935,0.00050810154,0.0007292993,0.001741491,0.0002731135,0.0006851357,0.0004987488,0.000716402,0.0035016777],"category_scores_gemma":[0.00029571878,0.00014879179,0.00040600298,0.0012039957,0.00033644002,0.0010436499,0.00050829555,0.0017424106,0.0016261169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082414634,0.00006615214,0.0001377554,0.007869905,0.00006224431,0.00025521574,0.000053951248,0.00024746766,0.0025721474,0.004521914,0.0334619,0.9506689],"study_design_scores_gemma":[0.000015382348,0.00008138713,0.00043756905,0.0013725903,0.000057825608,0.0013041603,0.0000311545,0.00006802018,0.0004159162,0.0015757565,0.99462897,0.000011298314],"about_ca_topic_score_codex":0.0007374658,"about_ca_topic_score_gemma":0.0020738018,"teacher_disagreement_score":0.0035016777,"about_ca_system_score_codex":0.0005562479,"about_ca_system_score_gemma":0.0007201943,"threshold_uncertainty_score":0.01171428},"labels":[],"label_agreement":null},{"id":"W4396677006","doi":"10.1080/14796694.2024.2342227","title":"Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Université Laval; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cisplatin; Kidney disease; Urothelial cancer; Chemotherapy; Intensive care medicine; Internal medicine; Oncology; Cancer; Disease; Renal function; Bladder cancer; Urology","score_opus":0.015251667884815143,"score_gpt":0.3354459150738934,"score_spread":0.32019424718907824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396677006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018747192,0.9987488,0.00006268322,0.00031505415,0.000085378786,0.0000052091877,0.000012864896,0.000003278708,0.00057915587],"genre_scores_gemma":[0.0012663716,0.9981654,0.00013403143,0.00018532976,0.0000778118,0.000005512715,0.000021249003,7.157716e-7,0.00014360479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975926,0.00007253334,0.000049831142,0.000026100379,0.000074026175,0.00001825039],"domain_scores_gemma":[0.99968934,0.00016457961,0.00005999757,0.000005508604,0.00006403871,0.000016603968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004581753,0.000393245,0.0008599181,0.0011673194,0.00021724451,0.00067656365,0.00051889865,0.0005963999,0.0019354047],"category_scores_gemma":[0.0011757431,0.00013251851,0.0005957002,0.00093754905,0.00019026396,0.0006101906,0.00044692846,0.0009113003,0.00046714387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005803306,0.000045933502,0.0005391166,0.038230013,0.0001972128,0.00022685115,0.000100529316,0.00028208614,0.000483344,0.0012978264,0.0202345,0.9383045],"study_design_scores_gemma":[0.000046801702,0.0001796767,0.004714251,0.042135768,0.00066037435,0.004171623,0.00020205525,0.00021264292,0.00035761992,0.002115343,0.94517714,0.000026665635],"about_ca_topic_score_codex":0.0013286656,"about_ca_topic_score_gemma":0.0033725407,"teacher_disagreement_score":0.0019354047,"about_ca_system_score_codex":0.0003827344,"about_ca_system_score_gemma":0.00094647944,"threshold_uncertainty_score":0.0064745545},"labels":[],"label_agreement":null},{"id":"W4397044878","doi":"10.2217/fon-2022-1228","title":"Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Breast cancer; Disease; Oncology; Cancer; Internal medicine","score_opus":0.006321741113262881,"score_gpt":0.29921723161172464,"score_spread":0.29289549049846175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983972,0.00026108665,0.000035250832,0.00008943336,0.0000026612188,0.000004584836,0.0006616615,0.0000026140528,0.0005454783],"genre_scores_gemma":[0.9989273,0.00013938553,0.00004132357,0.00008158551,0.0000025219367,0.0000069893977,0.00070036034,0.0000013326198,0.000099182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999658,0.00012935398,0.00004435599,0.00005409479,0.00004414297,0.0000701782],"domain_scores_gemma":[0.9992526,0.00012848753,0.0003478532,0.000018968509,0.00010172229,0.00015039604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036134143,0.000110204164,0.00022005448,0.00065570854,0.00027997035,0.0005571863,0.00017034213,0.00027665147,0.0012726585],"category_scores_gemma":[0.0010134499,0.00008980573,0.0002549979,0.0013215685,0.00018658284,0.00025848308,0.0004742572,0.0002244579,0.00013373079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010148733,0.000027301217,0.99729246,0.000010031333,0.000037686026,0.00004572734,0.0001294623,0.00005130997,0.0001296709,0.000022630871,0.00022746947,0.0019248601],"study_design_scores_gemma":[0.0000048617676,0.000050612827,0.9989139,0.000007688748,0.000012524171,0.00012603318,0.00050241227,0.000065793356,0.000033732715,0.000009318765,0.00027067686,0.000002471498],"about_ca_topic_score_codex":0.012042519,"about_ca_topic_score_gemma":0.016471503,"teacher_disagreement_score":0.012042519,"about_ca_system_score_codex":0.00035160515,"about_ca_system_score_gemma":0.00030959377,"threshold_uncertainty_score":0.023944855},"labels":[],"label_agreement":null},{"id":"W4399553361","doi":"10.1080/14796694.2024.2342224","title":"Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Canada Research Chairs; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Immunotherapy; Cancer; Intensive care medicine","score_opus":0.0218372023544261,"score_gpt":0.36493949076044885,"score_spread":0.34310228840602275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904331,0.0055203047,0.00064583967,0.0003184051,0.000066632136,0.00025248187,0.0017071213,0.000015401403,0.0010406395],"genre_scores_gemma":[0.99806124,0.00047983517,0.00037421563,0.00007811952,0.00003762918,0.00011737198,0.0007621729,0.0000024961914,0.0000869168],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948277,0.0032706186,0.00047440652,0.00066376885,0.0005487793,0.00021481224],"domain_scores_gemma":[0.97976524,0.009850402,0.0077724825,0.0013619793,0.00063743856,0.0006124145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0102288425,0.00037137038,0.0007333572,0.0005764107,0.00024928458,0.0010452614,0.00056064076,0.0007806769,0.002809258],"category_scores_gemma":[0.025819402,0.00022530482,0.0022039749,0.000507055,0.0004961724,0.00084452285,0.00047241832,0.00090582314,0.00028112534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.425717,0.0048752557,0.38506237,0.002836649,0.03239529,0.00027147387,0.00025873998,0.005512639,0.0027409839,0.00096898637,0.0041886526,0.13517195],"study_design_scores_gemma":[0.0949558,0.13023606,0.71567327,0.00081759604,0.030278563,0.0017355765,0.00031025492,0.0097957635,0.005397655,0.0020261903,0.008622316,0.00015085776],"about_ca_topic_score_codex":0.00086180016,"about_ca_topic_score_gemma":0.0009825237,"teacher_disagreement_score":0.0102288425,"about_ca_system_score_codex":0.0016844519,"about_ca_system_score_gemma":0.00080188864,"threshold_uncertainty_score":0.054095924},"labels":[],"label_agreement":null},{"id":"W4399553470","doi":"10.1080/14796694.2024.2343647","title":"Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Internal medicine; Overall survival; Cancer; Hormone","score_opus":0.04179467252351697,"score_gpt":0.4186372159170123,"score_spread":0.3768425433934953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979651,0.00024269184,0.00008849822,0.000059310216,0.0000035008197,0.000012027741,0.001200421,0.0000038524227,0.00042470396],"genre_scores_gemma":[0.9986193,0.000064379536,0.000058172995,0.000019231757,0.0000061519763,0.000009993408,0.0011650826,9.562226e-7,0.00005665513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949443,0.00017589983,0.0000683816,0.00010736843,0.00007961188,0.00007432258],"domain_scores_gemma":[0.99713933,0.00041745175,0.0018923846,0.00009797009,0.00015288335,0.0003000104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067979394,0.00016967491,0.0002100056,0.0005460547,0.00022467243,0.0007193201,0.00027675094,0.00031782317,0.0010747019],"category_scores_gemma":[0.0027262308,0.00009998074,0.00029867032,0.0007578293,0.00030187893,0.0007401,0.00042798463,0.00036411974,0.00015127241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003997388,0.000041402982,0.99685955,0.000019906807,0.000090345966,0.00006996365,0.00006626736,0.00032881508,0.00008598965,0.000022578459,0.00017649804,0.0018389011],"study_design_scores_gemma":[0.000022543743,0.00036486768,0.9977769,0.0000095579735,0.00003905293,0.00046782853,0.0001786328,0.0005985519,0.00010510298,0.000040058923,0.00038638394,0.000010625406],"about_ca_topic_score_codex":0.0029285345,"about_ca_topic_score_gemma":0.004846311,"teacher_disagreement_score":0.0029285345,"about_ca_system_score_codex":0.00071208354,"about_ca_system_score_gemma":0.0003107432,"threshold_uncertainty_score":0.0058229566},"labels":[],"label_agreement":null},{"id":"W4400775871","doi":"10.1080/14796694.2024.2373687","title":"TURALIO <sup>®</sup> Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Retrospective cohort study; Risk assessment; Internal medicine; Computer security; Computer science","score_opus":0.030062415351023095,"score_gpt":0.3388680507257841,"score_spread":0.30880563537476097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400775871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9470145,0.0008904079,0.0065075303,0.0007933127,0.000035521978,0.005213233,0.029373217,0.00037772025,0.009794502],"genre_scores_gemma":[0.95768857,0.00049772125,0.0058094603,0.0006726561,0.00008535901,0.0019738053,0.030934453,0.000044117845,0.002293766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996262,0.001436661,0.0006655273,0.00045665793,0.00097069604,0.0002084298],"domain_scores_gemma":[0.97693104,0.0022986543,0.014646168,0.0015945433,0.0036035066,0.0009261201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008464115,0.0003521226,0.00032035905,0.0014979552,0.00041240067,0.0007194374,0.0005194207,0.00035414723,0.0020792591],"category_scores_gemma":[0.009174082,0.00032920888,0.00065888395,0.0014390156,0.00027443402,0.00040366143,0.001083867,0.0005341529,0.0008674844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005989304,0.0005112432,0.9409819,0.00031175642,0.00030530232,0.00023492293,0.00020663186,0.0013951475,0.0013961311,0.00020798018,0.0076852427,0.04077447],"study_design_scores_gemma":[0.0008613211,0.005443779,0.9676055,0.00016701542,0.0003751677,0.00092313165,0.00018757215,0.003052919,0.0037593793,0.0001371012,0.017434942,0.000052364918],"about_ca_topic_score_codex":0.0051352414,"about_ca_topic_score_gemma":0.006247286,"teacher_disagreement_score":0.008464115,"about_ca_system_score_codex":0.0012050472,"about_ca_system_score_gemma":0.0036726207,"threshold_uncertainty_score":0.04476303},"labels":[],"label_agreement":null},{"id":"W4400959505","doi":"10.1080/14796694.2024.2363131","title":"The TALAPRO-3 study design: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Cancer; Internal medicine; Family medicine; Androgen receptor","score_opus":0.02806034429463618,"score_gpt":0.3820710198024786,"score_spread":0.35401067550784243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400959505","genre_codex":"protocol","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019079963,0.08618169,0.099570766,0.123937845,0.040403467,0.31900454,0.2428089,0.0021699462,0.066842966],"genre_scores_gemma":[0.042673644,0.02339685,0.06836092,0.09580057,0.010977736,0.70504016,0.025266148,0.0011619506,0.027322084],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9166844,0.06177703,0.010524571,0.0032044724,0.0063614934,0.0014480418],"domain_scores_gemma":[0.91091114,0.060075667,0.012140216,0.004121647,0.011189564,0.0015617064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.078843564,0.0022870905,0.0049874918,0.0017718761,0.0010871455,0.004303973,0.002478098,0.0039707874,0.08082359],"category_scores_gemma":[0.12334827,0.0015512013,0.0057992325,0.0022623828,0.0013199445,0.002373805,0.0014398263,0.0045558023,0.016218415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059271373,0.0012414725,0.009671706,0.07146692,0.0068384116,0.00045470393,0.0006114472,0.0022659793,0.001139024,0.013296992,0.61342674,0.22031519],"study_design_scores_gemma":[0.07723076,0.014847006,0.026482625,0.068666816,0.009264575,0.0005982789,0.00055798603,0.0028278937,0.0021288495,0.025300933,0.771548,0.0005463056],"about_ca_topic_score_codex":0.0017163075,"about_ca_topic_score_gemma":0.0023165739,"teacher_disagreement_score":0.08082359,"about_ca_system_score_codex":0.0037546447,"about_ca_system_score_gemma":0.00816635,"threshold_uncertainty_score":0.4169696},"labels":[],"label_agreement":null},{"id":"W4401091657","doi":"10.1080/14796694.2024.2355079","title":"Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"BeiGene","keywords":"Ibrutinib; Medicine; Nausea; Quality of life (healthcare); Waldenstrom macroglobulinemia; Vomiting; Internal medicine; Oncology; Population; Randomized controlled trial; Lymphoma; Nursing; Leukemia","score_opus":0.03221721800051643,"score_gpt":0.3559625639351439,"score_spread":0.3237453459346275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401091657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841024,0.010672975,0.000115578216,0.00061859697,0.00009892172,0.0004105135,0.001597991,0.00001630638,0.002366665],"genre_scores_gemma":[0.99089944,0.0033014813,0.0003295154,0.000696193,0.0001285413,0.0005762143,0.003206065,0.0000040119176,0.0008585816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995585,0.00027505282,0.000029903902,0.00004042673,0.000048577072,0.00004750585],"domain_scores_gemma":[0.999587,0.00010224426,0.00014981822,0.000022300945,0.000028578943,0.000110040986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015073654,0.00050734024,0.00070204464,0.00017970233,0.00019520566,0.0006199863,0.0002874446,0.00045428541,0.0017756645],"category_scores_gemma":[0.0011192508,0.00010022998,0.0009555712,0.00029234312,0.0002972375,0.00041044145,0.00033118294,0.00090955856,0.00018997608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7640351,0.0069052526,0.061514273,0.0025618158,0.0071947495,0.00020686272,0.00016634526,0.0023415582,0.003988865,0.00042422046,0.010602326,0.14005856],"study_design_scores_gemma":[0.5257412,0.121015154,0.32822222,0.0006691115,0.00555036,0.00056359515,0.00027114112,0.0027025668,0.0013800847,0.0010575933,0.012764942,0.000062061095],"about_ca_topic_score_codex":0.00046973513,"about_ca_topic_score_gemma":0.001407063,"teacher_disagreement_score":0.0017756645,"about_ca_system_score_codex":0.00040184535,"about_ca_system_score_gemma":0.0003585072,"threshold_uncertainty_score":0.007971823},"labels":[],"label_agreement":null},{"id":"W4401429946","doi":"10.1080/14796694.2024.2368952","title":"A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Biliary tract cancer; Biliary tract; Internal medicine; Phase (matter); Oncology; Cancer; Gemcitabine","score_opus":0.0364592644706835,"score_gpt":0.35599140225920667,"score_spread":0.3195321377885232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401429946","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021191945,0.096306026,0.008798073,0.103900276,0.044163823,0.011976802,0.6558689,0.0019782577,0.05581589],"genre_scores_gemma":[0.10810592,0.10534802,0.02085998,0.32914943,0.04416623,0.026311466,0.27098358,0.0012910023,0.093784444],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99482536,0.0022330382,0.0013090124,0.00034863516,0.0009594418,0.00032460052],"domain_scores_gemma":[0.97064835,0.017343475,0.0046020034,0.00051358645,0.0059513957,0.00094116584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072950246,0.0015916137,0.0025600672,0.0018432199,0.0007449857,0.002070613,0.0010844138,0.0018965635,0.0635229],"category_scores_gemma":[0.025032397,0.00068364077,0.0032579002,0.0018380431,0.00031350701,0.0012273559,0.00059222063,0.002738072,0.01206422],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009565167,0.00032467334,0.0034211085,0.016211629,0.0010529824,0.0002712711,0.00013273176,0.00032995042,0.0007224926,0.00031879236,0.9138814,0.05376781],"study_design_scores_gemma":[0.012844169,0.009166646,0.058210067,0.015100624,0.0048897546,0.0012445529,0.0005979205,0.00048534648,0.0020754319,0.002087771,0.8929406,0.00035717138],"about_ca_topic_score_codex":0.004826143,"about_ca_topic_score_gemma":0.006323416,"teacher_disagreement_score":0.0635229,"about_ca_system_score_codex":0.0015290013,"about_ca_system_score_gemma":0.0022031341,"threshold_uncertainty_score":0.21250528},"labels":[],"label_agreement":null},{"id":"W4401584219","doi":"10.1080/14796694.2024.2379228","title":"Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelodysplastic syndromes; Family medicine; Medical record; Gerontology; Internal medicine","score_opus":0.01580949038752389,"score_gpt":0.31466583726212866,"score_spread":0.2988563468746048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401584219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694122,0.016834605,0.000056890232,0.0006572893,0.00001248063,0.00003746309,0.010652605,0.000006692362,0.0023297162],"genre_scores_gemma":[0.9895371,0.005612846,0.00010878783,0.00022488585,0.0000128689935,0.000018216024,0.0043448806,0.0000025754289,0.00013789262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847585,0.00017561234,0.00041131917,0.0001956017,0.0005659539,0.00017563645],"domain_scores_gemma":[0.9895062,0.0016740981,0.006024337,0.00014059183,0.0021881938,0.00046655646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008950172,0.00009537562,0.00028142915,0.003385255,0.0005019088,0.0010297633,0.0004285033,0.00032309964,0.00087182457],"category_scores_gemma":[0.006573161,0.00008379076,0.0002451249,0.0081775505,0.00032506496,0.00035200192,0.00036031223,0.00019598559,0.00007606772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006685056,0.000010617894,0.9926577,0.00022531467,0.0000842672,0.00015060396,0.00021737865,0.000038802948,0.00012125939,0.000037259713,0.0007111561,0.0056787254],"study_design_scores_gemma":[0.0000048507445,0.000011972539,0.9977609,0.00014826196,0.00004646984,0.00029092218,0.0004496904,0.00004741083,0.00008141606,0.00000602399,0.001147589,0.000004477136],"about_ca_topic_score_codex":0.47246858,"about_ca_topic_score_gemma":0.60968536,"teacher_disagreement_score":0.47246858,"about_ca_system_score_codex":0.003335109,"about_ca_system_score_gemma":0.006244853,"threshold_uncertainty_score":0.93943703},"labels":[],"label_agreement":null},{"id":"W4401729249","doi":"10.1080/14796694.2024.2384257","title":"Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Oncology; Internal medicine; Prostate-specific antigen; Cancer; Pathology; Alternative medicine","score_opus":0.04384379995837404,"score_gpt":0.3853748239425174,"score_spread":0.3415310239841433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401729249","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005083931,0.98821414,0.00021887507,0.0027133778,0.00085796206,0.00008424619,0.0017819984,0.000009054685,0.0010364417],"genre_scores_gemma":[0.08327677,0.8977974,0.0018875814,0.007606517,0.0046687755,0.0005671153,0.0033054317,0.000028991653,0.00086132536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957533,0.0018344568,0.0012332133,0.00026502105,0.0008016503,0.00011239306],"domain_scores_gemma":[0.9825084,0.011258391,0.003563928,0.00028878843,0.002078137,0.00030226924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065165074,0.0007767936,0.0029135398,0.0036538076,0.00022539355,0.0019831453,0.0005741773,0.00081406866,0.0028333],"category_scores_gemma":[0.014399779,0.00036823418,0.0046596327,0.004057803,0.0003850339,0.0010183161,0.00082034356,0.0017571913,0.0003362037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015432157,0.00039445545,0.0539076,0.26470825,0.051471207,0.0003500639,0.0008076914,0.0010058796,0.0014582395,0.0014274805,0.060352292,0.5486847],"study_design_scores_gemma":[0.0061273077,0.009915431,0.35999158,0.2099004,0.11255218,0.0020127306,0.0015144584,0.0008369989,0.0016332817,0.0026088234,0.29240742,0.0004994778],"about_ca_topic_score_codex":0.002803536,"about_ca_topic_score_gemma":0.0051638274,"teacher_disagreement_score":0.0065165074,"about_ca_system_score_codex":0.0010684151,"about_ca_system_score_gemma":0.00129823,"threshold_uncertainty_score":0.03446299},"labels":[],"label_agreement":null},{"id":"W4402456192","doi":"10.1080/14796694.2024.2389769","title":"Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Narrative review; Narrative; Oncology; Internal medicine; Intensive care medicine","score_opus":0.05149807865167884,"score_gpt":0.39485149131668174,"score_spread":0.3433534126650029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402456192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093380375,0.9989004,0.0000678935,0.00022053959,0.00012020711,0.00001070526,0.00003506222,0.0000036790248,0.0005480599],"genre_scores_gemma":[0.0005386913,0.99890566,0.00012951475,0.00017787912,0.00007276734,0.000010089434,0.000028849909,9.995896e-7,0.0001355147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997216,0.000070154885,0.00007682181,0.000039618048,0.00007595194,0.000015858368],"domain_scores_gemma":[0.9990707,0.0006282383,0.00015276138,0.000015886495,0.00010854616,0.000023873394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068562495,0.00076702517,0.0012973407,0.0030485378,0.000291048,0.0011525222,0.0006869039,0.00078002067,0.0040594107],"category_scores_gemma":[0.0021583932,0.00023459145,0.00091171154,0.003078687,0.00031040268,0.001149254,0.00060791656,0.0009211927,0.0008595052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009249105,0.00004840094,0.00025013532,0.22352563,0.0005112704,0.0003690119,0.00025076134,0.0003634971,0.00077219744,0.0034783848,0.04327558,0.72706264],"study_design_scores_gemma":[0.000030546384,0.00011121989,0.0012154997,0.114127,0.0016145249,0.002774498,0.00019353541,0.00011529326,0.00025755144,0.001960865,0.87756944,0.00003003967],"about_ca_topic_score_codex":0.0012222718,"about_ca_topic_score_gemma":0.0027138083,"teacher_disagreement_score":0.0040594107,"about_ca_system_score_codex":0.0005607642,"about_ca_system_score_gemma":0.0017922216,"threshold_uncertainty_score":0.013580084},"labels":[],"label_agreement":null},{"id":"W4402567816","doi":"10.1080/14796694.2024.2394323","title":"A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Biotech; Sanofi Pasteur; AbbVie Biotherapeutics; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Janssen Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Daratumumab; Lenalidomide; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology","score_opus":0.02224847335936487,"score_gpt":0.34278931138209917,"score_spread":0.3205408380227343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402567816","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012667703,0.48639786,0.0037893595,0.14310093,0.04713622,0.009798813,0.24448079,0.0005908333,0.05203752],"genre_scores_gemma":[0.05640814,0.4472972,0.010609921,0.21127628,0.06601716,0.032093216,0.12361896,0.00074267376,0.05193649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914703,0.004422222,0.0021625657,0.00047778286,0.0011783597,0.00028874056],"domain_scores_gemma":[0.9704193,0.016959488,0.0042612953,0.0005576545,0.006499122,0.0013031674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010819373,0.0013297196,0.0025545075,0.0025215058,0.000692882,0.0028359634,0.0010321249,0.0014342613,0.034763925],"category_scores_gemma":[0.036629517,0.0006707352,0.0026248728,0.0031658194,0.00032389504,0.0012561735,0.00094684295,0.002438661,0.007624247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060499255,0.00027708418,0.0036432585,0.03212259,0.002165349,0.00020869504,0.00031448694,0.00017269183,0.0002740661,0.0008597325,0.8620388,0.09187339],"study_design_scores_gemma":[0.009014205,0.0030845872,0.027667107,0.0495865,0.004971681,0.0004205874,0.0005973014,0.00014440675,0.0003361261,0.0016421309,0.9023087,0.00022668205],"about_ca_topic_score_codex":0.0056031244,"about_ca_topic_score_gemma":0.007014043,"teacher_disagreement_score":0.034763925,"about_ca_system_score_codex":0.00184018,"about_ca_system_score_gemma":0.005195844,"threshold_uncertainty_score":0.11629695},"labels":[],"label_agreement":null},{"id":"W4402838411","doi":"10.1080/14796694.2024.2390821","title":"Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bayer HealthCare","keywords":"Medicine; Radiation oncology; Oncology; MEDLINE; Family medicine; Medical education; Internal medicine; Radiation therapy","score_opus":0.04744542064128006,"score_gpt":0.33670153736017533,"score_spread":0.2892561167188953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402838411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013852732,0.9970682,0.00016872966,0.0005560918,0.000070725364,0.00025443325,0.00020058498,0.00000617301,0.0002898482],"genre_scores_gemma":[0.013141217,0.98485005,0.0007228065,0.0004805003,0.00003982999,0.00052625575,0.00014034605,0.000005027701,0.00009397718],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9859201,0.0059984755,0.004511648,0.00076804205,0.0023519709,0.00044971233],"domain_scores_gemma":[0.92158484,0.062181678,0.009491854,0.00057424244,0.0055124885,0.00065486867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017602552,0.0012614802,0.005349722,0.008845005,0.0007890185,0.0027172433,0.0015895882,0.0016926997,0.0033373893],"category_scores_gemma":[0.074791834,0.0011303745,0.005920124,0.009687004,0.0008022296,0.0029853727,0.0019168295,0.0013017564,0.00027418815],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013673092,0.00002113631,0.0014777281,0.91789204,0.0050088963,0.00010327352,0.0007835583,0.000104911545,0.00010415202,0.00030807295,0.0019187809,0.072140835],"study_design_scores_gemma":[0.00010536366,0.00012815389,0.0042335503,0.948213,0.026274726,0.0002695625,0.0011076358,0.00007971962,0.00015203058,0.00024139819,0.0191593,0.00003556354],"about_ca_topic_score_codex":0.01155962,"about_ca_topic_score_gemma":0.03446336,"teacher_disagreement_score":0.017602552,"about_ca_system_score_codex":0.00420065,"about_ca_system_score_gemma":0.0243946,"threshold_uncertainty_score":0.09309226},"labels":[],"label_agreement":null},{"id":"W4403037895","doi":"10.1080/14796694.2024.2406597","title":"Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AOP Orphan; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Constellation Pharmaceuticals; Celgene","keywords":"Medicine; Ruxolitinib; Polycythemia vera; Internal medicine; Cancer; Oncology; Myelofibrosis; Bone marrow","score_opus":0.01271030447566842,"score_gpt":0.3285629588500332,"score_spread":0.3158526543743648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403037895","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008251641,0.8741317,0.0023146723,0.06133149,0.012907072,0.0033895068,0.020435695,0.00017140782,0.01706693],"genre_scores_gemma":[0.04279825,0.8006568,0.0057742274,0.0850678,0.030576004,0.0068140533,0.017819243,0.00022656395,0.010266996],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99412256,0.003064558,0.0013952063,0.00023439125,0.00095167855,0.00023170006],"domain_scores_gemma":[0.986257,0.0074285087,0.002949178,0.0003046583,0.0025315864,0.00052919134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009724081,0.00084484485,0.0029235624,0.0011764332,0.00031439628,0.0035523286,0.000919495,0.0013218637,0.010421633],"category_scores_gemma":[0.018650876,0.00047344455,0.0038212787,0.0019674234,0.00038620844,0.001426855,0.00070151896,0.00277515,0.0024052374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017226828,0.00058184593,0.00605943,0.10802072,0.008793797,0.00042405588,0.00027928417,0.0007310755,0.0008923288,0.0017790695,0.4258799,0.4293317],"study_design_scores_gemma":[0.036377195,0.010996781,0.034543872,0.14040463,0.022668479,0.00096671685,0.0004883908,0.000675649,0.001107498,0.0028687695,0.74855536,0.0003467504],"about_ca_topic_score_codex":0.0021753698,"about_ca_topic_score_gemma":0.0029973625,"teacher_disagreement_score":0.010421633,"about_ca_system_score_codex":0.0012341611,"about_ca_system_score_gemma":0.0028770305,"threshold_uncertainty_score":0.05142647},"labels":[],"label_agreement":null},{"id":"W4403099656","doi":"10.1080/14796694.2024.2406117","title":"Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BeiGene; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Internal medicine; Oncology; Dentistry","score_opus":0.01162281737132365,"score_gpt":0.35224840993712775,"score_spread":0.3406255925658041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403099656","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014354416,0.15661943,0.0031913733,0.24489379,0.13467419,0.0032137542,0.40475196,0.00081101863,0.037490092],"genre_scores_gemma":[0.11678747,0.10002857,0.005251024,0.37480703,0.16317126,0.009781989,0.16026077,0.0014051107,0.068506815],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912246,0.0043389536,0.0018716754,0.000478612,0.0016603423,0.00042584873],"domain_scores_gemma":[0.92299825,0.044134077,0.010670829,0.0020181,0.01745346,0.0027252308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013601355,0.001198879,0.003441566,0.0021922584,0.0006933203,0.00415532,0.0023410653,0.0025869075,0.07834928],"category_scores_gemma":[0.0834082,0.0005236244,0.0052552433,0.0033705651,0.00056696084,0.002233289,0.0012274511,0.0038124,0.014712257],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048290673,0.0000937304,0.0034082076,0.011940624,0.0021118515,0.0001727595,0.00007697709,0.0002149549,0.00012968453,0.00035658316,0.9508233,0.025842344],"study_design_scores_gemma":[0.034274857,0.0043477016,0.105516054,0.04243884,0.018493945,0.0008785991,0.0010961603,0.0008513673,0.0009328641,0.004113164,0.7864807,0.00057572394],"about_ca_topic_score_codex":0.0076888585,"about_ca_topic_score_gemma":0.00896807,"teacher_disagreement_score":0.07834928,"about_ca_system_score_codex":0.0020046015,"about_ca_system_score_gemma":0.003216645,"threshold_uncertainty_score":0.26210445},"labels":[],"label_agreement":null},{"id":"W4403763941","doi":"10.1080/14796694.2024.2416885","title":"Colorectal cancer research priorities in Uganda: perspectives from local key experts and stakeholders","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Medicine; Key (lock); Colorectal cancer; Cancer; Environmental resource management; Internal medicine; Computer science","score_opus":0.07337515650495452,"score_gpt":0.3884960520496344,"score_spread":0.31512089554467987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403763941","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2860062,0.046456277,0.0027226838,0.6298337,0.0028945403,0.00079915975,0.0007670478,0.00011932654,0.030401027],"genre_scores_gemma":[0.87542164,0.035417218,0.006204877,0.07034067,0.00076914317,0.0016293323,0.00038563242,0.000094472554,0.009736934],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.97566956,0.017191026,0.0011043648,0.00054884574,0.0011022263,0.0043839538],"domain_scores_gemma":[0.95900714,0.015322645,0.0023714008,0.00045663805,0.0060888124,0.016753428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03347472,0.00064754847,0.0010908648,0.0020352374,0.014152779,0.011671637,0.0021451234,0.0050340397,0.008715845],"category_scores_gemma":[0.033514038,0.0010056357,0.00075699604,0.0028413679,0.0044871126,0.005885843,0.01700301,0.0078903455,0.001004036],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005162231,0.0004893572,0.06046073,0.011873585,0.00020424605,0.012402394,0.6364176,0.0007735891,0.004216345,0.021675061,0.10296266,0.14800824],"study_design_scores_gemma":[0.0000673626,0.0003077754,0.011743754,0.0050392654,0.000091037946,0.0015106346,0.7620913,0.0002733485,0.0005807847,0.006001061,0.21214508,0.00014854998],"about_ca_topic_score_codex":0.01443002,"about_ca_topic_score_gemma":0.02059886,"teacher_disagreement_score":0.03347472,"about_ca_system_score_codex":0.0085781505,"about_ca_system_score_gemma":0.038550176,"threshold_uncertainty_score":0.17703342},"labels":[],"label_agreement":null},{"id":"W4403875478","doi":"10.1080/14796694.2024.2418804","title":"Part 1 – Highlights of the San Antonio Breast Cancer Symposium 2023","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Gerontology; Gynecology; Cancer","score_opus":0.006062885189194204,"score_gpt":0.265901607386362,"score_spread":0.2598387221971678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403875478","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017724131,0.24403733,0.0006975332,0.1779814,0.48240754,0.000350677,0.0010680892,0.00016695446,0.091518015],"genre_scores_gemma":[0.006662101,0.18786225,0.0014118302,0.059867073,0.46953356,0.00037838388,0.0017151701,0.00017845011,0.27239117],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893755,0.0001821159,0.000059990878,0.00014502273,0.00047584064,0.0001994837],"domain_scores_gemma":[0.9977552,0.0002657087,0.00014494425,0.00005464755,0.0006910572,0.0010884169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042656492,0.0020199183,0.0010193358,0.0015801183,0.0014830924,0.004311434,0.0014000916,0.00625736,0.03775256],"category_scores_gemma":[0.0020748165,0.0004530041,0.0012921059,0.0010243781,0.0006081014,0.0013745223,0.0019996918,0.0055529973,0.014565561],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015435631,0.00007146636,0.00016814156,0.0002701852,0.00001237926,0.00011166854,0.000015193343,0.000073948606,0.00041908282,0.00066391524,0.97016555,0.02787426],"study_design_scores_gemma":[0.000024269151,0.000052291645,0.0012738794,0.00030514965,0.000015271353,0.00013906909,0.00004850783,0.000050694212,0.00013598704,0.00030372757,0.9976427,0.000008450179],"about_ca_topic_score_codex":0.0032938875,"about_ca_topic_score_gemma":0.014615993,"teacher_disagreement_score":0.03775256,"about_ca_system_score_codex":0.0033296265,"about_ca_system_score_gemma":0.0036913813,"threshold_uncertainty_score":0.12629491},"labels":[],"label_agreement":null},{"id":"W4403875943","doi":"10.1080/14796694.2024.2418797","title":"Part 2 – Highlights of the San Antonio Breast Cancer Symposium 2023","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.009030785945327625,"score_gpt":0.3010043440202266,"score_spread":0.29197355807489894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403875943","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016178745,0.12776063,0.0005741519,0.20834368,0.5574191,0.00022237831,0.0011158315,0.00017659059,0.10276973],"genre_scores_gemma":[0.007463243,0.11125775,0.0012078186,0.06998374,0.4974502,0.00029314368,0.0017649548,0.00021202263,0.31036708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998852,0.00017722887,0.000049384915,0.00013932453,0.00055051764,0.00023159572],"domain_scores_gemma":[0.9978404,0.00020991074,0.0001444244,0.00004413673,0.00058303756,0.0011780771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036895366,0.0018641887,0.0008069605,0.0012256614,0.0015558382,0.0044771214,0.0012965186,0.0057175816,0.0478324],"category_scores_gemma":[0.002203091,0.0003842199,0.0011966531,0.0008484207,0.00059793744,0.0014034536,0.0020478142,0.006193295,0.01601881],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008797643,0.000047851478,0.000112184964,0.00014877523,0.0000070546407,0.00007362049,0.00001616876,0.0000643078,0.00025193012,0.00058686204,0.9796592,0.018944073],"study_design_scores_gemma":[0.00001894857,0.000037461323,0.0008443268,0.00021166225,0.0000085634065,0.000094346586,0.000056473873,0.000047155278,0.00008853875,0.0002645685,0.99832124,0.0000065898425],"about_ca_topic_score_codex":0.0032293547,"about_ca_topic_score_gemma":0.015093722,"teacher_disagreement_score":0.0478324,"about_ca_system_score_codex":0.0031841507,"about_ca_system_score_gemma":0.0046678204,"threshold_uncertainty_score":0.16001534},"labels":[],"label_agreement":null},{"id":"W4404275600","doi":"10.1080/14796694.2024.2421151","title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Government of Jiangsu Province","keywords":"Medicine; Tumor-infiltrating lymphocytes; Esophageal cancer; Immunotherapy; Oncology; Immunology; Cancer; Internal medicine; Pathology","score_opus":0.008220770756086012,"score_gpt":0.2852142627647132,"score_spread":0.27699349200862716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404275600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884015,0.00077121425,0.00011048656,0.000023558408,0.0000040427485,0.0000048857582,0.00008158983,0.000002598479,0.00016144852],"genre_scores_gemma":[0.99949324,0.00014762397,0.000102145015,0.000012240691,0.00001132001,0.000004871045,0.00012938053,6.0938044e-7,0.00009853815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99991333,0.000022595525,0.00001199227,0.000017349194,0.000015817785,0.00001885586],"domain_scores_gemma":[0.99976,0.000050724724,0.00011561681,0.000011088691,0.000023809302,0.000038719245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023301985,0.00019816757,0.00024081893,0.00030209686,0.00012860892,0.00025453954,0.000072905066,0.00018953877,0.0009798257],"category_scores_gemma":[0.00049144705,0.000065946915,0.00020756382,0.00031635215,0.000110915156,0.00014296414,0.00014758226,0.00022297712,0.00014205898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006252848,0.000044247132,0.9914185,0.000020925618,0.000044055218,0.000071442,0.000017601804,0.000104340616,0.002993076,0.000007366846,0.00006120161,0.0045918524],"study_design_scores_gemma":[0.000016790518,0.00031346493,0.99746215,0.000007022711,0.00007283182,0.00036659127,0.00004861445,0.0004327896,0.0010161572,0.000025157813,0.00023560676,0.0000027552392],"about_ca_topic_score_codex":0.00018600341,"about_ca_topic_score_gemma":0.00042199204,"teacher_disagreement_score":0.0009798257,"about_ca_system_score_codex":0.00010780976,"about_ca_system_score_gemma":0.00012054246,"threshold_uncertainty_score":0.0032777786},"labels":[],"label_agreement":null},{"id":"W4405308923","doi":"10.1080/14796694.2024.2426425","title":"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Biochemical recurrence; Radiation therapy; Cancer; Oncology; Testosterone (patch); Quality of life (healthcare); Adverse effect; Internal medicine; Prostatectomy; Urology","score_opus":0.013786439810920353,"score_gpt":0.34443305239049077,"score_spread":0.3306466125795704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405308923","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020624201,0.32675895,0.0013014898,0.42589626,0.1464813,0.0017965559,0.043275114,0.00046880156,0.051959053],"genre_scores_gemma":[0.019893602,0.39694855,0.0029670515,0.39274284,0.09886382,0.0033977698,0.023590652,0.00033806503,0.06125766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960484,0.0012114283,0.0011242542,0.00022645653,0.0011595587,0.00022996479],"domain_scores_gemma":[0.9703138,0.010368303,0.0064702225,0.00037895812,0.011500496,0.00096813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005013718,0.0011679484,0.004605725,0.0026701323,0.0007998309,0.0052283355,0.0026948983,0.0050112423,0.08759167],"category_scores_gemma":[0.0453653,0.0006965499,0.003430569,0.002466414,0.00073090586,0.0035044325,0.0010874164,0.0054389453,0.023488816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072304404,0.000056530927,0.00043204587,0.02031271,0.00039620715,0.000097547294,0.000048677157,0.00010730735,0.00013304554,0.0007609852,0.9275367,0.049395233],"study_design_scores_gemma":[0.0016448747,0.00058872346,0.0045964997,0.055176936,0.0016134907,0.00032556115,0.00024068964,0.00016540274,0.0003371697,0.0019874058,0.9331987,0.00012452088],"about_ca_topic_score_codex":0.005846437,"about_ca_topic_score_gemma":0.0066513503,"teacher_disagreement_score":0.08759167,"about_ca_system_score_codex":0.002586365,"about_ca_system_score_gemma":0.004985654,"threshold_uncertainty_score":0.29302335},"labels":[],"label_agreement":null},{"id":"W4405417317","doi":"10.1080/14796694.2024.2436342","title":"Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Cancer stage; Productivity; Cancer; Family medicine; Gerontology; Internal medicine; Economic growth","score_opus":0.040257847580596424,"score_gpt":0.31565611209725597,"score_spread":0.27539826451665955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405417317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964768,0.00032167332,0.00003700526,0.00046475476,0.0000058224127,0.000018152103,0.00186177,0.0000028020775,0.0008112265],"genre_scores_gemma":[0.99823916,0.0003546112,0.000060531358,0.0001525251,0.000009344845,0.00002076262,0.0010044941,9.0445803e-7,0.0001575749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993499,0.00021116383,0.00012208504,0.000041725532,0.00014489538,0.0001301979],"domain_scores_gemma":[0.9956299,0.00061417784,0.0026235103,0.00011262505,0.00044816863,0.00057162135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011230947,0.00013267454,0.00022548491,0.0009731441,0.0003631837,0.00050474255,0.00023526273,0.00026529303,0.0015085549],"category_scores_gemma":[0.005147187,0.00011812695,0.00032519826,0.001379959,0.00020698496,0.00041126937,0.0007261784,0.0005341791,0.00017675862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016297903,0.000036890284,0.99702436,0.000018293145,0.00001769249,0.00003490657,0.00013723302,0.000049565708,0.000013995283,0.000017281094,0.0006404478,0.0019929665],"study_design_scores_gemma":[0.0000027486892,0.00003661345,0.99859315,0.000023038758,0.000008915678,0.0000999013,0.00056397775,0.000082786886,0.000018870081,0.000023442108,0.0005434304,0.0000030467752],"about_ca_topic_score_codex":0.02439234,"about_ca_topic_score_gemma":0.031218007,"teacher_disagreement_score":0.02439234,"about_ca_system_score_codex":0.0005891714,"about_ca_system_score_gemma":0.00075211044,"threshold_uncertainty_score":0.048500717},"labels":[],"label_agreement":null},{"id":"W4405453061","doi":"10.1080/14796694.2024.2421152","title":"An early economic evaluation of active surveillance for low-risk ductal carcinoma <i>in situ</i>","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Psychosocial Oncology","funders":"KWF Kankerbestrijding; Cancer Research UK","keywords":"Medicine; Ductal carcinoma; In situ; Carcinoma in situ; Breast cancer; Carcinoma; Oncology; Cancer; Internal medicine","score_opus":0.04332710442107975,"score_gpt":0.38525093509850805,"score_spread":0.3419238306774283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405453061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646449,0.0028050335,0.017404763,0.0027934066,0.00016688307,0.0021430408,0.0021595699,0.00006297965,0.007819355],"genre_scores_gemma":[0.9942768,0.0004226028,0.0035663168,0.00021739771,0.000018125089,0.00041028406,0.0004658688,0.0000067602164,0.00061585184],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9952939,0.003905317,0.00007791748,0.0001434481,0.0002849918,0.00029436024],"domain_scores_gemma":[0.98143506,0.015638115,0.0009014535,0.00032841784,0.0009420458,0.0007549552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011883262,0.0011105615,0.0013410144,0.00065262837,0.00032628176,0.0017027071,0.0010277918,0.0013674013,0.0050602457],"category_scores_gemma":[0.025911754,0.00042322016,0.002599166,0.0004754295,0.0004594916,0.0011004433,0.000880652,0.0011113891,0.0001778182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071049646,0.0038017295,0.03001197,0.00231479,0.0025336938,0.0005434509,0.00018756837,0.79909366,0.0022830216,0.012432761,0.0037815291,0.07196616],"study_design_scores_gemma":[0.011231694,0.042047102,0.02932267,0.0010507384,0.003603269,0.00044916445,0.00050533004,0.8902627,0.0036277291,0.011930458,0.0058271647,0.00014198053],"about_ca_topic_score_codex":0.005674227,"about_ca_topic_score_gemma":0.0034468144,"teacher_disagreement_score":0.011883262,"about_ca_system_score_codex":0.0036981322,"about_ca_system_score_gemma":0.0038537763,"threshold_uncertainty_score":0.06284541},"labels":[],"label_agreement":null},{"id":"W4405696229","doi":"10.1080/14796694.2024.2442900","title":"Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; PARP inhibitor; Androgen receptor; Enzalutamide; Oncology; Internal medicine; PARP1; Cancer research; Androgen deprivation therapy; Abiraterone; Cancer; Poly ADP ribose polymerase; Gene; Biology","score_opus":0.10008847965426025,"score_gpt":0.46419381523950315,"score_spread":0.3641053355852429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405696229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002657888,0.99855226,0.000054131975,0.00007105187,0.00007385147,0.000007794212,0.000020161102,0.0000056861845,0.0009492796],"genre_scores_gemma":[0.0014296874,0.9976731,0.00010716316,0.00012408214,0.000058317746,0.000008575379,0.00004657191,0.0000012624666,0.00055126374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998498,0.000028573102,0.000025759497,0.000021845086,0.00006143761,0.00001268116],"domain_scores_gemma":[0.99989796,0.000042960302,0.000026200518,0.0000027525696,0.000021979338,0.000008173386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035147715,0.000542506,0.0011964423,0.0015720715,0.0001605498,0.0005536774,0.00068341446,0.0004722866,0.0034642136],"category_scores_gemma":[0.00034964105,0.00019602185,0.0006255655,0.0013456752,0.00019115607,0.00049978273,0.00036267008,0.0010501747,0.0012132538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021331635,0.00007638376,0.00012120159,0.031107008,0.00024717482,0.00017215151,0.00004233287,0.0003584076,0.0019407104,0.00098399,0.014751274,0.9499861],"study_design_scores_gemma":[0.00018875452,0.0004888427,0.0020466894,0.010806062,0.0007224065,0.0027923484,0.00006245733,0.00024976264,0.0013633821,0.0010707754,0.98018104,0.00002747584],"about_ca_topic_score_codex":0.0009575548,"about_ca_topic_score_gemma":0.0028461246,"teacher_disagreement_score":0.0034642136,"about_ca_system_score_codex":0.00042057844,"about_ca_system_score_gemma":0.00073635165,"threshold_uncertainty_score":0.011588991},"labels":[],"label_agreement":null},{"id":"W4406227864","doi":"10.1080/14796694.2024.2439178","title":"Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Bosutinib; Medicine; Myeloid leukemia; Oncology; Side effect (computer science); Internal medicine; Tyrosine-kinase inhibitor; Drug; Imatinib; Pharmacology; Nilotinib; Cancer","score_opus":0.017235741951038337,"score_gpt":0.3434522840867526,"score_spread":0.32621654213571427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406227864","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09841635,0.7300269,0.0027666655,0.06766305,0.024347708,0.011539763,0.03140656,0.00021838224,0.033614624],"genre_scores_gemma":[0.3610117,0.4090018,0.0076977555,0.09560213,0.050025064,0.026395896,0.02390765,0.00032973746,0.026028235],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927226,0.0046633533,0.0013064169,0.00024982184,0.0007935265,0.00026443932],"domain_scores_gemma":[0.9803843,0.011505159,0.0037313388,0.00046272165,0.0027697925,0.0011467094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012388224,0.00084669795,0.0032528576,0.0007706471,0.0004842752,0.0028802687,0.0007055905,0.0021751057,0.017150085],"category_scores_gemma":[0.020766601,0.0004172376,0.006329666,0.0013302566,0.00034146704,0.0014862629,0.00070019613,0.0035775648,0.0030217108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36119258,0.0039695995,0.008852193,0.07364971,0.020695362,0.00038034975,0.0004436137,0.00071403844,0.0016950304,0.0016155539,0.17001322,0.3567788],"study_design_scores_gemma":[0.30752152,0.12926215,0.06364373,0.0645902,0.04031989,0.00085766765,0.0010606989,0.0010099263,0.001764187,0.0030387607,0.38647336,0.000457943],"about_ca_topic_score_codex":0.0010330332,"about_ca_topic_score_gemma":0.0016063842,"teacher_disagreement_score":0.017150085,"about_ca_system_score_codex":0.0013472551,"about_ca_system_score_gemma":0.0017476478,"threshold_uncertainty_score":0.065515995},"labels":[],"label_agreement":null},{"id":"W4406468796","doi":"10.1080/14796694.2024.2441107","title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Sun Pharma; Rakuten Medical; STCube; FibroGen; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Relay Therapeutics; Seagen; Actuate Therapeutics; BeiGene; Taiho Pharmaceutical; Kyowa Kirin Pharmaceutical Development; Pfizer; Incyte; Daiichi Sankyo Europe; Servier; Gilead Sciences; Japan Society for the Promotion of Science; GlaxoSmithKline; Mersana Therapeutics; Japan Agency for Medical Research and Development; Roivant Sciences; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Agonist; Sting; Open label; Oncology; Internal medicine; Receptor; Clinical trial","score_opus":0.016672539311782555,"score_gpt":0.36328153072606967,"score_spread":0.34660899141428714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406468796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977111,0.0031268261,0.0017038832,0.0008623717,0.00038999168,0.0075089354,0.002536061,0.00034397907,0.0064170603],"genre_scores_gemma":[0.977089,0.0020023212,0.0032477553,0.0012376881,0.00028350356,0.0059675095,0.002517644,0.000051423205,0.007603069],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972457,0.000106975174,0.000012858518,0.000048683378,0.000029514506,0.00007732893],"domain_scores_gemma":[0.9995523,0.000052011994,0.00007675,0.000038511113,0.000033961896,0.00024643572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011644418,0.001383159,0.0018305593,0.0004007971,0.0004885603,0.00091811444,0.0007228922,0.0011325544,0.0057223896],"category_scores_gemma":[0.00063523964,0.0005409345,0.00065495033,0.0003918486,0.0008933413,0.0011283283,0.00029243284,0.002889985,0.0012959377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71170443,0.106244825,0.0032993879,0.0010833298,0.0009424401,0.00025158402,0.0003224147,0.0029130632,0.047559444,0.00089204445,0.009373319,0.11541376],"study_design_scores_gemma":[0.52290124,0.45977715,0.0049219322,0.000045175315,0.00019708955,0.0002087635,0.00008077685,0.0018107268,0.0038076658,0.0005108661,0.005711962,0.00002664693],"about_ca_topic_score_codex":0.00091323955,"about_ca_topic_score_gemma":0.0029943562,"teacher_disagreement_score":0.0057223896,"about_ca_system_score_codex":0.00092780293,"about_ca_system_score_gemma":0.0017544299,"threshold_uncertainty_score":0.019143343},"labels":[],"label_agreement":null},{"id":"W4406479425","doi":"10.1080/14796694.2025.2449782","title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Ovarian cancer; Genetic testing; Family medicine; Cancer; Biomarker; MEDLINE; Oncology; Internal medicine","score_opus":0.015628567683929017,"score_gpt":0.31745120063273,"score_spread":0.301822632948801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406479425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985436,0.00013967605,0.000041855685,0.00024164555,0.0000035323567,0.000013716629,0.00022325554,0.0000022448528,0.0007904129],"genre_scores_gemma":[0.9992144,0.00013110881,0.00010020789,0.00016327528,0.0000059507347,0.000011900431,0.00016955145,9.297716e-7,0.0002026546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934155,0.0002645135,0.00008829255,0.00006357898,0.00015101422,0.00009101276],"domain_scores_gemma":[0.9958889,0.0010842276,0.0019758902,0.00007980957,0.00036620226,0.0006049568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014687106,0.00012339058,0.00017256266,0.00042874657,0.00026906352,0.0004562385,0.00019289363,0.00041142252,0.002309116],"category_scores_gemma":[0.004665641,0.00015147448,0.00021498672,0.00046714168,0.0002169942,0.00047625476,0.000367785,0.00042705543,0.00026796397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026973943,0.00010507422,0.9971909,0.000014735351,0.0000145356635,0.000033367764,0.000571424,0.000033767534,0.000070040056,0.0000067464384,0.00022587547,0.001706644],"study_design_scores_gemma":[0.0000093432855,0.00016151195,0.9973922,0.000016915663,0.000011587456,0.00015686585,0.0016090844,0.00020630486,0.000047361093,0.000007940372,0.00037733783,0.000003568417],"about_ca_topic_score_codex":0.008045497,"about_ca_topic_score_gemma":0.009454787,"teacher_disagreement_score":0.008045497,"about_ca_system_score_codex":0.0003623007,"about_ca_system_score_gemma":0.0003805959,"threshold_uncertainty_score":0.01599735},"labels":[],"label_agreement":null},{"id":"W4406482305","doi":"10.1080/14796694.2024.2435208","title":"Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Javelin; Medicine; Urothelial cancer; Avelumab; Bladder cancer; Term (time); Oncology; Internal medicine; Urology; Intensive care medicine; Cancer; Immunotherapy; Pembrolizumab; Astronomy","score_opus":0.019722409884365175,"score_gpt":0.35553043528897854,"score_spread":0.33580802540461335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406482305","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06820257,0.82530576,0.0016028365,0.017445898,0.004291899,0.0019681382,0.06420952,0.00015675953,0.016816601],"genre_scores_gemma":[0.46844617,0.40952286,0.00465365,0.031158417,0.008585155,0.005878399,0.059631713,0.00035432557,0.011769304],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98810613,0.006183881,0.002585497,0.00049360935,0.002282706,0.00034820524],"domain_scores_gemma":[0.95508486,0.021550596,0.013797776,0.0012914626,0.007142286,0.0011330436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015493999,0.0006145692,0.0029179507,0.001386637,0.00044514882,0.002879383,0.0010409163,0.001496144,0.010548493],"category_scores_gemma":[0.035735622,0.00055516715,0.0073351976,0.0029596146,0.00040864316,0.0021164285,0.00087580393,0.0028008043,0.0018303781],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13421503,0.0010311978,0.05669195,0.16967785,0.0656262,0.0004687712,0.0008093586,0.0011599228,0.0015708384,0.0011347098,0.19203204,0.37558216],"study_design_scores_gemma":[0.10486316,0.030474044,0.31628963,0.09359665,0.18651955,0.0011776091,0.0014292977,0.0007904434,0.0019547495,0.0020808298,0.2601524,0.0006716495],"about_ca_topic_score_codex":0.002354588,"about_ca_topic_score_gemma":0.0048485356,"teacher_disagreement_score":0.015493999,"about_ca_system_score_codex":0.0012764364,"about_ca_system_score_gemma":0.0018116538,"threshold_uncertainty_score":0.08194113},"labels":[],"label_agreement":null},{"id":"W4406486966","doi":"10.1080/14796694.2024.2440277","title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Alberta; Precision Nanosystems (Canada); University of Ottawa; University of British Columbia; Ottawa Hospital; Queen's University","funders":"National Health and Medical Research Council; Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Hormone therapy; Cancer; Androgen receptor; Breast cancer","score_opus":0.01844197879047274,"score_gpt":0.35905948134062665,"score_spread":0.3406175025501539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406486966","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026473977,0.7731999,0.002466233,0.08692979,0.017328849,0.0045963954,0.031731255,0.00055135024,0.0567223],"genre_scores_gemma":[0.17278104,0.56286687,0.011328469,0.14147297,0.021800745,0.008214737,0.029316513,0.0004448837,0.051773842],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978726,0.0013135532,0.00030736777,0.00008535401,0.00033582587,0.000085339285],"domain_scores_gemma":[0.9966522,0.0014897157,0.0009812696,0.00010292525,0.0005435921,0.00023043997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042953216,0.0008430508,0.0022760015,0.0005652816,0.00028688362,0.0021003936,0.00073728984,0.0013923979,0.01476561],"category_scores_gemma":[0.008224444,0.00033658586,0.003448209,0.00093661336,0.00022988296,0.0011258584,0.00038927604,0.002768121,0.0023524931],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06019291,0.0006134188,0.001336385,0.05478282,0.0076476233,0.00023095023,0.000116957686,0.0012760098,0.0017762586,0.001868208,0.42763072,0.44252783],"study_design_scores_gemma":[0.16888145,0.02451089,0.021996066,0.045435537,0.02609004,0.0007649485,0.00028767576,0.0013887755,0.0018924776,0.00489687,0.7035567,0.00029849855],"about_ca_topic_score_codex":0.0020991047,"about_ca_topic_score_gemma":0.0053242575,"teacher_disagreement_score":0.01476561,"about_ca_system_score_codex":0.0010767048,"about_ca_system_score_gemma":0.0012879935,"threshold_uncertainty_score":0.04939592},"labels":[],"label_agreement":null},{"id":"W4406852237","doi":"10.1080/14796694.2025.2454895","title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Discontinuation; Internal medicine; Oncology; Pediatrics; Intensive care medicine","score_opus":0.017927463657704014,"score_gpt":0.3361532998949089,"score_spread":0.31822583623720485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406852237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871206,0.00035139357,0.000054713255,0.00007343827,0.0000022345807,0.000008529227,0.0005444805,0.0000020477016,0.00025112068],"genre_scores_gemma":[0.9993554,0.00008483253,0.000061086845,0.000023102368,0.0000044020553,0.0000050560375,0.0004353048,5.9662557e-7,0.000030319161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921095,0.00027136793,0.0001548287,0.00014495346,0.00011687908,0.00010100803],"domain_scores_gemma":[0.9947397,0.0006950188,0.0038961265,0.00012083239,0.00025498067,0.00029339668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009152108,0.0001103617,0.00021786346,0.0008778032,0.00028773688,0.0006149146,0.0002423816,0.0003747188,0.00078735896],"category_scores_gemma":[0.0038379615,0.00011512884,0.00023144975,0.000976336,0.00032891554,0.00056638854,0.0003792963,0.00028605497,0.00012373911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054851927,0.0000118124935,0.9989371,0.000007487348,0.000018580222,0.000040021103,0.00004446325,0.000031462154,0.000036167265,0.0000051250363,0.00004107087,0.000771979],"study_design_scores_gemma":[0.0000051252155,0.00008592174,0.9989147,0.000008445604,0.0000124742855,0.00040837823,0.00020539737,0.00014341126,0.00005292152,0.000008398818,0.00015122192,0.0000035859566],"about_ca_topic_score_codex":0.0062344666,"about_ca_topic_score_gemma":0.01131451,"teacher_disagreement_score":0.0062344666,"about_ca_system_score_codex":0.00070035894,"about_ca_system_score_gemma":0.00044389727,"threshold_uncertainty_score":0.012396336},"labels":[],"label_agreement":null},{"id":"W4407918416","doi":"10.1080/14796694.2025.2466416","title":"Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Real world data; Lung cancer; Clinical trial; Mesothelioma; Immunotherapy; Intensive care medicine; Oncology; Cancer; Internal medicine; Pathology; Data science","score_opus":0.10770230903221834,"score_gpt":0.501525485878789,"score_spread":0.39382317684657064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407918416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012390208,0.9761696,0.00091779616,0.019327505,0.0014166669,0.000058428486,0.00006620745,0.000016394653,0.0019034607],"genre_scores_gemma":[0.0033175831,0.9762556,0.0038831257,0.013768433,0.0021114473,0.00018396843,0.00011011877,0.000027907092,0.0003418112],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9634774,0.023503441,0.005168249,0.001600078,0.0049498077,0.0013011124],"domain_scores_gemma":[0.78671616,0.18462573,0.008905857,0.004853607,0.011620347,0.0032783553],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08231361,0.0010285141,0.0034531937,0.003914125,0.00083126203,0.008511891,0.0028139958,0.0052908743,0.00455238],"category_scores_gemma":[0.11329131,0.0007649755,0.0041820095,0.0056004287,0.0049130484,0.009869151,0.0067593805,0.010645493,0.0013712432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042556052,0.0000964911,0.00055532414,0.10018473,0.00086119684,0.00015206219,0.00086347724,0.00083103694,0.00035265775,0.07855626,0.05314143,0.7639798],"study_design_scores_gemma":[0.00020434882,0.00031071398,0.0011178607,0.19649461,0.00079775,0.0004632593,0.0006047407,0.00026089294,0.00031815306,0.054340843,0.7450114,0.00007538334],"about_ca_topic_score_codex":0.0017225804,"about_ca_topic_score_gemma":0.0028450112,"teacher_disagreement_score":0.9176864,"about_ca_system_score_codex":0.0046747886,"about_ca_system_score_gemma":0.021530567,"threshold_uncertainty_score":0.4353212},"labels":[],"label_agreement":null},{"id":"W4408042402","doi":"10.1080/14796694.2025.2459548","title":"CAMBRIA-1 &amp; CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Endocrine system; Metastatic breast cancer; Cancer; Gynecology; Hormone","score_opus":0.04278605245297019,"score_gpt":0.4233400671943058,"score_spread":0.3805540147413356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408042402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8748639,0.060702786,0.0032133653,0.006960271,0.001966628,0.019883571,0.007132239,0.00056616607,0.024711045],"genre_scores_gemma":[0.8918677,0.026692541,0.009898424,0.010595675,0.0018483406,0.028257275,0.009006496,0.00016996537,0.021663575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946207,0.00028211463,0.000027179476,0.00008246642,0.000053468266,0.00009272223],"domain_scores_gemma":[0.9992649,0.00019644861,0.00017710253,0.000053979646,0.000060709935,0.00024673567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019321468,0.0015665882,0.0018241397,0.00067093596,0.00045816938,0.0015315185,0.001280817,0.0025741176,0.0073484834],"category_scores_gemma":[0.0016805673,0.0005008006,0.0019654592,0.0005573898,0.0008865496,0.0011406157,0.00043218076,0.004223925,0.0011341096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8207796,0.023334516,0.0014969516,0.0036136536,0.001756322,0.00023667784,0.00020224252,0.0020898134,0.020407425,0.0023638988,0.014066651,0.10965217],"study_design_scores_gemma":[0.89252263,0.09088052,0.0018315294,0.00026474037,0.00046992075,0.00021023773,0.00004220306,0.0009200015,0.0017174479,0.00092854793,0.0101831425,0.000028916116],"about_ca_topic_score_codex":0.00081797293,"about_ca_topic_score_gemma":0.0026421354,"teacher_disagreement_score":0.0073484834,"about_ca_system_score_codex":0.0010157272,"about_ca_system_score_gemma":0.001434592,"threshold_uncertainty_score":0.024583101},"labels":[],"label_agreement":null},{"id":"W4408207552","doi":"10.1080/14796694.2025.2471200","title":"Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Docetaxel; Abiraterone acetate; Abiraterone; Oncology; Internal medicine; Pharmacology; Prostate cancer; Cancer; Androgen receptor","score_opus":0.09705332580578253,"score_gpt":0.4455255526695369,"score_spread":0.3484722268637544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408207552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22637989,0.74036074,0.008891298,0.0009791983,0.0019586217,0.009279563,0.005862059,0.00013672386,0.0061519104],"genre_scores_gemma":[0.92444634,0.060411498,0.0065979133,0.0009917741,0.0003640744,0.004341702,0.001675191,0.000024949419,0.0011465597],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9818786,0.013039703,0.0026051402,0.0011151953,0.0011032987,0.0002581114],"domain_scores_gemma":[0.9900629,0.0070156166,0.0019422134,0.00037065282,0.00045498557,0.00015358423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014330947,0.0014620529,0.004936139,0.0020104102,0.00029623572,0.0015193506,0.0009582275,0.0012631573,0.0058913315],"category_scores_gemma":[0.026461855,0.00050465186,0.014365953,0.001554293,0.00057052064,0.00086484797,0.0011710135,0.0013624623,0.0003198293],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12899368,0.0005289064,0.009890464,0.22150321,0.54838175,0.00015767784,0.00028975157,0.0023166358,0.0015349917,0.0016444995,0.0010163543,0.08374211],"study_design_scores_gemma":[0.0571813,0.017654834,0.01833377,0.012752254,0.88055074,0.0002296993,0.00019664469,0.0017048079,0.0010781562,0.0021012954,0.008123772,0.00009277603],"about_ca_topic_score_codex":0.0033186246,"about_ca_topic_score_gemma":0.004679559,"teacher_disagreement_score":0.014330947,"about_ca_system_score_codex":0.0013992938,"about_ca_system_score_gemma":0.0020675599,"threshold_uncertainty_score":0.07579023},"labels":[],"label_agreement":null},{"id":"W4408236824","doi":"10.1080/14796694.2025.2463318","title":"A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.004826428086192625,"score_gpt":0.321617607089152,"score_spread":0.3167911790029594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408236824","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010152171,0.32735163,0.0037170814,0.12215283,0.06077266,0.008374603,0.39776146,0.0008667541,0.068850815],"genre_scores_gemma":[0.07284502,0.2461426,0.009296927,0.24703233,0.0754117,0.015971135,0.23455305,0.0013619896,0.09738526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949399,0.0018147179,0.0014846702,0.00032007915,0.0011776745,0.00026291359],"domain_scores_gemma":[0.980164,0.008916675,0.004052147,0.00038170093,0.0057583833,0.0007270967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065836757,0.0013228946,0.0036306304,0.0016006457,0.00038070424,0.0032539633,0.0015962594,0.0023814803,0.05573947],"category_scores_gemma":[0.023897897,0.00061637885,0.0071939547,0.0020714535,0.00041066608,0.0018743317,0.00073289784,0.0030025898,0.014347876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011957363,0.0001594223,0.0014863088,0.03656767,0.0027023884,0.00020143279,0.00005720902,0.00028607098,0.0006077531,0.0004552607,0.88267606,0.06284316],"study_design_scores_gemma":[0.03579964,0.005759088,0.026298206,0.05015658,0.010892588,0.0009423976,0.00025524414,0.00035971464,0.001188659,0.002582274,0.86548126,0.0002843042],"about_ca_topic_score_codex":0.0028661226,"about_ca_topic_score_gemma":0.0040346636,"teacher_disagreement_score":0.05573947,"about_ca_system_score_codex":0.0014751492,"about_ca_system_score_gemma":0.002106516,"threshold_uncertainty_score":0.18646705},"labels":[],"label_agreement":null},{"id":"W4408237108","doi":"10.1080/14796694.2025.2468578","title":"A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine","score_opus":0.025476626718189566,"score_gpt":0.38500189559359743,"score_spread":0.35952526887540787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408237108","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018416481,0.25610408,0.010854464,0.2758379,0.09375203,0.047671966,0.20662113,0.0022162674,0.088525735],"genre_scores_gemma":[0.0736869,0.16047639,0.019116214,0.42583463,0.049200986,0.07342276,0.06689822,0.0009858997,0.1303781],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942081,0.0038243814,0.00085483515,0.00027047595,0.00059419736,0.00024787177],"domain_scores_gemma":[0.9842799,0.008668,0.0040683476,0.00041544065,0.0018183015,0.00074998115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009251399,0.002015205,0.0038679207,0.001073385,0.0006716048,0.004504724,0.0017337837,0.0045000073,0.054784443],"category_scores_gemma":[0.028738698,0.00094650284,0.0061804475,0.0012076033,0.0005419248,0.00185783,0.00080033904,0.0049404018,0.010829221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057025503,0.0004574934,0.00066410913,0.044212345,0.002828044,0.00030310923,0.000112695285,0.0011380779,0.0012214324,0.0026276424,0.77728736,0.1121222],"study_design_scores_gemma":[0.19590622,0.018578269,0.0061159786,0.04247985,0.008441633,0.0005244583,0.00023690354,0.0014158216,0.0014413599,0.008119624,0.71638256,0.00035726363],"about_ca_topic_score_codex":0.0023710513,"about_ca_topic_score_gemma":0.0037832265,"teacher_disagreement_score":0.054784443,"about_ca_system_score_codex":0.0019219192,"about_ca_system_score_gemma":0.0026388995,"threshold_uncertainty_score":0.18327224},"labels":[],"label_agreement":null},{"id":"W4408457164","doi":"10.1080/14796694.2025.2475728","title":"The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Medicine; Real world evidence; Value (mathematics); Oncology; Internal medicine; Intensive care medicine","score_opus":0.024923823832679836,"score_gpt":0.41306330247154305,"score_spread":0.3881394786388632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408457164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000106484666,0.9978947,0.00013565502,0.0010493125,0.00016584384,0.00001676723,0.000048613878,0.000004051653,0.0005785999],"genre_scores_gemma":[0.0030767715,0.99481946,0.0005662898,0.0011612074,0.00018317586,0.000036124136,0.00007151174,0.0000031991406,0.00008220815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921922,0.003480866,0.0018036921,0.00055657857,0.0017827746,0.00018379903],"domain_scores_gemma":[0.9069131,0.083214,0.004369176,0.0009770804,0.0041499883,0.00037664993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015570661,0.0009847793,0.0044070138,0.005027152,0.00039670506,0.0037789878,0.0021436827,0.0030677756,0.0056872717],"category_scores_gemma":[0.06141155,0.00060398586,0.0039596083,0.004166974,0.0013466688,0.0033680159,0.0014177037,0.004163428,0.00071201666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030813296,0.000043750297,0.00049608573,0.42897424,0.003932725,0.00013746026,0.00023245394,0.00067614706,0.00048364926,0.008973293,0.0099527035,0.54578936],"study_design_scores_gemma":[0.00019328,0.00021698604,0.0023285819,0.6513973,0.011181144,0.0005604865,0.00030976927,0.00032475137,0.00042673392,0.01202029,0.32098582,0.00005479364],"about_ca_topic_score_codex":0.0032634095,"about_ca_topic_score_gemma":0.0062777386,"teacher_disagreement_score":0.015570661,"about_ca_system_score_codex":0.0025353548,"about_ca_system_score_gemma":0.008700126,"threshold_uncertainty_score":0.0823465},"labels":[],"label_agreement":null},{"id":"W4408808751","doi":"10.1080/14796694.2025.2479374","title":"Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; McGill University; University of Calgary","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Bone metastasis; Androgen deprivation therapy; Oncology; Metastasis; Cancer","score_opus":0.02622886707316352,"score_gpt":0.3772367480505685,"score_spread":0.351007880977405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408808751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884897,0.0027085,0.00016509827,0.0012780767,0.00003300552,0.00011453039,0.0047254064,0.000018544706,0.0024671678],"genre_scores_gemma":[0.9960582,0.0011767203,0.00021773508,0.00041013485,0.000017309785,0.000020601035,0.0016106138,0.0000068889294,0.00048169759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829084,0.0001774341,0.000090693386,0.00021952794,0.00067195855,0.00054966606],"domain_scores_gemma":[0.99614954,0.00023286167,0.0010511506,0.00009829808,0.0012853425,0.0011827485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010445287,0.00045199326,0.00057847344,0.0013351331,0.0022435575,0.0016886169,0.0017261294,0.0006100461,0.0017218688],"category_scores_gemma":[0.002587754,0.00043637765,0.0006761083,0.0059296973,0.0011573447,0.00040283895,0.0009475144,0.0009662483,0.00015441078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015642017,0.000069478905,0.9925922,0.00008318289,0.000098753866,0.00015491247,0.00041862045,0.00021171458,0.00014935371,0.00012393174,0.00163382,0.0043075257],"study_design_scores_gemma":[0.000038533177,0.00005537971,0.99660975,0.00007822403,0.000060918497,0.00013481735,0.0013482096,0.00046565352,0.00004433255,0.00002830262,0.0011202624,0.000015654328],"about_ca_topic_score_codex":0.99561644,"about_ca_topic_score_gemma":0.997364,"teacher_disagreement_score":0.05271418,"about_ca_system_score_codex":0.05271418,"about_ca_system_score_gemma":0.06395315,"threshold_uncertainty_score":0.38246995},"labels":[],"label_agreement":null},{"id":"W4408833196","doi":"10.1080/14796694.2025.2476929","title":"Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Antigen; Cancer; Immunology","score_opus":0.024508294236586032,"score_gpt":0.3871047592680317,"score_spread":0.36259646503144566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408833196","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07037031,0.7463001,0.003405741,0.078923,0.018602025,0.0053608883,0.05424754,0.00028721694,0.022503143],"genre_scores_gemma":[0.35820556,0.4411489,0.007066282,0.08446345,0.043406546,0.012870104,0.03806295,0.0003894972,0.014386689],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98525244,0.009885864,0.0023571574,0.0005685367,0.0015292234,0.00040678884],"domain_scores_gemma":[0.94780546,0.034916088,0.011299778,0.0009541852,0.003850155,0.0011743765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017553613,0.000902282,0.0046371575,0.0010463613,0.0003716677,0.0037837154,0.0010530299,0.0018615855,0.010724427],"category_scores_gemma":[0.04427013,0.0004626627,0.007776926,0.0021330705,0.0005841183,0.0019729573,0.0007067968,0.003633766,0.0014494958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15815987,0.00096488517,0.022299003,0.14125724,0.03982037,0.0005191436,0.00051786605,0.0035868692,0.0009531167,0.0030459575,0.3156858,0.31318983],"study_design_scores_gemma":[0.26828718,0.047542244,0.14245819,0.121968456,0.10135409,0.00092570984,0.0010614713,0.0031282064,0.0018279447,0.011039577,0.29946733,0.00093959924],"about_ca_topic_score_codex":0.0014965386,"about_ca_topic_score_gemma":0.0022169359,"teacher_disagreement_score":0.017553613,"about_ca_system_score_codex":0.0014184235,"about_ca_system_score_gemma":0.0022794486,"threshold_uncertainty_score":0.09283346},"labels":[],"label_agreement":null},{"id":"W4408838099","doi":"10.1080/14796694.2025.2474789","title":"Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Medicine; Docetaxel; KRAS; Oncology; Internal medicine; Lung cancer; Cancer; Cancer research; Colorectal cancer","score_opus":0.00967252552037447,"score_gpt":0.36812172813231336,"score_spread":0.3584492026119389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408838099","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07512105,0.73628056,0.0021724363,0.08799344,0.027670475,0.00782333,0.022871299,0.00027530978,0.039792128],"genre_scores_gemma":[0.24476142,0.5278459,0.00522551,0.11578743,0.046411715,0.007894345,0.0148706185,0.00021888358,0.036984067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979013,0.0011469413,0.000435378,0.00009397274,0.0003000722,0.00012239187],"domain_scores_gemma":[0.98910224,0.00619791,0.002790388,0.00012096539,0.0013058314,0.00048264832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004679341,0.0008069232,0.0027019188,0.00084962364,0.00029021094,0.0021826655,0.000912429,0.0015470168,0.016035503],"category_scores_gemma":[0.008965985,0.00036354468,0.0041953614,0.000920183,0.0003024473,0.0014676717,0.0003545952,0.0023901046,0.0021031199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12399675,0.0018991873,0.005121377,0.06213607,0.0048210258,0.00038237218,0.00020644748,0.002335948,0.0024968751,0.0015150561,0.32493407,0.4701548],"study_design_scores_gemma":[0.09785561,0.09083524,0.047643024,0.058816787,0.0171608,0.0013345908,0.00088712777,0.002834456,0.0031207695,0.002910653,0.67624784,0.00035323054],"about_ca_topic_score_codex":0.0010385005,"about_ca_topic_score_gemma":0.0024253468,"teacher_disagreement_score":0.016035503,"about_ca_system_score_codex":0.0015200647,"about_ca_system_score_gemma":0.0011770373,"threshold_uncertainty_score":0.05364406},"labels":[],"label_agreement":null},{"id":"W4408956663","doi":"10.1080/14796694.2025.2481022","title":"Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Cochrane Library; Internal medicine; MEDLINE; Oncology; Checklist; Meta-analysis; Incidence (geometry); Systematic review","score_opus":0.02311140128761007,"score_gpt":0.41173944101363935,"score_spread":0.3886280397260293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408956663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00146124,0.9958912,0.00022198171,0.00029977493,0.00011811473,0.00036867286,0.0012130822,0.000013357088,0.0004125022],"genre_scores_gemma":[0.016206142,0.98060405,0.000983457,0.00056500884,0.000081173595,0.0007107746,0.00066920597,0.000010006433,0.00017022237],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99029726,0.0029381337,0.0043258383,0.0007981135,0.0013258863,0.00031484844],"domain_scores_gemma":[0.96744466,0.023350187,0.005451568,0.00051471585,0.0029624319,0.00027645665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009251193,0.001694571,0.0076685883,0.018027145,0.0006094972,0.0024760375,0.0017095878,0.0014860131,0.0053458014],"category_scores_gemma":[0.039634466,0.0010850189,0.008529248,0.015923254,0.0007005916,0.0024340206,0.0018243352,0.0010617701,0.0004399981],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101829886,0.000008153654,0.00096087327,0.96675414,0.0082404055,0.000087958746,0.00013992867,0.00009318912,0.000114892595,0.00020856908,0.0014516191,0.021838324],"study_design_scores_gemma":[0.00012073293,0.00012189774,0.004837241,0.9105444,0.06375604,0.00041869038,0.00025858768,0.00007189683,0.00017129787,0.00028583087,0.019381424,0.000031859363],"about_ca_topic_score_codex":0.010151627,"about_ca_topic_score_gemma":0.030316303,"teacher_disagreement_score":0.018027145,"about_ca_system_score_codex":0.0035039964,"about_ca_system_score_gemma":0.01251661,"threshold_uncertainty_score":0.04892558},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4408990988","doi":"10.1080/14796694.2025.2470106","title":"A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Internal medicine; Oncology; Cancer; Androgen deprivation therapy","score_opus":0.008952118645876158,"score_gpt":0.29775299261104465,"score_spread":0.2888008739651685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408990988","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010709285,0.18062381,0.009061671,0.14513753,0.08838132,0.007383827,0.4889126,0.0023212107,0.06746882],"genre_scores_gemma":[0.06878175,0.18869153,0.027610118,0.22984499,0.071405046,0.013591793,0.29525825,0.002520463,0.10229613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901979,0.0030120974,0.0032164615,0.00042728896,0.0028063308,0.0003399393],"domain_scores_gemma":[0.9284849,0.032651916,0.008953078,0.0011772589,0.02744804,0.0012846517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010578531,0.0016752636,0.0029846106,0.0050615785,0.00061292894,0.0034727263,0.001564009,0.0018971305,0.07038409],"category_scores_gemma":[0.055859268,0.00075065123,0.005577833,0.0041766535,0.0004706305,0.0022066263,0.00092727446,0.0027847798,0.020024465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026036177,0.00011809297,0.0023589197,0.020291427,0.00080202037,0.00020398488,0.00010454559,0.00022448825,0.0005585805,0.0003595491,0.9070839,0.06529078],"study_design_scores_gemma":[0.0019420878,0.0019360252,0.031281978,0.03019331,0.0028259128,0.0007265234,0.00048368998,0.00021449689,0.0011475991,0.0014225654,0.92761254,0.00021328624],"about_ca_topic_score_codex":0.005449763,"about_ca_topic_score_gemma":0.006753061,"teacher_disagreement_score":0.07038409,"about_ca_system_score_codex":0.0023425126,"about_ca_system_score_gemma":0.0038174866,"threshold_uncertainty_score":0.2354582},"labels":[],"label_agreement":null},{"id":"W4409271532","doi":"10.1080/14796694.2025.2488635","title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Observational study; Pathology","score_opus":0.015846928618200307,"score_gpt":0.2868730438023099,"score_spread":0.2710261151841096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409271532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971796,0.00020997768,0.00012605025,0.00006176064,0.0000049029973,0.000027727614,0.0021689623,0.0000032216892,0.00021788648],"genre_scores_gemma":[0.99730515,0.00017010252,0.00017655859,0.00007780816,0.000011580855,0.00004837359,0.0021754971,0.0000026874973,0.00003223449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765116,0.00082622987,0.0004265769,0.00051838043,0.00033262357,0.0002450471],"domain_scores_gemma":[0.9910239,0.0022259175,0.004269441,0.00094472244,0.0008132894,0.00072275643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023472635,0.0002758082,0.00048221156,0.0012116607,0.00049962004,0.00096935435,0.00062711665,0.0005248157,0.0013844827],"category_scores_gemma":[0.007608569,0.00042630822,0.00052952743,0.0026636424,0.00045484913,0.0008542003,0.0011698417,0.00063192664,0.0002724202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040153012,0.000028280476,0.99891174,0.000025212255,0.000062348874,0.00007263792,0.00013193204,0.00003060804,0.000032980806,0.000018584253,0.00021175796,0.00043372225],"study_design_scores_gemma":[0.000025342577,0.000087236374,0.9978236,0.000030910152,0.000080485486,0.00043195166,0.00090627425,0.00026413842,0.000028829214,0.000022755881,0.00028928043,0.000009246253],"about_ca_topic_score_codex":0.0106465025,"about_ca_topic_score_gemma":0.015123772,"teacher_disagreement_score":0.0106465025,"about_ca_system_score_codex":0.00060058216,"about_ca_system_score_gemma":0.0010067986,"threshold_uncertainty_score":0.021169066},"labels":[],"label_agreement":null},{"id":"W4409565762","doi":"10.1080/14796694.2025.2485015","title":"STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Royal Ottawa Mental Health Centre","funders":"Exelixis; American Society of Clinical Oncology","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.01271133484206635,"score_gpt":0.32109144347390917,"score_spread":0.30838010863184284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409565762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98585784,0.0045280564,0.0005381661,0.0005248616,0.0002663032,0.0037087733,0.0011788132,0.00018730552,0.0032099148],"genre_scores_gemma":[0.98559594,0.002998779,0.0017729857,0.0013774226,0.00017575372,0.0028185046,0.0022161666,0.000032246233,0.003012321],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99960953,0.00018363586,0.000024304898,0.00005953726,0.0000513683,0.00007169028],"domain_scores_gemma":[0.9995827,0.00005179306,0.00008137778,0.00002562461,0.000044466833,0.00021405294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017860952,0.0012433769,0.002345971,0.0004988722,0.00037057203,0.0009994721,0.00085942785,0.001142794,0.00339808],"category_scores_gemma":[0.0006810539,0.00053924,0.0018473716,0.00031319633,0.0009192374,0.0008320037,0.00039662927,0.002176811,0.0011918333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8787318,0.028680561,0.0028825528,0.0016288561,0.0021891682,0.00010019001,0.00018051513,0.0019525135,0.0217882,0.00038934377,0.0032065315,0.058269907],"study_design_scores_gemma":[0.6845342,0.30087015,0.007672189,0.00008140439,0.000876242,0.0001320039,0.00008566907,0.0014467033,0.001887387,0.00027791582,0.0021028323,0.000033189495],"about_ca_topic_score_codex":0.0018399828,"about_ca_topic_score_gemma":0.0056104832,"teacher_disagreement_score":0.00339808,"about_ca_system_score_codex":0.001089527,"about_ca_system_score_gemma":0.0021173481,"threshold_uncertainty_score":0.011367738},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4409774343","doi":"10.1080/14796694.2025.2489319","title":"Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; EMD Serono; Jazz Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Sanofi; G1 Therapeutics; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Plain language; Oncology; Order (exchange); Intensive care medicine; Internal medicine; Linguistics","score_opus":0.003513448381446309,"score_gpt":0.33379465714999235,"score_spread":0.33028120876854605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409774343","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28084114,0.3164739,0.0035459585,0.20702729,0.0105402535,0.00076816435,0.15151565,0.0002491542,0.02903845],"genre_scores_gemma":[0.68467635,0.19375004,0.006115862,0.044663493,0.012160838,0.0012865753,0.049771167,0.00017558663,0.0074000866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396175,0.0028417034,0.001631495,0.0003925056,0.0009715747,0.00020092097],"domain_scores_gemma":[0.9241719,0.052059866,0.0126450565,0.00088526646,0.009223271,0.0010145018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004966063,0.0004060537,0.00074400095,0.0036003292,0.00054236146,0.002680524,0.000660789,0.0008448094,0.014407441],"category_scores_gemma":[0.047426973,0.00031432285,0.0017559554,0.0044475184,0.00036857382,0.00344594,0.00078330294,0.0016018014,0.0017042762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024330197,0.0004535271,0.37720278,0.037804145,0.0023885586,0.0007441231,0.004636331,0.00078136334,0.00035824397,0.0023410262,0.36581266,0.20504422],"study_design_scores_gemma":[0.00057041465,0.001507719,0.7096855,0.035741422,0.0032512099,0.0017118739,0.015709871,0.0014137172,0.0007069213,0.0029953404,0.22635649,0.00034957062],"about_ca_topic_score_codex":0.008649721,"about_ca_topic_score_gemma":0.012200061,"teacher_disagreement_score":0.014407441,"about_ca_system_score_codex":0.0016919859,"about_ca_system_score_gemma":0.0018439947,"threshold_uncertainty_score":0.048197627},"labels":[],"label_agreement":null},{"id":"W4410406044","doi":"10.1080/14796694.2025.2489339","title":"Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.0034647502534123713,"score_gpt":0.296094019994754,"score_spread":0.2926292697413416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410406044","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011194874,0.3031627,0.004175814,0.17213562,0.09041429,0.01242743,0.2777416,0.001470478,0.12727721],"genre_scores_gemma":[0.07683782,0.19577108,0.0068360167,0.30154425,0.08887868,0.023328416,0.12186733,0.0011212224,0.18381518],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596316,0.001959893,0.00087169645,0.00020548947,0.0007968999,0.00020289682],"domain_scores_gemma":[0.9830124,0.008716683,0.00360006,0.00032673148,0.0035551484,0.00078905147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005562582,0.001193908,0.0038501755,0.001348833,0.0005097344,0.003083522,0.0017529709,0.0023264019,0.1081572],"category_scores_gemma":[0.023249732,0.0007313284,0.0040137935,0.0019679263,0.00039345687,0.0017316731,0.0006356279,0.0032111532,0.01829874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01356961,0.000162817,0.0010053096,0.024732161,0.0013101735,0.00017019715,0.000055187305,0.0002497238,0.00051285024,0.0006403458,0.8955479,0.062043652],"study_design_scores_gemma":[0.047021348,0.006090036,0.0180928,0.03337698,0.0051113013,0.00064964284,0.00027355252,0.00048623022,0.0006393399,0.002594816,0.8854253,0.00023858763],"about_ca_topic_score_codex":0.0030584433,"about_ca_topic_score_gemma":0.0040133665,"teacher_disagreement_score":0.1081572,"about_ca_system_score_codex":0.0014813853,"about_ca_system_score_gemma":0.002244891,"threshold_uncertainty_score":0.3618219},"labels":[],"label_agreement":null},{"id":"W4410522286","doi":"10.1080/14796694.2025.2500915","title":"A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; University College London; Cancer Research UK; F. Hoffmann-La Roche; CRUK Lung Cancer Centre of Excellence; University College London Hospitals NHS Foundation Trust; Pfizer","keywords":"Atezolizumab; Medicine; Chemotherapy; Oncology; Lung cancer; Internal medicine; Cancer; Intensive care medicine; Immunotherapy; Pembrolizumab","score_opus":0.02306044395468954,"score_gpt":0.35097972535087146,"score_spread":0.3279192813961819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410522286","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019509468,0.31653774,0.0039106817,0.07143229,0.05944957,0.016222648,0.47620964,0.0011743591,0.035553616],"genre_scores_gemma":[0.14174318,0.31080088,0.019181326,0.16686456,0.054567806,0.07005103,0.18152301,0.0013691084,0.05389906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98752916,0.006020695,0.003861124,0.00059395895,0.0016419451,0.0003530809],"domain_scores_gemma":[0.9392936,0.03661654,0.012420415,0.00073871424,0.009488179,0.0014424898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01061402,0.0015001256,0.004721167,0.0027593013,0.00071645353,0.0029358729,0.0014135048,0.002415705,0.07234159],"category_scores_gemma":[0.060712274,0.00075963984,0.0068624294,0.0027511977,0.00037763777,0.0020203884,0.0009059194,0.003192647,0.0072220243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028962169,0.000465524,0.0034039484,0.14993876,0.005784806,0.00021773689,0.00030847997,0.00030085078,0.0005706298,0.0010023752,0.7135313,0.095513426],"study_design_scores_gemma":[0.049185365,0.012693736,0.05297946,0.13894485,0.018726617,0.0006079063,0.00090011425,0.00045926098,0.00090162415,0.002889274,0.7212857,0.00042624652],"about_ca_topic_score_codex":0.0039889426,"about_ca_topic_score_gemma":0.005431542,"teacher_disagreement_score":0.07234159,"about_ca_system_score_codex":0.0017578581,"about_ca_system_score_gemma":0.0033637693,"threshold_uncertainty_score":0.24200672},"labels":[],"label_agreement":null},{"id":"W4410770658","doi":"10.1080/14796694.2025.2511587","title":"Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Glioma; Mutant; Clinical trial; Oncology; Indigo; Internal medicine; Cancer research; Genetics; Biology; Gene","score_opus":0.028939306623785556,"score_gpt":0.4262713615564876,"score_spread":0.397332054932702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410770658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090857786,0.9985689,0.000054586333,0.000644983,0.0001869287,0.000003095468,0.000011897892,0.000004512504,0.00043419798],"genre_scores_gemma":[0.000650562,0.9979772,0.00013388021,0.0006468618,0.00022647198,0.000007169369,0.000025918542,0.0000019012904,0.00033011273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997441,0.00007049563,0.000037469665,0.000040327526,0.00007796497,0.000029728535],"domain_scores_gemma":[0.99940884,0.00029919719,0.00007481086,0.000013172249,0.00015278175,0.00005128506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014353873,0.0006025301,0.0014434996,0.0014975601,0.0002096073,0.0011833897,0.0010146807,0.0012381503,0.0031446037],"category_scores_gemma":[0.001488223,0.00024619765,0.0007176248,0.0015603639,0.00046395932,0.0015401578,0.00057403423,0.0024774687,0.0013268397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024388744,0.00007770484,0.00013620363,0.014602507,0.00011686703,0.00016764904,0.000052509477,0.00043416233,0.0007879104,0.004548754,0.03659864,0.9422332],"study_design_scores_gemma":[0.00011017078,0.00023248205,0.00071843254,0.0081120115,0.00022449625,0.0009774474,0.00006495379,0.00022575608,0.0003318477,0.0036774077,0.98530036,0.000024503148],"about_ca_topic_score_codex":0.0008493055,"about_ca_topic_score_gemma":0.002806641,"teacher_disagreement_score":0.0031446037,"about_ca_system_score_codex":0.000901135,"about_ca_system_score_gemma":0.0015426765,"threshold_uncertainty_score":0.010519683},"labels":[],"label_agreement":null},{"id":"W4410950112","doi":"10.1080/14796694.2025.2502318","title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen receptor; Abiraterone acetate; Oncology; Internal medicine; Docetaxel; Randomized controlled trial; Clinical endpoint; Clinical trial; Androgen deprivation therapy; Pharmacology; Cancer","score_opus":0.01713607726596698,"score_gpt":0.3317622043259618,"score_spread":0.3146261270599948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410950112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833974,0.0029129805,0.0009440464,0.0013908509,0.0005917628,0.0056329165,0.0012961891,0.00020481885,0.0036290246],"genre_scores_gemma":[0.9840894,0.0015886257,0.0020176445,0.0016166805,0.00051377976,0.004972489,0.0012749345,0.000047453887,0.0038789383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992142,0.00046642005,0.000031377112,0.00011125923,0.000055104003,0.000121682926],"domain_scores_gemma":[0.9990079,0.0002712605,0.00022648093,0.000084312174,0.000044091634,0.00036600113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026452118,0.0017037571,0.0018666666,0.00039418953,0.00044737326,0.0011956197,0.0010813979,0.0016977111,0.0070770956],"category_scores_gemma":[0.0018895144,0.00052495726,0.0013991158,0.00043634605,0.0015448263,0.0016572594,0.00047773198,0.003584861,0.0009652462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95861477,0.011941859,0.00075401703,0.0003219851,0.000428786,0.000047839505,0.000085027976,0.000611811,0.0036854285,0.00035179034,0.0016623833,0.021494327],"study_design_scores_gemma":[0.9041436,0.09264731,0.0009773594,0.000015850415,0.00014213852,0.00003766188,0.000029875768,0.00047669254,0.0003938404,0.00031437416,0.00080778316,0.000013490512],"about_ca_topic_score_codex":0.00071893015,"about_ca_topic_score_gemma":0.0022254284,"teacher_disagreement_score":0.0070770956,"about_ca_system_score_codex":0.00086753536,"about_ca_system_score_gemma":0.0013528205,"threshold_uncertainty_score":0.023675263},"labels":[],"label_agreement":null},{"id":"W4410968310","doi":"10.1080/14796694.2025.2510890","title":"Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Johnson and Johnson","keywords":"Medicine; Prostate cancer; Family medicine; Pill; Caregiver burden; Urination; Disease; Internal medicine; Cancer; Nursing","score_opus":0.05312816492137521,"score_gpt":0.3882538557149905,"score_spread":0.33512569079361526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410968310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979905,0.00045461959,0.000056187888,0.0005990826,0.000010110951,0.000021569473,0.0002806366,0.0000015290109,0.0005857914],"genre_scores_gemma":[0.99887735,0.00046518334,0.0000778327,0.00020508493,0.0000046947134,0.00003631984,0.00017768082,0.0000012408401,0.00015469319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985904,0.00084677147,0.00011489352,0.000070476286,0.00015021741,0.00022726475],"domain_scores_gemma":[0.99724317,0.0008480438,0.00093968684,0.000058772453,0.00038449912,0.0005259822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023815336,0.00018212835,0.00031855516,0.0005835348,0.0013064967,0.000994576,0.00031845737,0.00039205112,0.0012249495],"category_scores_gemma":[0.0062544453,0.00022020141,0.00040670915,0.00080391736,0.0005274254,0.0009442236,0.0016068814,0.00069471984,0.00013833465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112495516,0.00012052698,0.8727646,0.00030447816,0.00006575731,0.00056086073,0.11059571,0.000074857104,0.000242463,0.00010514203,0.0019276179,0.013125532],"study_design_scores_gemma":[0.000012041052,0.00018984189,0.6684931,0.00023646286,0.000026005622,0.00065901765,0.32624397,0.00014254737,0.00009454379,0.000060222657,0.0038194032,0.00002290759],"about_ca_topic_score_codex":0.013362924,"about_ca_topic_score_gemma":0.025172474,"teacher_disagreement_score":0.013362924,"about_ca_system_score_codex":0.0011421171,"about_ca_system_score_gemma":0.001258393,"threshold_uncertainty_score":0.02657026},"labels":[],"label_agreement":null},{"id":"W4411249025","doi":"10.1080/14796694.2025.2514402","title":"Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"MSD Italia","keywords":"Merkel cell carcinoma; Medicine; Immunotherapy; Oncology; Internal medicine; Carcinoma; Cancer research; Cancer","score_opus":0.014809492180150275,"score_gpt":0.31033339140170524,"score_spread":0.295523899221555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411249025","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07332205,0.012058386,0.012465505,0.0067267204,0.0052811503,0.8651238,0.007918379,0.000379805,0.016724262],"genre_scores_gemma":[0.13192177,0.004069087,0.01875103,0.006324648,0.00140146,0.8289369,0.002658517,0.00007556038,0.0058611254],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911213,0.006314096,0.0005180786,0.00086770445,0.00063160446,0.00054711866],"domain_scores_gemma":[0.9969813,0.000739578,0.0004805504,0.00048012208,0.00045329035,0.0008651045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019993413,0.0026987381,0.003996342,0.0006123264,0.0013928283,0.0024949114,0.0018165185,0.0033714063,0.010773356],"category_scores_gemma":[0.013494652,0.0014229612,0.0023634387,0.00095239637,0.0023060674,0.0017515052,0.0010827457,0.005574916,0.004210223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86304814,0.010018495,0.0046038534,0.009436395,0.0026222283,0.0004887411,0.00042341696,0.0034154968,0.006006793,0.011259215,0.01983217,0.06884515],"study_design_scores_gemma":[0.8092263,0.08755452,0.0054265,0.0023168782,0.0033345406,0.00032587067,0.00016838688,0.0036741074,0.0021699045,0.010326414,0.07533728,0.00013918354],"about_ca_topic_score_codex":0.00048013704,"about_ca_topic_score_gemma":0.0013442764,"teacher_disagreement_score":0.019993413,"about_ca_system_score_codex":0.0014041762,"about_ca_system_score_gemma":0.004786373,"threshold_uncertainty_score":0.105736494},"labels":[],"label_agreement":null},{"id":"W4411281412","doi":"10.1080/14796694.2025.2511470","title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"Genentech; Astellas Pharma; Eisai; EMD Serono; Rakuten Medical; Daiichi Sankyo Europe; Sanofi; Exelixis; Amgen; Relay Therapeutics; Gilead Sciences; Pfizer; Break Through Cancer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.04745932149046059,"score_gpt":0.42577289509448113,"score_spread":0.3783135736040205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411281412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779652,0.006149544,0.0008967232,0.00080270367,0.0003443213,0.00558032,0.0018292262,0.0002689926,0.006163009],"genre_scores_gemma":[0.9724291,0.0042121173,0.0029626933,0.0018055914,0.00018291945,0.0059041493,0.0036500148,0.000054407574,0.008798931],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99941814,0.0003005352,0.000029184217,0.00007387189,0.00006230878,0.00011596636],"domain_scores_gemma":[0.99957436,0.00006266686,0.000093444985,0.000044242024,0.000041568193,0.00018376025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019846617,0.0010043747,0.0013520573,0.0003400813,0.00039691708,0.0009962465,0.0008675911,0.001501905,0.0038252668],"category_scores_gemma":[0.00078603544,0.0005176293,0.0016368617,0.00028115296,0.0008041591,0.00084729923,0.00031789648,0.0026653188,0.0007084146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8000542,0.039003868,0.0024580858,0.0014465577,0.0021600174,0.00017550979,0.0002828329,0.0026396322,0.04431905,0.00089361105,0.0070637725,0.09950292],"study_design_scores_gemma":[0.66089123,0.31945613,0.005709018,0.00010880967,0.0006229059,0.00018105765,0.000087951186,0.0011444287,0.005404313,0.0004139691,0.0059450716,0.000035192876],"about_ca_topic_score_codex":0.0015613486,"about_ca_topic_score_gemma":0.0057240664,"teacher_disagreement_score":0.0038252668,"about_ca_system_score_codex":0.0012806553,"about_ca_system_score_gemma":0.0014773908,"threshold_uncertainty_score":0.012796819},"labels":[],"label_agreement":null},{"id":"W4411453748","doi":"10.1080/14796694.2025.2513219","title":"Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"BeiGene; Sanofi; AstraZeneca; Pfizer","keywords":"Brentuximab vedotin; Medicine; Oncology; Internal medicine; Lymphoma; Diffuse large B-cell lymphoma; Medical physics; Hodgkin lymphoma","score_opus":0.0047277561266267035,"score_gpt":0.26764125658082977,"score_spread":0.2629135004542031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411453748","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01830987,0.4186452,0.002549548,0.19502291,0.05936707,0.006720573,0.21492198,0.0005916866,0.083871186],"genre_scores_gemma":[0.11198083,0.28701174,0.0052278,0.3530846,0.059603218,0.01676914,0.09233983,0.00065289036,0.07332997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944291,0.003161024,0.0011408619,0.0002548519,0.0008295546,0.00018461526],"domain_scores_gemma":[0.98210806,0.009090735,0.003955599,0.0003641916,0.0035440417,0.0009375151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006687024,0.00094692316,0.0031817365,0.0011360359,0.0004842807,0.0029630798,0.0014200095,0.0023660676,0.056281462],"category_scores_gemma":[0.024427941,0.0006197492,0.0031476049,0.0018138093,0.0003974625,0.0015853251,0.00063525967,0.0031135574,0.00986992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02131829,0.00023701477,0.0025943024,0.027648062,0.0022141922,0.00018720145,0.00010321775,0.00020474121,0.00042829555,0.0005138885,0.8672499,0.07730102],"study_design_scores_gemma":[0.1068881,0.010259366,0.0356219,0.0466855,0.010282815,0.000790335,0.00042494657,0.00042398457,0.0008235035,0.0020981133,0.7853541,0.0003473432],"about_ca_topic_score_codex":0.0027342986,"about_ca_topic_score_gemma":0.0033013788,"teacher_disagreement_score":0.056281462,"about_ca_system_score_codex":0.0012995723,"about_ca_system_score_gemma":0.0018700912,"threshold_uncertainty_score":0.18828022},"labels":[],"label_agreement":null},{"id":"W4411842050","doi":"10.1080/14796694.2025.2475730","title":"Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Disease; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.017160304996255038,"score_gpt":0.4120309966057451,"score_spread":0.39487069160949007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411842050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000685695,0.9991155,0.000028454044,0.00018953478,0.00012592152,0.0000113991555,0.000040716342,0.000003588734,0.000416302],"genre_scores_gemma":[0.0006280122,0.9987716,0.00006852198,0.00025692963,0.00007539338,0.00001242559,0.000035033063,0.0000012369212,0.00015084392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994648,0.00015239143,0.00013383768,0.00006579964,0.00015605989,0.000027089753],"domain_scores_gemma":[0.99830437,0.0009733393,0.0003885727,0.0000254632,0.0002686921,0.000039590606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012021764,0.0007226463,0.0020492598,0.0022637232,0.00022153169,0.001314722,0.00095318333,0.0008551499,0.004606106],"category_scores_gemma":[0.0031209681,0.00027307626,0.0012339513,0.0024486727,0.0003467453,0.00096038304,0.0004528556,0.0009776186,0.0010380667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033017845,0.0000424535,0.00019701006,0.31779185,0.0011787299,0.000092290094,0.00006876821,0.0002632688,0.00095263077,0.0014844751,0.045228545,0.6323697],"study_design_scores_gemma":[0.00025497834,0.00044934062,0.0018235989,0.23815264,0.0052079535,0.0012988909,0.000116561925,0.00014030385,0.0007224465,0.0014727819,0.7503188,0.00004173047],"about_ca_topic_score_codex":0.001995118,"about_ca_topic_score_gemma":0.004774298,"teacher_disagreement_score":0.004606106,"about_ca_system_score_codex":0.0008107538,"about_ca_system_score_gemma":0.0021441358,"threshold_uncertainty_score":0.015408933},"labels":[],"label_agreement":null},{"id":"W4412008298","doi":"10.1080/14796694.2025.2521871","title":"The significance of mitochondrial DNA changes during the onset and progression of head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal College of Physicians and Surgeons of Canada","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Mitochondrial DNA; Head and neck; Basal cell; Oncology; Head and neck cancer; Cancer research; Internal medicine; Pathology; Cancer; Biology; Genetics; Surgery; Gene","score_opus":0.02303350771498091,"score_gpt":0.34729497971041423,"score_spread":0.3242614719954333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412008298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001282583,0.9994771,0.000018758243,0.00008387865,0.00005428752,0.000002106502,0.000014314763,0.0000018661096,0.0002194112],"genre_scores_gemma":[0.0009135715,0.9988135,0.00003385927,0.000067930465,0.00003955282,0.0000028531063,0.000020622236,4.32509e-7,0.00010772477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999826,0.00002738491,0.000047017747,0.00003132792,0.00005179988,0.000016486629],"domain_scores_gemma":[0.99971765,0.00012678257,0.00006147626,0.0000054633574,0.000072999566,0.000015571999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003661158,0.00044248224,0.0009633386,0.0025018943,0.00021697061,0.0007261376,0.0005456972,0.0007609381,0.0016802138],"category_scores_gemma":[0.00090332376,0.00019477525,0.00059051363,0.0026033588,0.0003099875,0.0009313826,0.00048647905,0.00067737495,0.00053679495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014981191,0.00003959246,0.000905313,0.09526259,0.0002903875,0.00060597324,0.00018316816,0.0003197062,0.0019220359,0.0016578635,0.017927641,0.88073593],"study_design_scores_gemma":[0.000044879383,0.00023464602,0.011596047,0.035188027,0.00141945,0.008894657,0.00035117922,0.00018015984,0.001597563,0.0018668785,0.9385596,0.00006688393],"about_ca_topic_score_codex":0.0023895418,"about_ca_topic_score_gemma":0.0036371786,"teacher_disagreement_score":0.0025018943,"about_ca_system_score_codex":0.0006520079,"about_ca_system_score_gemma":0.0012870628,"threshold_uncertainty_score":0.005620897},"labels":[],"label_agreement":null},{"id":"W4412072814","doi":"10.1080/14796694.2025.2529151","title":"Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Trastuzumab","score_opus":0.029248126771143183,"score_gpt":0.4596720816154097,"score_spread":0.4304239548442665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412072814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007567636,0.9991007,0.000039251994,0.00017664199,0.00008800926,0.000002891288,0.000008981869,0.0000034170487,0.00050450856],"genre_scores_gemma":[0.00039692223,0.9991142,0.000059945552,0.00011815293,0.00005721523,0.000002965753,0.000015007255,8.035536e-7,0.00023471109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980277,0.000044857785,0.000026175649,0.000027222599,0.00007797907,0.000021000375],"domain_scores_gemma":[0.99973124,0.00013269595,0.00003964697,0.000006893376,0.00006675776,0.000022720402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061586354,0.00059148984,0.0011445447,0.0022476525,0.00023031802,0.0010485217,0.00071607204,0.00076924753,0.003995681],"category_scores_gemma":[0.0007245367,0.00019511,0.00068350666,0.002078545,0.0003273898,0.0010894269,0.00062215904,0.001959164,0.0016184958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087658904,0.00005380408,0.000098493656,0.021529678,0.00011223083,0.00010832918,0.00006431918,0.00032171715,0.0008634742,0.0029382922,0.028921815,0.94490016],"study_design_scores_gemma":[0.000034187913,0.00011274434,0.0006702723,0.008858546,0.00018333612,0.0008944608,0.0000547214,0.000112540554,0.0002437962,0.0017861753,0.9870344,0.000014691591],"about_ca_topic_score_codex":0.0011937938,"about_ca_topic_score_gemma":0.0029922202,"teacher_disagreement_score":0.003995681,"about_ca_system_score_codex":0.00062381476,"about_ca_system_score_gemma":0.00087981287,"threshold_uncertainty_score":0.013366878},"labels":[],"label_agreement":null},{"id":"W4412724750","doi":"10.1080/14796694.2025.2535280","title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Seagen; Pfizer","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Antibody-drug conjugate; Chemotherapy; Metastatic Urothelial Carcinoma; Antibody; Immunotherapy; Cancer; Urothelial carcinoma; Monoclonal antibody; Immunology; Bladder cancer","score_opus":0.012634334458240302,"score_gpt":0.3140959120053023,"score_spread":0.301461577547062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412724750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6399741,0.32902429,0.001820787,0.0037571413,0.00088287477,0.0018003449,0.0016095797,0.00021720218,0.020913778],"genre_scores_gemma":[0.9221842,0.06563849,0.0035984842,0.001403423,0.00027221636,0.00058360526,0.0014394986,0.000019146995,0.0048609246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974126,0.000106914435,0.00003826995,0.000040824765,0.000049539172,0.000023135213],"domain_scores_gemma":[0.9997738,0.00005598154,0.00007977346,0.000012379764,0.00002631696,0.000051753676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012378537,0.0002750215,0.00058841467,0.00040455762,0.00014263639,0.00047839116,0.00034268494,0.00041506012,0.002798608],"category_scores_gemma":[0.0006026846,0.00011815962,0.00047682598,0.00038571982,0.0002165713,0.00034461738,0.0002279646,0.0006876627,0.00041173992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052604675,0.0019310043,0.0033625725,0.0070449384,0.00096546346,0.00031293312,0.00011323498,0.0010912453,0.034271184,0.0010857437,0.008513587,0.8887036],"study_design_scores_gemma":[0.16785243,0.24751863,0.073387526,0.0060341903,0.0057159066,0.0074989893,0.00024469194,0.0052660536,0.087732635,0.0020285144,0.3965886,0.00013176848],"about_ca_topic_score_codex":0.0007841061,"about_ca_topic_score_gemma":0.0030914152,"teacher_disagreement_score":0.002798608,"about_ca_system_score_codex":0.00083798624,"about_ca_system_score_gemma":0.00084585656,"threshold_uncertainty_score":0.00936228},"labels":[],"label_agreement":null},{"id":"W4414167802","doi":"10.1080/14796694.2025.2550930","title":"Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Incyte; Seagen; Gilead Sciences; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Palbociclib; Metastatic breast cancer; Plain language; Breast cancer; MEDLINE","score_opus":0.010316438650245988,"score_gpt":0.35812746572584897,"score_spread":0.34781102707560296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024683175,0.9277828,0.0022422022,0.015501691,0.007802669,0.008973603,0.030856457,0.00024792334,0.0041244337],"genre_scores_gemma":[0.026211428,0.8990408,0.005451481,0.025455747,0.00334098,0.025094897,0.010578957,0.00012766359,0.0046981075],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9877819,0.003958757,0.0050277277,0.000662144,0.0021646332,0.00040489197],"domain_scores_gemma":[0.95374763,0.02527277,0.012550394,0.00057370367,0.0073307063,0.00052471645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0104989195,0.002363785,0.0092627695,0.009432217,0.0007079253,0.0044117505,0.002189892,0.0031633389,0.03622713],"category_scores_gemma":[0.07630345,0.0016690412,0.0093693435,0.010638635,0.0007275119,0.004150828,0.00211179,0.0021266444,0.0030640822],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023905824,0.000008480218,0.0002841742,0.9678192,0.0036543314,0.00006967164,0.000105194915,0.00006919343,0.00015583838,0.00021901265,0.016821695,0.010554049],"study_design_scores_gemma":[0.0006745616,0.00017136047,0.0021826604,0.914002,0.029054696,0.0001774585,0.00016414389,0.00009796021,0.00016785417,0.0005121287,0.05273311,0.00006200609],"about_ca_topic_score_codex":0.008120645,"about_ca_topic_score_gemma":0.01737095,"teacher_disagreement_score":0.03622713,"about_ca_system_score_codex":0.0049765976,"about_ca_system_score_gemma":0.013662728,"threshold_uncertainty_score":0.12119186},"labels":[],"label_agreement":null},{"id":"W4414948966","doi":"10.1080/14796694.2025.2557174","title":"A plain language summary of LocoMMotion – an observational study of treatments used for pretreated multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Legend Biotech","keywords":"Observational study; Multiple myeloma; Plain language; MEDLINE; English language","score_opus":0.0831085566720721,"score_gpt":0.41474552715769386,"score_spread":0.33163697048562174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948966","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018142559,0.106954455,0.0071809385,0.19359984,0.10513275,0.0071179587,0.54123324,0.0006702818,0.019967869],"genre_scores_gemma":[0.08867581,0.13899647,0.013125264,0.19435662,0.13126859,0.029243905,0.3682732,0.0010997829,0.034960374],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97891873,0.010687089,0.006164211,0.00081949146,0.0029638847,0.00044656818],"domain_scores_gemma":[0.87912464,0.06712171,0.023214111,0.0045577595,0.022701815,0.0032799207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018352345,0.0011504972,0.0023150225,0.0037476614,0.00059136783,0.0033090382,0.0015895133,0.0027548503,0.034893706],"category_scores_gemma":[0.12817289,0.00076891773,0.0021527244,0.0055228,0.0005466361,0.0015964882,0.0012751076,0.0027730945,0.009419114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012002707,0.00015663375,0.008674453,0.009843867,0.00066023704,0.00018163958,0.00011714701,0.00012796161,0.00010758967,0.00052812014,0.95507085,0.023331217],"study_design_scores_gemma":[0.0036212495,0.0014768547,0.10134931,0.050083857,0.0016258049,0.00061268004,0.00056695106,0.000524149,0.00036371648,0.0018235844,0.8376138,0.00033798962],"about_ca_topic_score_codex":0.0068416162,"about_ca_topic_score_gemma":0.005460181,"teacher_disagreement_score":0.034893706,"about_ca_system_score_codex":0.002024332,"about_ca_system_score_gemma":0.0046805693,"threshold_uncertainty_score":0.11673111},"labels":[],"label_agreement":null},{"id":"W4414948984","doi":"10.1080/14796694.2025.2560134","title":"A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency; University of Alberta; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Daratumumab; Multiple myeloma; Dexamethasone; Plain language; Stem cell","score_opus":0.014462611549110644,"score_gpt":0.2932345295906881,"score_spread":0.2787719180415774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948984","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051836814,0.07134793,0.0038145273,0.4331038,0.14773506,0.011836536,0.24241285,0.0019816628,0.082583964],"genre_scores_gemma":[0.022302512,0.074279286,0.008615706,0.461871,0.12814295,0.034420077,0.08689618,0.0012905283,0.18218176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919154,0.0045929467,0.0017562838,0.0003624972,0.0010277808,0.00034499163],"domain_scores_gemma":[0.9476567,0.030423902,0.0068403045,0.0007465997,0.011392633,0.0029398075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010732809,0.0016662206,0.0037263562,0.0018255207,0.0012532246,0.0034200263,0.0016159789,0.004000122,0.13094255],"category_scores_gemma":[0.05104808,0.0010199565,0.0026104988,0.002044812,0.000546119,0.0023408951,0.0012190911,0.0044873576,0.032425903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001200451,0.000093412214,0.0003029689,0.0037761482,0.00007801363,0.00007659852,0.00005421107,0.000046593304,0.00009623535,0.00026177795,0.97941405,0.014599628],"study_design_scores_gemma":[0.0060412344,0.001575368,0.007906092,0.010916247,0.00040380584,0.00026497972,0.00026673856,0.00019163707,0.00019646788,0.0009939995,0.9711085,0.00013493335],"about_ca_topic_score_codex":0.0057571474,"about_ca_topic_score_gemma":0.007871928,"teacher_disagreement_score":0.13094255,"about_ca_system_score_codex":0.0019169068,"about_ca_system_score_gemma":0.004637574,"threshold_uncertainty_score":0.43804646},"labels":[],"label_agreement":null},{"id":"W4415965680","doi":"10.1080/14796694.2025.2582807","title":"Thyroid cancers reveal significant age- and gender-specific associations in papillary, medullary, and multinodularity types in Ha’il, Saudi Arabia: retrospective analysis","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"West Park Healthcare Centre","funders":"University of Hail","keywords":"Thyroid; Thyroid cancer; Medullary thyroid cancer; Retrospective cohort study; Cancer; Thyroid hormones; Medullary cavity","score_opus":0.017709230361629292,"score_gpt":0.3042675091880909,"score_spread":0.2865582788264616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415965680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990396,0.00033058328,0.00003235565,0.000016540911,0.0000021530902,0.000004257581,0.0004345798,0.0000016257181,0.00013828368],"genre_scores_gemma":[0.9992136,0.00016061876,0.000033116456,0.000015797343,0.0000045741976,0.0000053268386,0.00045540123,8.690088e-7,0.0001107729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950075,0.0000794328,0.00009898307,0.000118784665,0.00008190191,0.00012014797],"domain_scores_gemma":[0.9990632,0.00012839874,0.00046643364,0.000083654944,0.00014499466,0.00011343366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005519089,0.00028643978,0.000204598,0.0012681385,0.0003468374,0.00046704727,0.00037198354,0.00030225125,0.0017544241],"category_scores_gemma":[0.00086706463,0.00037349836,0.00044784785,0.0011913882,0.00028595573,0.0003054456,0.0005151778,0.00024307636,0.00026632877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026929443,0.0000035520313,0.9993383,0.000006574299,0.000015122971,0.000036260655,0.000047428985,0.000007382644,0.00006855223,0.0000055847468,0.000039533617,0.00040477264],"study_design_scores_gemma":[0.0000020955897,0.000028744991,0.9987863,0.000007713573,0.000027435543,0.00043791058,0.00036642558,0.000060354658,0.00005880022,0.000007275854,0.00021493174,0.000002055914],"about_ca_topic_score_codex":0.01597574,"about_ca_topic_score_gemma":0.02170457,"teacher_disagreement_score":0.01597574,"about_ca_system_score_codex":0.0005608797,"about_ca_system_score_gemma":0.0004254354,"threshold_uncertainty_score":0.03176552},"labels":[],"label_agreement":null},{"id":"W4416187331","doi":"10.1080/14796694.2025.2577633","title":"Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Bayer","keywords":"Biochemical recurrence; Prostate cancer; Clinical endpoint; Prostatectomy; Prostate-specific antigen; Placebo; Radiation therapy; Glutamate carboxypeptidase II; Adjuvant","score_opus":0.01653389836474592,"score_gpt":0.3473627806221141,"score_spread":0.3308288822573682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416187331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886785,0.003884887,0.00030568225,0.00023686577,0.00011628476,0.0013046652,0.0014182477,0.00006775854,0.0039870213],"genre_scores_gemma":[0.9898168,0.0027655163,0.0012237924,0.0004895917,0.00012883259,0.001167178,0.0019623216,0.0000079956035,0.0024379878],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997124,0.00016277535,0.00002367217,0.000030676892,0.00003917962,0.000031185282],"domain_scores_gemma":[0.999595,0.00010225376,0.00011531233,0.00003773768,0.000034582845,0.000115158364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008406165,0.00033469475,0.000734694,0.0002613602,0.000104720275,0.00039625002,0.0004749496,0.000368372,0.0040541147],"category_scores_gemma":[0.0007736086,0.00014539433,0.0008614246,0.0003004227,0.0002646231,0.0002695313,0.00033885168,0.0009436166,0.000529428],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6721299,0.018401505,0.013913737,0.0032179663,0.002634461,0.00027557963,0.00015956163,0.002531625,0.023451412,0.00093939004,0.004848382,0.2574965],"study_design_scores_gemma":[0.4901773,0.45076355,0.036919642,0.0002298222,0.0015209983,0.0004743818,0.000098497316,0.0013106149,0.0034535227,0.00053680735,0.014477125,0.00003773122],"about_ca_topic_score_codex":0.0005086006,"about_ca_topic_score_gemma":0.002869743,"teacher_disagreement_score":0.0040541147,"about_ca_system_score_codex":0.00026311135,"about_ca_system_score_gemma":0.000703057,"threshold_uncertainty_score":0.013562441},"labels":[],"label_agreement":null},{"id":"W4416307752","doi":"10.1080/14796694.2025.2589058","title":"Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Johnson and Johnson","keywords":"Multiple myeloma; Resource use; Health care; Healthcare system; MEDLINE; Clinical trial","score_opus":0.03811956074926689,"score_gpt":0.3619815659137525,"score_spread":0.32386200516448566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416307752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988734,0.00024947705,0.000018475745,0.00010456837,0.000002683071,0.000004977538,0.00050337316,0.0000023111218,0.00024055986],"genre_scores_gemma":[0.99938405,0.00008233504,0.00001932686,0.00003982294,0.0000041637936,0.0000033879433,0.00042531348,4.7310306e-7,0.000041072442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995584,0.000095567346,0.000047467893,0.000074336276,0.00011434074,0.00010984869],"domain_scores_gemma":[0.99861395,0.00013111165,0.00081971055,0.000036098405,0.00009494143,0.00030403602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042039645,0.00012329778,0.0001953494,0.00042978453,0.00034262286,0.00068413094,0.0003280678,0.00030656325,0.0010830902],"category_scores_gemma":[0.0016253354,0.00009938882,0.00031566794,0.00093572587,0.00018233861,0.00027115384,0.00043173027,0.0005408169,0.00011367513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050274924,0.00003143557,0.9985386,0.000006063194,0.000026702135,0.000035104382,0.00003742409,0.00004963374,0.00003843956,0.000008256118,0.0001195371,0.0010585609],"study_design_scores_gemma":[0.000004907797,0.00004614604,0.99934834,0.000008100183,0.00001233092,0.00009464355,0.00016500855,0.00019750369,0.000020604099,0.00000975751,0.00009049762,0.0000021235903],"about_ca_topic_score_codex":0.05495243,"about_ca_topic_score_gemma":0.062390298,"teacher_disagreement_score":0.05495243,"about_ca_system_score_codex":0.0013038266,"about_ca_system_score_gemma":0.0010391363,"threshold_uncertainty_score":0.10926515},"labels":[],"label_agreement":null},{"id":"W4416598843","doi":"10.1080/14796694.2025.2589057","title":"LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"MEDLINE; Cancer; Chemotherapy; Clinical trial; Radiation therapy","score_opus":0.012988930198728882,"score_gpt":0.3348446924409227,"score_spread":0.3218557622421938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416598843","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03160053,0.0017615963,0.014762493,0.003109435,0.000633863,0.7887805,0.14757116,0.0006207487,0.011159781],"genre_scores_gemma":[0.023881475,0.00051454763,0.012288166,0.0017090407,0.00017161084,0.91337633,0.046501733,0.000112034766,0.0014450332],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9768664,0.017039653,0.0023967542,0.00152092,0.0015069454,0.00066917925],"domain_scores_gemma":[0.97529817,0.0053235656,0.006390892,0.004841752,0.0055895695,0.002556057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034695636,0.0024203553,0.0028051923,0.0011942699,0.0015288753,0.0030592212,0.00328137,0.002537705,0.020945752],"category_scores_gemma":[0.03219419,0.0015490899,0.0025434655,0.002899483,0.0016300482,0.002164949,0.002533818,0.0039073746,0.008225561],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37485835,0.01352712,0.06019152,0.025321933,0.0059754974,0.0007073599,0.0016647828,0.0064635025,0.004758953,0.011932933,0.40877396,0.085824125],"study_design_scores_gemma":[0.40496638,0.02721236,0.13461664,0.009106843,0.0034653558,0.00083556457,0.0010569025,0.006969831,0.0025573296,0.005681665,0.40305668,0.00047448033],"about_ca_topic_score_codex":0.002767651,"about_ca_topic_score_gemma":0.005998774,"teacher_disagreement_score":0.034695636,"about_ca_system_score_codex":0.0032620633,"about_ca_system_score_gemma":0.013654838,"threshold_uncertainty_score":0.18349028},"labels":[],"label_agreement":null},{"id":"W4416790102","doi":"10.1080/14796694.2025.2592722","title":"A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma Europe; Astellas Pharma; Bayer HealthCare","keywords":"Enzalutamide; Prostate cancer; Plain language; Cancer; Prostate","score_opus":0.011137181841712232,"score_gpt":0.31419172156580727,"score_spread":0.303054539724095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416790102","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013994976,0.22719848,0.0045311516,0.12976874,0.051934604,0.024325715,0.46323633,0.0010345374,0.08397542],"genre_scores_gemma":[0.072840095,0.18102033,0.013940996,0.3237308,0.042704012,0.042208873,0.18974693,0.0014222604,0.1323857],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99549496,0.002363849,0.0010107189,0.00024050997,0.00067705644,0.0002129019],"domain_scores_gemma":[0.9849881,0.008789485,0.002827339,0.00025548422,0.00247676,0.0006628315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006819106,0.0013698165,0.0041543893,0.0014833573,0.0005463431,0.0026594894,0.0012895286,0.0019195508,0.07748098],"category_scores_gemma":[0.020409653,0.0009310459,0.005508919,0.002314255,0.00042880626,0.0015003906,0.00062613183,0.003059048,0.012128364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024041018,0.00027603065,0.0015399844,0.037788115,0.002302236,0.00021921955,0.000090531605,0.0005354623,0.0009749675,0.00085283536,0.8616225,0.06975717],"study_design_scores_gemma":[0.052983195,0.010217548,0.020594595,0.031008294,0.0065309354,0.00059706095,0.00034040716,0.00042664647,0.000824161,0.0027023843,0.87349594,0.00027885806],"about_ca_topic_score_codex":0.0043371776,"about_ca_topic_score_gemma":0.006940501,"teacher_disagreement_score":0.07748098,"about_ca_system_score_codex":0.0021397553,"about_ca_system_score_gemma":0.0026170076,"threshold_uncertainty_score":0.25919968},"labels":[],"label_agreement":null},{"id":"W4417105636","doi":"10.1080/14796694.2025.2577005","title":"Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"Celgene; Pfizer","keywords":"Lymphoblastic Leukemia; Disease; Plain language; Stem cell; Cancer; Transplantation; Leukemia; Acute leukemia","score_opus":0.005246984083700796,"score_gpt":0.2637353523276733,"score_spread":0.25848836824397253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417105636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4868311,0.2138294,0.001462229,0.12364782,0.005633262,0.0006837185,0.13657565,0.00018024426,0.031156598],"genre_scores_gemma":[0.7768095,0.13724816,0.001582102,0.020559074,0.0059425803,0.0012993058,0.051624987,0.00009778484,0.0048364974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975987,0.00079244375,0.0007149829,0.000156985,0.00053535396,0.0002014847],"domain_scores_gemma":[0.98740226,0.004228868,0.00468772,0.00018242028,0.0028084654,0.0006902279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021435183,0.00033375158,0.0008089049,0.0020684907,0.00038935934,0.0013906242,0.0004752881,0.0006827332,0.0062293457],"category_scores_gemma":[0.013054703,0.00018846453,0.0017708061,0.0030478756,0.0003087387,0.0020897016,0.00081451796,0.0013590391,0.00085591903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035803476,0.0003626696,0.4344961,0.025732514,0.002180932,0.0010383744,0.003512827,0.0011266799,0.00034910705,0.0017521792,0.31323045,0.21263778],"study_design_scores_gemma":[0.0006445833,0.0015162416,0.8682711,0.018507399,0.0019480737,0.0010990747,0.0075140297,0.0004515957,0.00029941596,0.0011243405,0.098382205,0.00024194362],"about_ca_topic_score_codex":0.006719389,"about_ca_topic_score_gemma":0.0068430644,"teacher_disagreement_score":0.006719389,"about_ca_system_score_codex":0.001375864,"about_ca_system_score_gemma":0.0012043077,"threshold_uncertainty_score":0.020839214},"labels":[],"label_agreement":null},{"id":"W4417187153","doi":"10.1080/14796694.2025.2599082","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital","funders":"Seagen; Bristol-Myers Squibb","keywords":"Nivolumab; Brentuximab vedotin; Lymphoma; Ipilimumab; Chemoimmunotherapy; Immunotherapy","score_opus":0.009151288919165883,"score_gpt":0.2901132775739707,"score_spread":0.2809619886548048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417187153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064964,0.0071590254,0.00036472277,0.0001816486,0.000053417938,0.0001904135,0.0001249453,0.00007948152,0.0011967418],"genre_scores_gemma":[0.9971614,0.001418051,0.00045007534,0.00019654725,0.000038611975,0.000048810485,0.00019934733,0.000006837208,0.00048035078],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998714,0.000051155872,0.000013529978,0.000018210987,0.000020749103,0.000024966212],"domain_scores_gemma":[0.99988127,0.000025015746,0.00002326959,0.000009557356,0.000009754253,0.000051116385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051580917,0.00029653497,0.00066029927,0.00014903177,0.0001749102,0.0002453351,0.00030120215,0.00019686848,0.00071765424],"category_scores_gemma":[0.00030316872,0.00009573107,0.00028289825,0.00014155098,0.0001307829,0.0002061937,0.00015411174,0.00053803483,0.00029201328],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0635852,0.0070399307,0.05240812,0.0019556948,0.0012790478,0.0026938906,0.00047360302,0.0050367545,0.10373291,0.00022213782,0.00605918,0.7555136],"study_design_scores_gemma":[0.093846634,0.37239233,0.3788348,0.0007466624,0.0021885624,0.017551312,0.0005561247,0.01901299,0.05750689,0.00070770015,0.05653356,0.00012242109],"about_ca_topic_score_codex":0.00062362035,"about_ca_topic_score_gemma":0.0023445573,"teacher_disagreement_score":0.00071765424,"about_ca_system_score_codex":0.0004120837,"about_ca_system_score_gemma":0.0003633392,"threshold_uncertainty_score":0.0029898286},"labels":[],"label_agreement":null},{"id":"W4417427056","doi":"10.1080/14796694.2025.2598016","title":"Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diagnostic accuracy; Prostate; Prostate biopsy; Prostate cancer; Biopsy; MEDLINE","score_opus":0.04685428374219517,"score_gpt":0.39584589066345377,"score_spread":0.3489916069212586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417427056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046710772,0.99165267,0.00097213464,0.0003714183,0.0001958333,0.0008640637,0.00088378025,0.00004062703,0.0003483807],"genre_scores_gemma":[0.16672508,0.81991255,0.0054296497,0.0013401052,0.0005277327,0.004170338,0.0013975173,0.0000617571,0.00043527636],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9813665,0.008761437,0.005496054,0.0016677524,0.0023093845,0.00039881343],"domain_scores_gemma":[0.9690522,0.021254826,0.0063645937,0.00085586385,0.0022174027,0.00025514906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026231216,0.0027751166,0.019375205,0.007497211,0.0006723285,0.0046092593,0.002072329,0.002266606,0.0040998925],"category_scores_gemma":[0.06427372,0.0014772683,0.038508415,0.0065587107,0.0010017458,0.0021693625,0.0017702777,0.0016409805,0.00037408544],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017995328,0.000019000518,0.0024260571,0.63260883,0.34882292,0.000057802732,0.00009152635,0.00037046548,0.00022403758,0.0001343121,0.00051643915,0.012929226],"study_design_scores_gemma":[0.0008959063,0.00024171229,0.0034870415,0.07985039,0.91278505,0.00009091074,0.00003841046,0.00018712544,0.00018011815,0.00028808808,0.0019214144,0.000033849945],"about_ca_topic_score_codex":0.0060164314,"about_ca_topic_score_gemma":0.010421048,"teacher_disagreement_score":0.026231216,"about_ca_system_score_codex":0.0041495333,"about_ca_system_score_gemma":0.0047706356,"threshold_uncertainty_score":0.13872558},"labels":[],"label_agreement":null},{"id":"W7117573986","doi":"10.1080/14796694.2025.2610171","title":"The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Research Society","funders":"","keywords":"Lung cancer; Delphi method; Delphi; MEDLINE; Cancer; Cornerstone; Treatment of lung cancer; Consensus conference","score_opus":0.018985541569063753,"score_gpt":0.3397855648429782,"score_spread":0.3208000232739145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117573986","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015450562,0.074183546,0.07589785,0.69703674,0.03870722,0.021284444,0.004405875,0.0006178247,0.07241593],"genre_scores_gemma":[0.12270397,0.08276397,0.63227826,0.0851222,0.00460011,0.029866708,0.008351088,0.00036660465,0.03394706],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.896959,0.061214086,0.018122375,0.0020555737,0.018044908,0.003604089],"domain_scores_gemma":[0.84441644,0.037960757,0.008842928,0.0023354248,0.0996422,0.00680227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11911708,0.0018137532,0.0019752786,0.007830994,0.0037260554,0.00498092,0.00469713,0.008485985,0.0055434676],"category_scores_gemma":[0.18137749,0.0015013303,0.0053298892,0.0034537024,0.0019165768,0.0041228994,0.0065788776,0.0088911075,0.002963388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032776213,0.0003719575,0.0036073646,0.020480415,0.0004289407,0.0015770346,0.01364256,0.002243455,0.0021956998,0.017015148,0.5573968,0.38071293],"study_design_scores_gemma":[0.0003066317,0.0003055799,0.0062193945,0.08189186,0.0005430247,0.0016577967,0.012910983,0.002266526,0.0014543575,0.01959521,0.8725722,0.0002764747],"about_ca_topic_score_codex":0.0123612005,"about_ca_topic_score_gemma":0.016983462,"teacher_disagreement_score":0.11911708,"about_ca_system_score_codex":0.011333314,"about_ca_system_score_gemma":0.059009526,"threshold_uncertainty_score":0.62995887},"labels":[],"label_agreement":null}]}